Quorum Health (QHCCQ) 10-Q 15 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	May 10, 2017
Document And Entity Information [Abstract]
Entity Registrant Name	QUORUM HEALTH CORPORATION
Entity Central Index Key	1,650,445
Document Type	10-Q
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Trading Symbol	QHC
Amendment Flag	false
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		30,303,900

CONDENSED CONSOLIDATED AND COMB

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Statement [Abstract]
Operating revenues, net of contractual allowances and discounts	$ 587,945	$ 614,484
Provision for bad debts	60,305	64,933
Net operating revenues	527,640	549,551
Operating costs and expenses:
Salaries and benefits	264,602	256,862
Supplies	63,822	63,661
Other operating expenses	163,424	164,463
Depreciation and amortization	22,120	31,157
Rent	12,102	12,549
Electronic health records incentives earned	(2,452)	(4,208)
Legal, professional and settlement costs	535	241
Impairment of long-lived assets and goodwill	3,300	0
Loss (gain) on sale of hospitals, net	(870)	0
Transaction costs related to the Spin-off	31	3,735
Total operating costs and expenses	526,614	528,460
Income (loss) from operations	1,026	21,091
Interest expense, net	27,530	27,452
Income (loss) before income taxes	(26,504)	(6,361)
Provision for (benefit from) income taxes	701	(1,674)
Net income (loss)	(27,205)	(4,687)
Less: Net income (loss) attributable to noncontrolling interests	356	315
Net income (loss) attributable to Quorum Health Corporation	$ (27,561)	$ (5,002)
Earnings (loss) per share attributable to Quorum Health Corporation stockholders:
Basic and diluted	$ (0.99)	$ (0.18)
Weighted-average shares outstanding:
Basic and diluted	27,800,597	28,412,054

CONDENSED CONSOLIDATED AND COM3

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net income (loss)	$ (27,205)	$ (4,687)
Amortization and recognition of unrecognized pension cost components, net of income taxes	122	0
Comprehensive income (loss)	(27,083)	(4,687)
Less: Comprehensive income (loss) attributable to noncontrolling interests	356	315
Comprehensive income (loss) attributable to Quorum Health Corporation	$ (27,439)	$ (5,002)

CONDENSED CONSOLIDATED AND COM4

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 89,542	$ 25,455			$ 996	$ 1,106
Patient accounts receivable, net of allowance for doubtful accounts of $357,197 and $360,796 at March 31, 2017 and December 31, 2016, respectively	396,030	380,685
Inventories	53,368	58,124
Prepaid expenses	22,595	23,028
Due from third-party payors	106,380	116,235
Current assets of hospitals held for sale	9,067	1,502
Other current assets	62,529	57,942
Total current assets	739,511	662,971
Property and equipment, at cost	1,435,272	1,519,975
Less: Accumulated depreciation and amortization	(714,908)	(786,075)
Total property and equipment, net	720,364	733,900
Goodwill	408,580	416,833
Intangible assets, net	76,529	84,982
Long-term assets of hospitals held for sale	26,773	6,851
Other long-term assets	109,953	88,833
Total assets	2,081,710	1,994,370
Current liabilities:
Current maturities of long-term debt	1,664	5,683
Accounts payable	174,880	169,684
Accrued liabilities:
Accrued salaries and benefits	98,130	98,803
Accrued interest	31,206	19,915
Due to third-party payors	43,723	42,537
Current liabilities of hospitals held for sale	2,351	492
Other current liabilities	49,532	53,268
Total current liabilities	401,486	390,382
Long-term debt	1,317,985	1,241,142	$ 1,250,497	$ 24,179
Deferred income tax liabilities, net	32,075	31,474
Other long-term liabilities	136,916	108,996
Total liabilities	1,888,462	1,771,994
Redeemable noncontrolling interests	6,279	6,807			8,335	8,958
Quorum Health Corporation stockholders' equity:
Preferred stock, $0.0001 par value per share, 100,000,000 shares authorized, none issued	0	0
Common stock, $0.0001 par value per share, 300,000,000 shares authorized; 30,203,170 shares issued and outstanding at March 31, 2017, and 29,482,050 shares issued and outstanding at December 31, 2016	3	3
Additional paid-in capital	539,727	537,911
Accumulated other comprehensive income (loss)	(2,638)	(2,760)
Accumulated deficit	(361,587)	(334,026)
Total Quorum Health Corporation stockholders' equity	175,505	201,128
Nonredeemable noncontrolling interests	11,464	14,441
Total equity	186,969	215,569			$ 14,211	$ 15,943
Total liabilities and equity	$ 2,081,710	$ 1,994,370

CONDENSED CONSOLIDATED AND COM5

CONDENSED CONSOLIDATED AND COMBINED BALANCE SHEETS (Parenthetical) (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Apr. 29, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful patient accounts	$ 357,197	$ 360,796
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	30,203,170	29,482,050
Common stock, shares outstanding	30,203,170	29,482,050	28,412,054

CONDENSED CONSOLIDATED AND COM6

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Parent [Member]	Nonredeemable Noncontrolling Interests [Member]
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2015	$ 8,958
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(392)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(92)
Redeemable Noncontrolling Interests, Purchases of shares from noncontrolling investors	(31)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests investments	66
Redeemable Noncontrolling Interests, Noncontrolling interest in acquired entity	(174)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2016	8,335
Stockholders' equity, beginning balance at Dec. 31, 2015	15,943					$ 3,184	$ 12,759
Comprehensive income (loss)	(4,295)					(5,002)	707
Transfers to Parent (prior to Spin-off)	5,002					5,002
Cash distributions to noncontrolling investors	(2,392)						(2,392)
Purchases of shares from noncontrolling investors	19					19
Adjustments to redemption values of redeemable noncontrolling interests investments	(66)					(66)
Stockholders' equity, ending balance at Mar. 31, 2016	14,211					$ 3,137	11,074
Redeemable noncontrolling interests, beginning balance at Dec. 31, 2016	6,807
Redeemable Noncontrolling Interests, Comprehensive income (loss)	(466)
Redeemable Noncontrolling Interests, Cash distributions to noncontrolling investors	(15)
Redeemable Noncontrolling Interests, Adjustments to redemption values of redeemable noncontrolling interests investments	(47)
Redeemable noncontrolling interests, ending balance at Mar. 31, 2017	6,279
Stockholders' equity, beginning balance at Dec. 31, 2016	$ 215,569	$ 3	$ 537,911	$ (2,760)	$ (334,026)		14,441
Stockholders' equity, beginning balance, shares at Dec. 31, 2016	29,482,050	29,482,050
Comprehensive income (loss)	$ (26,617)			122	(27,561)		822
Stock-based compensation expense	2,797		2,797
Stock-based compensation expense, shares		854,126
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,028)		(1,028)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares, shares		(133,006)
Cash distributions to noncontrolling investors	(3,799)						(3,799)
Adjustments to redemption values of redeemable noncontrolling interests investments	47		47
Stockholders' equity, ending balance at Mar. 31, 2017	$ 186,969	$ 3	$ 539,727	$ (2,638)	$ (361,587)		$ 11,464
Stockholders' equity, ending balance, shares at Mar. 31, 2017	30,203,170	30,203,170

CONDENSED CONSOLIDATED AND COM7

CONDENSED CONSOLIDATED AND COMBINED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net income (loss)	$ (27,205)	$ (4,687)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	22,120	31,157
Non-cash interest expense	730	0
Provision for (benefit from) deferred income taxes	601	0
Stock-based compensation expense	2,797	0
Impairment of long-lived assets and goodwill	3,300	0
Loss (gain) on sale of hospitals, net	(870)	0
Changes in reserves for self-insurance claims, net of payments	4,212	7,990
Changes in reserves for legal, professional and settlement costs, net of payments	(3,651)	0
Other non-cash expense (income), net	(42)	(554)
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Patient accounts receivable, net	(17,163)	(12,122)
Due from and due to third-party payors, net	11,041	12,339
Inventories, prepaid expenses and other current assets	(16,674)	(2,589)
Accounts payable and accrued liabilities	38,065	(7,626)
Long-term assets and liabilities, net	1,265	489
Net cash provided by (used in) operating activities	18,526	24,397
Cash flows from investing activities:
Capital expenditures for property and equipment	(23,217)	(12,840)
Capital expenditures for software	(1,506)	(2,526)
Proceeds from the sale of hospitals	4,282	0
Proceeds from other asset sales	0	858
Other investing activities	0	52
Net cash provided by (used in) investing activities	(20,441)	(14,456)
Cash flows from financing activities:
Borrowings (repayments) of revolving credit facilities, net	78,000	0
Borrowings of long-term debt	0	20
Repayments of long-term debt	(7,109)	(1,089)
Increase (decrease) in Due to Parent, net	0	(6,486)
Payments of debt issuance costs	(47)	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares	(1,028)	0
Cash distributions to noncontrolling investors	(3,814)	(2,484)
Purchases of shares from noncontrolling investors	0	(12)
Net cash provided by (used in) financing activities	66,002	(10,051)
Net change in cash and cash equivalents	64,087	(110)
Cash and cash equivalents at beginning of period	25,455	1,106
Cash and cash equivalents at end of period	89,542	996
Supplemental cash flow information:
Interest payments, net	15,468	27,452
Income tax payments, net of refunds (after the Spin-off)	0	0
Non-cash purchases of property and equipment under capital lease obligations	$ 0	$ 2,023

Description of the Business and

Description of the Business and Spin-Off	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of the Business and Spin-off	NOTE 1 – DESCRIPTION OF THE BUSINESS AND SPIN-OFF Description of the Business The principal business of Quorum Health Corporation, a Delaware Corporation, and its subsidiaries (collectively, “QHC” or the “Company”) is to provide hospital and outpatient healthcare services in its markets across the United States. As of March 31, 2017, the Company owned or leased 35 hospitals in rural and mid-sized markets, which are located in 16 states and have a total of 3,399 licensed beds. The Company provides outpatient healthcare services through its hospitals and affiliated facilities, including urgent care centers, diagnostic and imaging centers, physician clinics and surgery centers. The Company’s wholly-owned subsidiary, Quorum Health Resources, LLC (“QHR”), provides management advisory and consulting services to non-affiliated hospitals located throughout the United States. Over 95% of the Company’s net operating revenues are attributable to its hospital operations business. Description of the Spin-off On April 29, 2016, Community Health Systems, Inc. (“CHS”, or “Parent” when referring to the carve-out period prior to April 29, 2016) completed the spin-off of 38 hospitals, including their affiliated facilities, and QHR to form Quorum Health Corporation through the distribution of 100% of the common stock of QHC, issued at a par value of $0.0001 per share, to CHS stockholders of record as of the close of business on April 22, 2016 (the “Record Date”) and cash proceeds to CHS of $1.2 billion (the “Spin-off”). Each CHS stockholder received a distribution of one share of QHC common stock for every four shares of CHS common stock held as of the Record Date plus cash in lieu of fractional shares. Quorum Health Corporation began trading on the New York Stock Exchange (“NYSE”) under the ticker symbol “QHC” on May 2, 2016. In connection with the Spin-off, QHC issued $400 million in aggregate principal amount of 11.625% Senior Notes due 2023 (the “Senior Notes”) on April 22, 2016, pursuant to an indenture (the “Indenture”) by and between the Company and Regions Bank, as Trustee. The Senior Notes were issued at a discount of $6.9 million, or 1.734%. The gross offering proceeds of the Senior Notes were deposited into a segregated escrow account at the closing of the offering on April 22, 2016. On April 29, 2016, the Company entered into a credit agreement (the “Senior Credit Facility”) consisting of an $880 million senior secured term loan facility (the “Term Loan Facility”), which was issued at a discount of $17.6 million, or 98% of par value, and a $100 million senior secured revolving credit facility (the “Revolving Credit Facility”). In addition, the Company entered into a $125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”) on April 29, 2016. The net offering proceeds of the Senior Notes were released to QHC from the escrow account on April 29, 2016. The net offering proceeds of the Senior Notes, together with the net borrowings under the Term Loan Facility, were used to pay $1.2 billion of the cash proceeds to CHS, as mentioned above, and to pay the Company’s fees and expenses related to the Spin-off. The cash proceeds paid to CHS were characterized as a one-time, tax-free cash distribution. In connection with the Spin-off, QHC and CHS entered into a Separation and Distribution Agreement, a Tax Matters Agreement and an Employee Matters Agreement on April 29, 2016, which, collectively, governed or continue to govern the allocation of employees, assets and liabilities that were transferred to QHC from CHS, including but not limited to investments, working capital, property and equipment, employee benefits and deferred tax assets and liabilities. In addition, QHC and CHS entered into various transition services agreements and other ancillary agreements that govern certain relationships and activities of QHC and CHS for five years following the Spin-off. See Note 16 — Related Party Transactions for additional information on the agreements that exist between QHC and CHS after the Spin-off. In connection with the Spin-off, CHS contributed $530.6 million of additional paid-in capital to QHC and made a $13.5 million cash contribution to QHC, pursuant to the Separation and Distribution Agreement. This contribution consisted of $20.0 million of cash contributed to fund a portion of QHC’s initial working capital, reduced by $6.5 million for the difference in estimated and actual financing transaction fees related to the Spin-off. The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands): Additional Long-Term Due to Common Stock Paid-in Parent's Debt Parent, Net Shares Amount Capital Equity Balance at April 29, 2016 (prior to the Spin-off) $ 24,179 $ 1,813,836 — $ — $ — $ 3,137 Borrowings of long-term debt, net of debt issuance discounts 1,255,464 — — — — — Payments of debt issuance costs (29,146 ) — — — — — Cash proceeds paid to Parent — (1,217,336 ) — — — — Transfer of liabilities from Parent — (22,292 ) — — — — Net deferred income tax liability resulting from the Spin-off — (46,783 ) — — — — Non-cash capital contribution from Parent — (527,425 ) — — 530,562 (3,137 ) Distribution of common stock — — 27,719,645 3 (3 ) — Distribution of restricted stock awards — — 692,409 — — — Balance at April 29, 2016 (after the Spin-off) $ 1,250,497 $ — 28,412,054 $ 3 $ 530,559 $ — The following table provides a summary of the liabilities transferred to QHC from CHS in connection with the Spin-off (in thousands): April 29, Accounts payable $ 13,607 Benefit plan liabilities 5,964 Other liabilities 2,721 Total liabilities transferred from Parent $ 22,292

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	NOTE 2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The condensed consolidated and combined financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the condensed consolidated and combined financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the interim periods presented. Results of operations for interim periods should not be considered indicative of the results of operations expected for the full year ending December 31, 2017. Certain information and disclosures have been condensed or omitted as presented herein and as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim period presentation. The Company’s management believes the financial statements and disclosures presented herein are adequate in order to make the information presented not misleading. The condensed consolidated and combined financial statements should be read in conjunction with the consolidated and combined financial statements and accompanying notes thereto for the year ended December 31, 2016, contained in the Company’s Annual Report on Form 10-K filed with the SEC on April 12, 2017 (the “2016 Form 10-K”). Prior to its separation from CHS on April 29, 2016, QHC did not operate as a separate company and stand-alone financial statements were not historically prepared; however, QHC was comprised of certain stand-alone legal entities for which discrete financial information was available under CHS’ ownership. The accompanying condensed consolidated and combined financial statements include amounts and disclosures for QHC that have been derived from the consolidated financial statements and accounting records of CHS for the periods prior to the Spin-off in combination with the amounts and disclosures related to the stand-alone financial statements and accounting records of QHC after the Spin-off. The accompanying condensed consolidated and combined financial statements may not necessarily be indicative of the results of operations, financial position and cash flows of QHC in the future or those that would have occurred had the Company operated on a stand-alone basis during the entirety of the periods presented herein. See Note 16 — Related Party Transactions for additional information on the carve-out of financial information from CHS. The Company’s financial statements have been prepared under the assumption that it will continue as a going concern. The Company has limited stand-alone operating history and has experienced net losses in each of the quarters subsequent to the Spin-off from CHS. On December 31, 2016, the Company adopted Financial Accounting Standards Board’s (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements — Going Concern, which requires management to evaluate if there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern. As a result of adopting ASU No. 2014-15, management was required to evaluate the Company’s ability to comply with the Secured Net Leverage Ratio under its Senior Credit Facility for one year following the issuance of the financial statements for the three month period ended March 31, 2017. Although the Company was in compliance with its financial covenants as of March 31, 2017, the new standard requires management to base its evaluation about the ability to continue to comply with those covenants on results and events considered “probable” of occurring considering historical results, implemented plans, and executed agreements as of the date the financial statements are issued. In light of (i) the Company’s historical net operating results; (ii) delays in the approval by Centers for Medicare and Medicaid Services (“CMS”) of the California Hospital Quality Assurance Fee program for the 2017 to 2019 program period, which impacts the Company due to the inability to recognize any earned revenues until CMS approval of the program has been issued; and (iii) the amount of net operating losses from hospitals the Company intends to divest, management amended certain provisions of its Senior Credit Facility. On April 11, 2017, the Company executed an agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Amendment”) to, among other things, raise the maximum Secured Net Leverage Ratio (as defined in the credit agreement (the “CS Agreement”), among the Company, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent) to 4.75x from 4.25x for the period July 1, 2017 to December 31, 2018 (which was previously 4.25x for the period July 1, 2017 to June 30, 2018), at which point it drops to 4.00x for the remainder of the agreement. The CS Amendment also provides for additional Consolidated EBITDA add backs under the covenant calculation for certain items. For additional information related to the CS Amendment, see Note 7 — Long-term Debt. Management has concluded that the CS Amendment alleviates any substantial doubt about its ability to continue as a going concern for the one year period following the issuance of its financial statements for the three month period ended March 31, 2017. The Company is actively engaged in initiatives to divest underperforming hospitals and outpatient facilities, for which proceeds will be used to pay down the Company’s term loan under its credit facility. For all defined terms related to the Company’s Senior Credit Facility, see Note 7 – Long-term Debt. Principles of Consolidation and Combination The consolidated and combined financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the consolidated and combined balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company’s consolidated and combined statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the consolidated and combined balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation. Additionally, all significant transactions with CHS that occurred prior to the Spin-off were included in the consolidated and combined balance sheets within Due to Parent, net. This liability to CHS was settled in the Spin-off. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. In the third quarter of 2016, the Company reclassified and separately presented certain items in its consolidated and combined statements of cash flows. Specifically, changes in self-insurance reserves related to employee health, professional and general liability and workers’ compensation liability were reclassified to changes in reserves for self-insurance claims, net of payments, and changes in reserves for legal, professional and settlement costs were reclassified to changes in reserves for legal, professional and settlement costs, net of payments. The Company believes the current presentation more accurately distinguishes the changes in these liabilities from changes in operating assets and liabilities considered to be part of its normal business operations. Both items are included in cash flows from operating activities. Beginning in the second quarter of 2016, the Company began classifying equity in earnings of unconsolidated subsidiaries as other operating expenses in the consolidated and combined statements of income. Previously, these amounts were classified as non-operating income. These amounts are immaterial to the Company. This change in classification has no effect on the Company’s net income or cash flows included in previously issued consolidated and combined financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated and combined financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions. Revenues and Accounts Receivable Revenue Recognition The Company recognizes revenues from patient services at its hospitals and affiliated facilities in the period services are performed and reports these revenues at the net realizable amount expected to be collected from patients and third-party payors. Billings and collections are outsourced to CHS under the transition services agreements that were entered into in connection with the Spin-off. See Note 16 — The amounts that are collected for patient services are generally less than established billing rates, or standard billing charges, due to contractual agreements with third-party payors, governmental programs that require reduced billing rates, discounts offered as incentives for payment, and a portion related to bad debts. The Company recognizes revenues related to its QHR business when management advisory and consulting services are provided and reports these revenues at the net realizable amount expected to be collected from the non-affiliated hospital clients. The following table provides a summary of the components of net operating revenues, before the provision for bad debts (in thousands): Three Months Ended March 31, 2017 2016 Operating revenues $ 3,068,323 $ 3,080,653 Less: Contractual allowances (2,371,292 ) (2,361,035 ) Less: Discounts (109,086 ) (105,134 ) Total net operating revenues, before the provision for bad debts $ 587,945 $ 614,484 Payor Sources The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers’ compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR’s hospital management advisory and consulting services business, rental income and hospital cafeteria sales. The following table provides a summary of net operating revenues, before the provision for bad debts, by payor source (dollars in thousands): Three Months Ended March 31, 2017 2016 $ Amount % of Total $ Amount % of Total Medicare $ 175,293 29.8 % $ 175,534 28.6 % Medicaid 96,669 16.4 % 103,068 16.8 % Managed care and commercial plans 231,557 39.4 % 244,284 39.8 % Self-pay 59,080 10.0 % 64,754 10.5 % Non-patient 25,346 4.4 % 26,844 4.3 % Total net operating revenues, before the provision for bad debts $ 587,945 100.0 % $ 614,484 100.0 % Beginning in the second quarter of 2016, the Company began classifying its revenues related to Medicare Advantage Plans as Medicare revenues. As a result, the Company retroactively reclassified $41.7 million for the three months ended March 31, 2016 from managed care and commercial revenues to Medicare revenues. Revenues from Medicare Advantage Plans that are included in Medicare revenues in the table above were $48.3 million and $41.7 million for the three months ended March 31, 2017 and 2016, respectively. Contractual Allowances and Discounts The net realizable amount of patient service revenues due from third-party payors is subject to complexities and interpretations of payor-specific contractual agreements and governmental regulations that are frequently changing. The Medicare and Medicaid programs, which represent a large portion of the Company’s operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. Contractual allowances, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third–party payors, are recorded based on management’s best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual allowances are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual allowance adjustments in the periods in which they become known and may be subject to further revisions. Self-pay and other payor discounts are incentives offered to uninsured or underinsured payors to reduce their costs of healthcare services with the purpose of maximizing the Company’s collection efforts. Third-Party Program Reimbursements Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans are estimated and recorded in the period the related services are performed and are adjusted in future periods, as needed, until the final cost report settlements are determined. Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, “provider taxes”) levied on the providers. Similar programs are also currently being considered by other states. These amounts are included in due from and due to third-party payors in the consolidated and combined balance sheets. The following table provides a summary of the components of amounts due from and due to third-party payors (in thousands): March 31, December 31, 2017 2016 Amounts due from third-party payors: Previous program reimbursements and final cost report settlements $ 23,573 $ 23,876 State supplemental payment programs 82,807 92,359 Total amounts due from third-party payors $ 106,380 $ 116,235 Amounts due to third-party payors: Previous program reimbursements and final cost report settlements $ 34,675 $ 33,366 State supplemental payment programs 9,048 9,171 Total amounts due to third-party payors $ 43,723 $ 42,537 After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes revenue and related expenses based on the terms of the program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the consolidated and combined statements of income. The following table provides a summary of the portion of Medicaid reimbursements attributable to state supplemental payment programs (in thousands): Three Months Ended March 31, 2017 2016 Medicaid revenues $ 45,297 $ 52,215 Provider taxes and other expenses 16,893 19,426 Reimbursements attributable to state supplemental payment programs, net of expenses $ 28,404 $ 32,789 The California Department of Health Care Services implemented the California Hospital Quality Assurance Fee (“HQAF”) program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medi-Cal and uninsured patients. Under the most recent phase of the program, covering the period January 2014 through December 2016, the Company recognized $11.0 million of Medicaid revenues and $2.7 million of provider taxes for the three months ended March 31, 2016 with no corresponding amounts for the three months ended March 31, 2017. The current program expired on December 31, 2016 and CMS has not approved a new program. Consistent with the first four phases of the HQAF program, the Company is not recognizing revenues under the pending program in 2017 or thereafter until CMS completes the approval process. Charity Care In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the poverty level guidelines established by the federal government. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual allowances. The gross amounts of charity care revenues were $12.5 million and $7.8 million for the three months ended March 31, 2017 and 2016, respectively. Accounts Receivable and Allowance for Doubtful Accounts Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities. The following table provides a summary of the components of accounts receivable before contractual allowances, discounts and allowance for doubtful accounts (dollars in thousands): March 31, 2017 December 31, 2016 $ Amount % of Total $ Amount % of Total Third-parties $ 2,050,321 75.8 % $ 1,930,103 74.6 % Self-pay 654,955 24.2 % 656,373 25.4 % Total patient accounts receivable, gross $ 2,705,276 100.0 % $ 2,586,476 100.0 % Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category. The allowance percentage is based on a model that considers the historical write-off activity and is adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. For insured receivables, which are the non-self-pay receivables, the Company estimates the allowance for doubtful accounts based on a model that considers the uncontractualized portion of all accounts aging over 365 days from the date of patient discharge, reduced by an estimate for recoveries. The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands): Three Months Ended March 31, 2017 Balance at beginning of period $ 360,796 Provision for bad debts 60,305 Amounts written off, net of recoveries (63,904 ) Balance at end of period $ 357,197 Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS’ billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 16 — Related Party Transactions for additional information on these agreements. Significant changes in payor mix, centralized business office operations, including the CHS shared service centers’ efforts in collecting the Company’s accounts receivable, economic conditions or trends in federal and state governmental healthcare coverage, among others, could affect the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall allowance adequacy by monitoring historical cash collections as a percentage of trailing net operating revenues after the provision for bad debts, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent acquisitions and dispositions. Concentration of Credit Risk The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s hospitals and affiliated facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s markets and non-governmental third-party payors, Medicare represents a significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare were $72.8 million and $72.6 million, or 9.7% and 9.8% of total patient accounts receivable, net as of March 31, 2017 and December 31, 2016, respectively. Additionally, due to fiscal problems in the state of Illinois, the Company believes Illinois Medicaid represents a concentration of credit risk. The Company’s accounts receivable, net of contractual allowances, from Illinois Medicaid were $38.5 million and $34.8 million, or 5.1% and 4.7% of total patient accounts receivable, net as of March 31, 2017 and December 31, 2016, respectively. The Company’s revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company’s results of operations, financial condition or cash flows. Changes to Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect. The following table provides a summary of the states in which the Company generates more than 5% of total net patient revenues, before the provision for bad debts, as determined in each period (dollars in thousands): Number of Three Months Ended March 31, Hospitals at 2017 2016 March 31, 2017 $ Amount % of Total $ Amount % of Total Illinois 9 $ 203,372 36.1 % $ 201,851 34.3 % Oregon 1 52,996 9.4 % 52,848 9.0 % Georgia 3 45,876 8.2 % 54,254 9.2 % California 2 38,957 6.9 % 51,045 8.7 % Kentucky 3 30,984 5.5 % 30,892 5.3 % Alabama 2 28,629 5.1 % 27,312 4.6 % Other Operating Expenses The following table provides a summary of the major components of other operating expenses (in thousands): Three Months Ended March 31, 2017 2016 Purchased services $ 45,596 $ 44,438 Taxes and insurance 34,243 35,306 Medical specialist fees 28,463 24,350 Transition services agreements and allocations from Parent 16,282 16,257 Repairs and maintenance 11,443 11,236 Utilities 6,665 7,155 Management fees from Parent — 8,826 Other miscellaneous operating expenses 20,732 16,895 Total other operating expenses $ 163,424 $ 164,463 Following the Spin-off, the Company began recording costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements and allocations from Parent” in the table above. Amounts allocated to the Company by CHS for periods prior to the Spin-off are also included in “Transition services agreements and allocations from Parent” in the table above. Prior to the Spin-off, QHC recorded a monthly corporate management fee from CHS that represented a portion of CHS’ corporate office costs, and this fee was included in other operating expenses. Following the Spin-off, the costs for corporate office functions are primarily included in salaries and benefits expenses in the consolidated and combined statements of income. See Note 16 — General and Administrative Costs Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs are primarily salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were $15.7 million and $12.0 million during the three months ended March 31, 2017 and 2016, respectively. Prior to the Spin-off, the majority of these costs were allocations from CHS. See Note 16 — Electronic Health Records Incentives Earned Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), the Company is eligible to receive incentive payments under the Medicare and Medicaid programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified Electronic Health Records (“EHR”) technology. Each of the Company’s eligible hospitals and physician clinics has completed the initial adoption phase of EHR implementation and is currently in the process of implementing the remaining two phases. EHR incentive payments are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based are further subject to audit. The Company utilizes a gain contingency model to recognize EHR incentive payments. When the recognition criteria have been fully met, the Company recognizes the income from EHR incentives payments as a part of operating costs and expenses in the consolidated and combined statements of income. Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals demonstrate meaningful use of certified EHR technology. Medicare EHR incentive payments are calculated when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year used to determine the final incentive payment is available. In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the income from EHR incentive payments is deferred until all recognition criteria are met. The Company recognizes r eceivables for EHR incentive payments that have been earned, but are uncollected at period end, as other current assets in the consolidated and combined balance sheets. The receivables are adjusted for any known audit or retrospective adjustments related to prior periods. Deferred revenue from EHR incentive payments is recorded in other current liabilities in the consolidated and combined balance sheets. The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. As the Company completes its full implementation of certified EHR technology in accordance with all three phases of the program, its EHR incentive payments will decline and ultimately end. The following table provides a summary of activity related to EHR incentives (in thousands): Three Months Ended March 31, 2017 2016 Electronic health records incentives receivable at beginning of period $ 4,189 $ 11,227 Electronic health records incentives earned 2,452 4,208 Cash incentive payments received (842 ) (7,625 ) Adjustments to receivable based on final cost report settlement or audit (221 ) (1,925 ) Electronic health records incentives receivable at end of period $ 5,578 $ 5,885 Deferred revenue related to electronic health records incentives at beginning of period $ — $ — Cash received and deferred during period — (4,693 ) Recognition of deferred incentives as earned — — Deferred revenue related to electronic health records incentives at end of period $ — $ (4,693 ) Total electronic health records incentives earned during period $ 2,452 $ 4,208 Total cash incentive payments received during period 842 12,318 Legal, Professional and Settlement Costs Legal, professional and settlement costs in the consolidated and combined statements of income primarily includes legal costs and related settlements, if any, related to regulatory claims, government investigations into reimbursement payments and claims associated with QHR’s hospital management contracts. Professional costs include legal costs for investigations, data gathering and analysis associated with investigation projects approved by the Company’s Board of Directors (the “Board”). Loss (Gain) on Sale of Hospitals, Net Loss (gain) on sale of hospitals, net is the loss (gain) related to the Company’s divestiture of hospitals and their related ancillary facilities. It is calculated as the difference between the cash received from the sale and the carrying value of the associated net assets at the date of sale, less certain incremental direct selling costs. Transaction Costs Related to the Spin-off Transaction costs related to the Spin-off consists of QHC’s portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for income taxes in the consolidated and combined statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of income tax expense. See Note 11 — Cash and Cash Equivalents Cash includes cash on hand and cash with banks. Cash equivalents are short-term, highly liquid investments with a maturity of three months or less from the date acquired that are subject to an insignificant risk of change in value. Inventories Inventories, primarily consisting of medical supplies and drugs, are stated at the lower of cost or market on a first-in, first-out basis. Other Current Assets Other current assets consists of the current po

Impairment of Long-Lived Assets

Impairment of Long-Lived Assets and Goodwill	3 Months Ended
	Mar. 31, 2017
Disclosure Text Block Supplement [Abstract]
Impairment of Long-Lived Assets and Goodwill	NOTE 3 – IMPAIRMENT OF LONG-LIVED ASSETS AND GOODWILL 2017 Impairments During the three months ended March 31, 2017, management made a decision to classify certain additional hospitals as held for sale. In connection with this decision, the Company evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2016 measurement date, which was the measurement date of the Company’s most recent annual goodwill impairment analysis, and recognized $3.3 million of impairment to long-lived assets and goodwill during the three months ended March 31, 2017, which consisted of $1.1 million of property and equipment, $0.8 million of capitalized software costs and $1.4 million of goodwill. 2016 Impairments During the second quarter of 2016, management made a decision to classify certain hospitals as held for sale and evaluate other hospitals for divestiture. Due to the increase in net operating losses associated with these hospitals, the Company analyzed the long-lived assets of all of its hospitals to test for impairment and recorded $45.4 million of impairment related to long-lived assets in this quarter. In addition, the Company evaluated the estimated relative fair value of the hospitals classified as held for sale in relation to the overall fair value of the hospital operations reporting unit utilizing a September 30, 2015 measurement date, which was the measurement date of the Company’s most recent annual goodwill impairment analysis, and recognized $5.0 million of goodwill impairment in the second quarter of 2016. In this same quarter, management identified certain indicators of goodwill impairment related to the hospital operations reporting unit and concluded that such indicators necessitated an interim goodwill impairment evaluation. The primary indicators were declining market capitalization, as compared to the carrying value of equity, and a decrease in estimated future earnings of the hospital operations reporting unit. The Company performed a calculation of the overall fair value of this reporting unit in step one of the impairment test and concluded that the carrying value of the hospital operations reporting unit as of June 30, 2016 exceeded the estimated fair value. The Company performed a preliminary step two calculation of goodwill impairment to determine the implied fair value of goodwill of the hospital operations reporting unit in a hypothetical purchase price allocation. Based on this preliminary analysis, the Company estimated and recorded goodwill impairment of $200 million in the second quarter of 2016. For step two goodwill impairment testing, the Company engaged a professional valuation firm to perform a hypothetical purchase price valuation of each of its hospitals utilizing a September 30, 2016 measurement date. The results of the third-party valuation, which was completed in the fourth quarter of 2016, indicated that the carrying values of certain of the Company’s individual hospitals exceeded their fair values. Considering these results to be an indicator of potential impairment and to assess whether any additional impairment of long-lived assets existed, the Company utilized a September 30, 2016 measurement date to perform an analysis of undiscounted cash flows for each hospital in which an indicator of impairment was identified. Based on the results of these analyses, the Company recorded impairment of $82.7 million related to long-lived assets at certain hospitals and a downward adjustment to its previously recorded goodwill estimate by $80 million in the fourth quarter of 2016. The net impact in the fourth quarter of 2016, in comparison to the $200 million estimate recorded as of June 30, 2016, was $2.7 million of additional impairment beyond this initial estimate. In addition to the above, the Company experienced a decline in operating results at several hospitals in the fourth quarter of 2016. This led management to perform additional testing for impairment using a December 31, 2016 measurement date. As a result of this analysis, the Company recorded additional impairment of $38.8 million related to long-lived assets in the fourth quarter of 2016. The carrying values of long-lived assets, including those classified as held for sale, are reported net of these impairment charges on the consolidated and combined balance sheet as of December 31, 2016.

Divestitures

Divestitures	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Divestitures	NOTE 4 –DIVESTITURES Trinity Hospital of Augusta On March 30, 2017, the Company announced that it had entered into a definitive agreement to sell 231-bed Trinity Hospital of Augusta, and its affiliated outpatient facilities located in Augusta, Georgia. The Company anticipates completing the sale of this hospital in the second quarter of 2017. Cherokee Medical Center On March 31, 2017, the Company sold 60-bed Cherokee Medical Center and its affiliated outpatient facilities (“Cherokee”), located in Centre, Alabama, for $4.3 million. For the three months ended March 31, 2017 and 2016, the Company’s operating results included pre-tax losses of $0.9 million and $1.7 million, respectively, related to Cherokee. In addition to the above, the Company recorded a $0.8 million gain on the sale in the three months ended March 31, 2017. The Company also recorded $3.9 million and $2.0 million of impairment to property, equipment and capitalized software costs of Cherokee during the years ended December 31, 2016 and 2015, respectively. Barrow Regional Medical Center Effective December 31, 2016, the Company sold 56-bed Barrow Regional Medical Center and its affiliated outpatient facilities (“Barrow”), located in Winder, Georgia, for $6.6 million. For the three months ended March 31, 2017 and 2016, the Company’s operating results included a pre-tax gain of $0.6 million and a pre-tax loss of $2.9 million, respectively, related to Barrow. In addition to the above, the Company recorded a $1.2 million loss on the sale and $4.0 million of impairment to property, equipment and capitalized software costs of Barrow during the year ended December 31, 2016. Sandhills Regional Medical Center Effective December 1, 2016, the Company sold 64-bed Sandhills Regional Medical Center and its affiliated outpatient facilities (“Sandhills”), located in Hamlet, North Carolina, for $7.2 million. For the three months ended March 31, 2017 and 2016, the Company’s operating results included pre-tax losses of $0.6 million related to Sandhills. In addition to the above, the Company recorded a $1.0 million loss on the sale and $4.8 million of impairment to property, equipment and capitalized software costs of Sandhills during the year ended December 31, 2016.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Property and Equipment	NOTE 5 – PROPERTY AND EQUIPMENT The following table provides a summary of the components of property and equipment (in thousands): March 31, December 31, 2017 2016 Property and equipment, at cost: Land and improvements $ 80,846 $ 84,474 Building and improvements 756,040 782,892 Equipment and fixtures 532,830 592,463 Construction in progress 65,556 60,146 Total property and equipment, at cost 1,435,272 1,519,975 Less: Accumulated depreciation and amortization (714,908 ) (786,075 ) Total property and equipment, net $ 720,364 $ 733,900 Depreciation expense was $15.8 million and $22.4 million for the three months ended March 31, 2017 and 2016, respectively. See Note 6 Purchases of property and equipment accrued in accounts payable were $6.9 million and $15.7 million as of March 31, 2017 and December 31, 2016, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 6 – GOODWILL AND INTANGIBLE ASSETS Goodwill The following table provides a summary of changes in goodwill (in thousands): Three Months Ended March 31, 2017 Balance at beginning of period $ 416,833 Reclassification to held-for-sale (6,885 ) Impairment (1,368 ) Balance at end of period $ 408,580 Goodwill related to the hospital operations reporting unit was $375.3 million and $383.5 million as of March 31, 2017 and December 31, 2016, respectively. Goodwill related to the hospital management advisory and consulting services reporting unit was $33.3 million at both March 31, 2017 and December 31, 2016. See Note 3 — Intangible Assets The following table provides a summary of intangible assets (in thousands): March 31, December 31, 2017 2016 Finite-lived intangible assets: Capitalized software costs: Cost $ 164,006 $ 180,855 Accumulated amortization (107,611 ) (118,391 ) Capitalized software costs, net 56,395 62,464 Physician guarantee contracts: Cost 8,148 11,355 Accumulated amortization (4,409 ) (6,329 ) Physician guarantee contracts, net 3,739 5,026 Other finite-lived intangible assets: Cost 43,883 44,342 Accumulated amortization (33,169 ) (33,059 ) Other finite-lived intangible assets, net 10,714 11,283 Total finite-lived intangible assets Cost 216,037 236,552 Accumulated amortization (145,189 ) (157,779 ) Total finite-lived intangible assets, net $ 70,848 $ 78,773 Indefinite-lived intangible assets: Tradenames $ 4,000 $ 4,000 Medical licenses and other indefinite-lived intangible assets 1,681 2,209 Total indefinite-lived intangible assets $ 5,681 $ 6,209 Total intangible assets: Cost $ 221,718 $ 242,761 Accumulated amortization (145,189 ) (157,779 ) Total intangible assets, net $ 76,529 $ 84,982 As of March 31, 2017, the Company had $3.2 million of capitalized software costs that are currently in the development stage. Amortization of these capitalized costs will begin once the software projects are complete and ready for their intended use. Amortization Expense The following table provides a summary of the components of amortization expense (in thousands): Three Months Ended March 31, 2017 2016 Amortization of finite-lived intangible assets: Capitalized software costs $ 4,744 $ 6,595 Physician guarantee contracts 557 711 Other finite-lived intangible assets 569 757 Total amortization expense related to finite-lived intangible assets 5,870 8,063 Amortization of leasehold improvements and property and equipment assets held under capital lease obligations 456 683 Total amortization expense $ 6,326 $ 8,746 As of March 31, 2017, the weighted-average remaining amortization period of the Company’s intangible assets subject to amortization, except for capitalized software costs and physician guarantee contracts, was approximately 5.3 years.

Long-Term Debt

Long-Term Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Long-Term Debt	NOTE 7 – LONG-TERM DEBT The following table provides a summary of the components of long-term debt (in thousands): March 31, December 31, 2017 2016 Senior Credit Facility: Revolving Credit Facility, maturing 2021 $ 39,000 $ — Term Loan Facility, maturing 2022 861,869 868,419 ABL Credit Facility, maturing 2021 39,000 — Senior Notes, maturing 2023 400,000 400,000 Unamortized debt issuance costs and discounts (46,831 ) (48,764 ) Capital lease obligations 25,224 25,588 Other debt 1,387 1,582 Total debt 1,319,649 1,246,825 Less: Current maturities of long-term debt (1,664 ) (5,683 ) Total long-term debt $ 1,317,985 $ 1,241,142 In connection with the Spin-off, the Company entered into two credit agreements and issued senior notes. In addition, the previous indebtedness with CHS, which was classified on the consolidated and combined balance sheets as Due to Parent, net was fully settled. See Note 1 — Description of the Business and Spin-off and Note 16 — Related Party Transactions for additional information on the use of proceeds from the new debt instruments and the settlement of Due to Parent, net. Senior Credit Facility On April 29, 2016, the Company entered into the CS Agreement, among the Company, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent. On April 11, 2017, the Company executed the CS Amendment with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility, as described below. The CS Agreement initially provided for an $880 million senior secured term loan facility and a $100 million senior secured revolving credit facility. The Term Loan Facility was issued at a discount of $17.6 million, or 98% of par value, and has a maturity date of April 29, 2022, subject to customary acceleration events and repayment, extension or refinancing. The Revolving Credit Facility has a maturity date of April 29, 2021, subject to certain customary acceleration events and repayment, extension or refinancing. The CS Amendment reduced the Revolving Credit Facility’s borrowing capacity from $100 million to $87.5 million until December 31, 2017, at which time the borrowing capacity decreases to $75.0 million. The CS Agreement contains customary covenants, including a maximum permitted Secured Net Leverage Ratio, as determined based on 12 month trailing Consolidated EBITDA, as defined in the CS Agreement. As of March 31, 3017 and December 31, 2016, the Company had a Secured Net Leverage Ratio of 3.83 to 1.00 and 3.93 to 1.00, respectively, implying additional borrowing capacity of $152.6 million as of March 31, 2017. On April 11, 2017, the Company executed the CS Amendment with its Senior Credit Facility lenders to amend the calculation of the Secured Net Leverage Ratio beginning January 1, 2017 to December 31, 2018, among other provisions. The CS Amendment raised the maximum Secured Net Leverage Ratio required for the Company to remain in compliance for certain periods, and also changed the calculation of compliance for specified periods. After giving effect to the CS Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA and as defined in the CS Agreement, follows: Maximum Secured Net Period Leverage Ratio Period from January 1, 2017 to June 30, 2017 4.50 to 1.00 Period from July 1, 2017 to December 31, 2018 4.75 to 1.00 Period from January 1, 2019 and thereafter 4.00 to 1.00 In addition to amending the calculation of the Secured Net Leverage Ratio and the Maximum Secured Net Leverage Ratio, the CS Amendment also affects other terms of the CS Agreement as follows: • Through December 31, 2018, the Company is required to use asset sales proceeds to make mandatory redemptions under the Term Loan Facility. After December 31, 2018, the Company is required to use asset sale proceeds to make mandatory redemptions under the Term Loan Facility to the extent those proceeds are not expected to be reinvested within 15 months. • Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of $100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00. • Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only if the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00. Prior to the CS Amendment, interest under the Term Loan Facility accrued, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 5.75%, or the alternate base rate plus 4.75%. The effective interest rate on the Term Loan Facility was 7.69% as of March 31, 2017. Following the CS Amendment, interest under the Term Loan Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 1% plus 6.75%, or the alternate base rate plus 5.75%. Interest under the Revolving Credit Facility accrues, at the option of the Company, at adjusted LIBOR, subject to statutory reserves and a floor of 0% plus 2.75%, or the alternate base rate plus 1.75%, and remains unchanged under the CS Amendment. If the CS Amendment had been effective as of March 31, 2017, the effective interest rate on the Term Loan Facility would have been 8.73%. Borrowings from the Revolving Credit Facility are used for working capital and general corporate purposes. As of March 31, 2017, the Company had $39.0 million outstanding under the Revolving Credit Facility and had $6.5 million of letters of credit outstanding that were primarily related to the self-insured retention levels of professional and general liability and workers’ compensation liability insurance as security for the payment of claims. As of March 31, 2017, the Company had borrowing capacity under its Revolving Credit Facility of $42.0 million. ABL Credit Facility On April 29, 2016, the Company entered into an ABL Credit Agreement (the “UBS Agreement,” and together with the CS Agreement, collectively, the “Credit Agreements”), among the Company, the lenders party thereto and UBS AG, Stamford Branch (“UBS”), as administrative agent and collateral agent. The UBS Agreement provides for a $125 million senior secured asset-based revolving credit facility (the “ABL Credit Facility”). The available borrowings from the ABL Credit Facility, which are based on eligible patient accounts receivable, are used for working capital and general corporate purposes. As of March 31, 2017, the Company had $39.0 million outstanding on the ABL Credit Facility and borrowing capacity of $86.0 million. The ABL Credit Facility has a maturity date of April 29, 2021, subject to customary acceleration events and repayment, extension or refinancing. Interest under the ABL Credit Facility accrues, at the option of the Company, at a base rate or LIBOR, subject to statutory reserves The ABL Credit Facility has a “Covenant Trigger Event” definition that requires the Company to maintain excess availability under the ABL Credit Facility equal to or greater than the greater of (i) $12.5 million and (ii) 10% of the aggregate commitments under the ABL Credit Facility. If a Covenant Trigger Event occurs, then the Company is required to maintain a minimum Consolidated Fixed Charge Ratio of 1.10 to 1.00 until such time that a Covenant Trigger Event is no longer continuing. In addition, if excess availability under the ABL Credit Facility were to fall below the greater of (i) 12.5% of the aggregate commitments under the ABL Credit Facility and (ii) $15.0 million, then a “Cash Dominion Event” would be triggered upon which the lenders could assume control of the Company’s cash. Credit Agreement Covenants In addition to the specific covenants described above, the Credit Agreements contain customary negative covenants which limit the Company’s ability to, among other things, incur additional indebtedness, create liens, make investments, transfer assets, merge or acquire assets, and make restricted payments, including dividends, distributions and specified payments on other indebtedness. They include customary events of default, including payment defaults, material breaches of representations and warranties, covenant defaults, default on other material indebtedness, customary Employee Retirement Income Security Act (“ERISA”) Senior Notes On April 22, 2016, the Company issued $400 million aggregate principal amount of 11.625% Senior Notes due 2023, pursuant to the Indenture. The Senior Notes were issued at a discount of $6.9 million, or 1.734%, in a private placement and are senior unsecured obligations of the Company guaranteed on a senior basis by certain of the Company’s subsidiaries (the “Guarantors”). The Senior Notes mature on April 15, 2023 and bear interest at a rate of 11.625% per annum, payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016. Interest on the Senior Notes accrues from the date of original issuance and is calculated on the basis of a 360-day year comprised of twelve 30-day months. The effective interest rate on the Senior Notes was 12.469% as of March 31, 2017. The Indenture contains covenants that, among other things, limit the ability of the Company and certain of its subsidiaries to incur or guarantee additional indebtedness, pay dividends or make other restricted payments, make certain investments, create or incur certain liens, sell assets and subsidiary stock, transfer all or substantially all of its assets or enter into merger or consolidation transactions. On April 17, 2017, the Company launched an offer to exchange the 11.625% Senior Notes due 2023 (the “Initial Notes”) in the aggregate principal amount of $400 million, which are not registered under the Securities Act of 1933, as amended (the “Securities Act”), for a like principal amount of 11.625% Senior Notes due 2023 (the “Exchange Notes”), which have been registered under the Securities Act (the “Exchange Offer”). The Exchange Offer expires on May 17, 2017, unless extended by the Company. The Exchange Notes are substantially identical to the Initial Notes, except that the Exchange Notes will be registered under the Securities Act and will not be subject to the transfer restrictions and certain registration rights agreement provisions applicable to the Initial Notes. On and after April 15, 2019, the Company is entitled, at its option, to redeem all or a portion of the Senior Notes upon not less than 30 nor more than 60 days’ notice, at the following redemption prices, plus accrued and unpaid interest, if any, to the redemption date. The redemption prices are expressed as a percentage of the principal amount on the redemption date. Holders of record on the relevant record date have the right to receive interest due on the relevant interest payment date. In addition, prior to April 15, 2019, the Company may redeem some or all of the Senior Notes at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, plus a “make whole” premium, as set forth in the Indenture. The Company is entitled to redeem up to 35% of the aggregate principal amount of the Senior Notes until April 15, 2019 with the net proceeds from certain equity offerings at the redemption price set forth in the Indenture. The following table provides a summary of the redemption dates and prices related to the Senior Notes: Redemption Period Prices Period from April 15, 2019 to April 14, 2020 108.719 % Period from April 15, 2020 to April 14, 2021 105.813 % Period from April 15, 2021 to April 14, 2022 102.906 % Period from April 15, 2022 to April 14, 2023 100.000 % Debt Issuance Costs and Discounts The following table provides a summary of unamortized debt issuance costs and discounts (in thousands): March 31, December 31, 2017 2016 Debt issuance costs $ 29,193 $ 29,146 Debt discounts 24,536 24,536 Total debt issuance costs and discounts 53,729 53,682 Less: Amortization of debt issuance costs and discounts (6,898 ) (4,918 ) Total unamortized debt issuance costs and discounts $ 46,831 $ 48,764 Capital Lease Obligations and Other Debt The Company’s debt arising from capital lease obligations primarily relates to its new corporate office in Brentwood, Tennessee. As of March 31, 2017, this capital lease obligation was $18.5 million. The remainder of the Company’s capital lease obligations relate to property and equipment at its hospitals and corporate office. Other debt consists of physician loans and miscellaneous notes payable to banks. Debt Maturities The following table provides a summary of debt maturities for the next five years and thereafter (in thousands): March 31, 2017 Remainder of 2017 $ 1,312 2018 7,786 2019 10,144 2020 10,245 2021 10,356 Thereafter 1,326,637 Total debt, excluding unamortized debt issuance costs and discounts $ 1,366,480 Interest Expense, Net The following table provides a summary of the components of interest expense, net (in thousands): Three Months Ended March 31, 2017 2016 Senior Credit Facility: Revolving Credit Facility $ 139 $ — Term Loan Facility 14,641 — ABL Credit Facility 256 — Senior Notes 11,626 — Amortization of debt issuance costs and discounts 1,980 — All other interest expense (income), net (1,112 ) 569 Total interest expense, net from long-term debt 27,530 569 Due to Parent, net — 26,883 Total interest expense, net $ 27,530 $ 27,452

Other Long-Term Liabilities

Other Long-Term Liabilities	3 Months Ended
	Mar. 31, 2017
Other Liabilities Disclosure [Abstract]
Other Long-Term Liabilities	NOTE 8 – OTHER LONG-TERM LIABILITIES The following table provides a summary of the components of other long-term liabilities (in thousands): March 31, December 31, 2017 2016 Professional and general liability insurance reserves $ 76,062 $ 74,194 Workers' compensation liability insurance reserves 19,862 17,416 Benefit plan liabilities 34,737 10,722 Deferred rent 3,586 4,001 Other miscellaneous long-term liabilities 2,669 2,663 Total other long-term liabilities $ 136,916 $ 108,996 See Note 17 — Commitments and Contingencies for additional information about the Company’s insurance reserves.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 9 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of the Company’s cash and cash equivalents, patient accounts receivable, amounts due from and due to third-party payors, and accounts payable approximate their fair values due to the short-term maturity of these financial instruments. The Company recorded impairment charges related to long-lived assets and goodwill during the three months ended March 31, 2017 and the year ended December 31, 2016. See Note 3 — The following table provides a summary of the carrying amounts and estimated fair values of the Company’s long-term debt (in thousands): March 31, 2017 December 31, 2016 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Revolving Credit Facility $ 39,000 $ 39,000 $ — $ — Term Loan Facility 861,869 843,554 868,419 849,427 ABL Credit Facility 39,000 39,000 — — Senior Notes 400,000 349,456 400,000 334,720 Other debt 26,611 26,611 27,170 27,170 Total debt, excluding unamortized debt issuance costs and discounts $ 1,366,480 $ 1,297,621 $ 1,295,589 $ 1,211,317 The Company considers its long-term debt instruments to be measured based on Level 2 inputs. Information about the valuation methodologies used in the determination of the fair values for the Company’s long-term debt instruments follows: • Term loan facility . • Senior notes . • All other debt .

Equity

Equity	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Equity	NOTE 10 – EQUITY Preferred Stock In connection with the Spin-off, the Company authorized 100,000,000 shares of preferred stock, par value of $0.0001 per share. No shares have been issued as of March 31, 2017. The Board has the discretion, subject to limitations prescribed by Delaware law and by its amended and restated certificate of incorporation, to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock, when and if issued. Common Stock In connection with the Spin-off, the Company authorized 300,000,000 shares of common stock, par value of $0.0001 per share, and issued 28,412,054 shares of common stock on April 29, 2016 to CHS stockholders of record on the Record Date, or April 22, 2016. The common stock began trading on the NYSE on May 2, 2016 under the ticker symbol “QHC.” As of March 31, 2017 and December 31, 2016, the Company had 30,203,170 shares and 29,482,050 shares, respectively, of common stock issued and outstanding. Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company’s common stock will not have cumulative voting rights in the election of directors. There are no preemptive rights, conversion, redemption or sinking fund provisions applicable to the common stock. In the event of liquidation, dissolution or winding up, holders of common stock are entitled to share ratably in the assets available for distribution. Delaware law prohibits the Company from paying any dividends unless it has capital surplus or net profits available for this purpose. In addition, the Company’s Credit Agreements impose restrictions on its ability to pay dividends. Additional Paid-in Capital In connection with the Spin-off, the Company issued common stock, as described above, to CHS stockholders. In addition, pursuant to the Separation and Distribution Agreement, CHS contributed capital in excess of par value of common stock of $530.6 million, in lieu of a cash settlement payment, related to the remaining intercompany indebtedness with CHS and the Parent’s equity attributable to CHS. See Note 1 — Description of the Business and Spin-off for a summary of the major transactions to effect the Spin-off. Accumulated Deficit Accumulated deficit of the Company, as shown on the consolidated and combined balance sheets as of March 31, 2017 and December 31, 2016, represents the Company’s cumulative net losses since the Spin-off date. The cumulative earnings and losses of the Company prior to the Spin-off were included in Due to Parent, net on the consolidated and combined balance sheets.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 – INCOME TAXES The Company, or one of its subsidiaries, is subject to U.S. federal income tax and income tax of multiple state and local jurisdictions. The Company provides for income taxes based on the enacted tax laws and rates in jurisdictions in which it conducts its operations. Prior to the Spin-off, the Company was included in the consolidated federal, state and local income tax returns filed by CHS and calculated income taxes for the purpose of carve-out financial statements using the “separate return method.” The Company deemed the amounts that it would have paid to or received from the U.S. Internal Revenue Service and certain state jurisdictions, had QHC not been a member of CHS’ consolidated tax group, to be immediately settled with CHS through Due to Parent, net in the consolidated and combined balance sheets. The Company is filing its own consolidated federal, state and local income tax returns after the Spin-off. The Company’s effective tax rates were (2.6)% and 26.3% for the three months ended March 31, 2017 and 2016, respectively. The decrease in the Company’s effective tax rate for the three months ended March 31, 2017, when compared to the three months ended March 31, 2016, was primarily due to recording a valuation allowance against the deferred tax assets arising from the Company’s pre-tax loss in the 2017 period that are not more likely than not to be recognized. The Company’s deferred income tax liabilities, net were $32.1 million as of March 31, 2017, compared to $31.5 million as of December 31, 2016, a $0.6 million increase. This increase was primarily due to a deferred tax provision for tax deductible amortization on indefinite-lived intangible assets and goodwill, net of a deferred tax benefit on the impairment of goodwill related to the reclassification of QHC hospitals to assets held for sale in the 2017 period. In the ordinary course of business there is inherent uncertainty in quantifying the Company’s income tax positions. The Company assesses its income tax positions and records income tax benefits for all tax years subject to examination based on management’s evaluation of the facts, circumstances, and information available at the reporting date. The Company is not aware of any unrecognized tax benefits; therefore, it has not recorded any such amounts for the three months ended March 31, 2017 and 2016.

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	NOTE 12 – EARNINGS PER SHARE The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares): Three Months Ended March 31, 2017 2016 Numerator: Net income (loss) $ (27,205 ) $ (4,687 ) Less: Net income (loss) attributable to noncontrolling interests 356 315 Net income (loss) attributable to Quorum Health Corporation $ (27,561 ) $ (5,002 ) Denominator: Weighted-average shares outstanding - basic and diluted 27,800,597 28,412,054 Basic and diluted earnings (loss) per share attributable to Quorum Health Corporation stockholders $ (0.99 ) $ (0.18 ) For comparative purposes, the Company used 28,412,054 shares as the number of basic and diluted shares outstanding for all periods prior to the Spin-off in calculating basic and diluted earnings (loss) per share. This number of shares represents the number of shares issued on the Spin-off date. Due to the net loss attributable to Quorum Health Corporation in the three months ended March 31, 2017 and March 31, 2016, no incremental shares are included in diluted earnings (loss) per share for these periods because the effect of the incremental shares would be anti-dilutive. No incremental shares were considered for any periods prior to the Spin-off.

Segments

Segments	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Segments	NOTE 13 – SEGMENTS The Company operates in two distinct operating segments, its hospital operations business and its hospital management advisory and healthcare consulting services business. The hospital operations segment includes the operations of the Company’s owned and leased hospitals and their affiliated outpatient facilities that provide inpatient and outpatient healthcare services. Prior to the Spin-off, management fees allocated from Parent were included in the hospital operations segment. Subsequent to the Spin-off, the Company began presenting general and administrative costs for corporate functions in the all other reportable segment. The hospital management advisory and healthcare consulting services segment includes the operations of QHR. Only the hospital operations segment meets the criteria as a separate reportable segment. The financial information for QHR has been combined with the Company’s corporate functions and reported below as part of the all other reportable segment. The following tables provide a summary of financial information related to the Company’s segments (in thousands): Three Months Ended March 31, 2017 2016 Net operating revenues: Hospital operations $ 506,418 $ 527,424 All other 21,222 22,127 Total net operating revenues $ 527,640 $ 549,551 Adjusted EBITDA: Hospital operations $ 37,466 $ 52,171 All other (11,324 ) 4,053 Total Adjusted EBITDA $ 26,142 $ 56,224 March 31, December 31, 2017 2016 Assets: Hospital operations $ 1,812,402 $ 1,802,121 All other 269,308 192,249 Total assets $ 2,081,710 $ 1,994,370 The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands): Three Months Ended March 31, 2017 2016 Adjusted EBITDA $ 26,142 $ 56,224 Interest expense, net (27,530 ) (27,452 ) Provision for (benefit from) income taxes (701 ) 1,674 Depreciation and amortization (22,120 ) (31,157 ) Legal, professional and settlement costs (535 ) (241 ) Impairment of long-lived assets and goodwill (3,300 ) — Gain (loss) on sale of hospitals, net 870 — Transaction costs related to the Spin-off (31 ) (3,735 ) Net income (loss) $ (27,205 ) $ (4,687 )

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	NOTE 14 – STOCK-BASED COMPENSATION On April 1, 2016, the Company adopted the Quorum Health Corporation 2016 Stock Award Plan (“2016 Stock Award Plan”). The Company filed a Registration Statement on Form S-8 on April 29, 2016 to register 4,700,000 shares of QHC common stock that may be issued under the plan. As defined in the Separation and Distribution Agreement, QHC and CHS employees who held CHS restricted stock awards on the Record Date received QHC restricted stock awards for the number of whole shares, rounded down, of QHC common stock that they would have received as a shareholder of CHS as if the underlying CHS stock were unrestricted on the Record Date, except, that with respect to a portion of CHS restricted stock awards granted to any QHC employees on March 1, 2016, as discussed above, that were cancelled and forfeited on the Spin-off date. The QHC restricted stock awards received by QHC and CHS employees in connection with the Spin-off vest on the same terms as the CHS restricted stock awards to which they relate, through the continued service by such employees with their respective employer. CHS restricted stock awards were adjusted by increasing the number of shares of CHS stock subject to restricted stock awards by an amount of whole shares, rounded down, necessary to preserve the intrinsic value of such awards at the Spin-off date. QHC did not issue any stock options as part of the distribution of shares to holders of CHS stock options. On February 22, 2017, the Compensation Committee of the Board of Directors (the “Compensation Committee”) granted 230,000 performance-based restricted stock awards to the Company’s executive officers. The grants were made pursuant to the 2016 Stock Award Plan and a performace-based restricted stock award agreement. If the performance-based objectives are attained in accordance with the targets set forth in the performance-based restricted stock award agreement, the restrictions on the restricted stock awards will lapse in equal installments on each of the first three anniversaries of the grant date. On February 22, 2017, the Compensation Committee granted 230,000 time-based restricted stock awards to the Company’s executive officers, as well as 420,000 time-based restricted stock awards to certain employees of the Company. The grants were made pursuant to the 2016 Stock Award Plan and a restricted stock award agreement. The restrictions on the time-vested restricted stock awards will lapse in equal installments on each of the first three anniversaries of the grant date. On May 3, 2016, the Compensation Committee granted 460,000 performance-based restricted stock awards to the Company’s executive officers. The grants were made pursuant to the 2016 Stock Award Plan and a performance-based restricted stock award agreement. If the performance-based objectives are attained in accordance with the targets set forth in the performance-based restricted stock award agreement, the restrictions on the restricted stock awards will lapse in equal installments on each of the first three anniversaries of the grant date. On May 3, 2016, the Compensation Committee granted 551,005 time-vested restricted stock awards to certain employees of the Company. The grants were made pursuant to the 2016 Stock Award Plan and a restricted stock award agreement. The restrictions on the time-vested restricted stock awards will lapse in equal installments on each of the first three anniversaries of the grant date, except for 106,005 restricted stock awards, referred to by the Company as recoupment awards, which have a different vesting period. The recoupment awards were issued to a select group of QHC employees that were granted restricted stock awards by CHS on March 1, 2016. Pursuant to the Separation and Distribution Agreement, two-thirds of the shares granted to the QHC employee group on this grant date were canceled by CHS in connection with the Spin-off. The recoupment awards were issued by QHC and included in the May 3, 2016 grant of QHC restricted stock awards for the purpose of restoring the benefit previously provided by CHS to this employee group. Restrictions on the recoupment awards lapse in equal installments on the second and third anniversaries of the grant date. On May 3, 2016, the Board, upon recommendation of its Compensation Committee and its Governance and Nominating Committee, granted 10,000 time-vested restricted stock awards to each of its seven non-employee directors. The grants were made pursuant to the 2016 Stock Award Plan and a director restricted stock award agreement. The restrictions on the time-vested restricted stock awards will lapse on the first anniversary of the grant date. The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees during the three months ended March 31, 2017 that were distributed in the Spin-off (in shares): QHC Awards Distributed in Spin-off QHC Employees CHS Employees Total Unvested restricted stock awards at December 31, 2016 52,462 621,525 673,987 Vested (33,599 ) (200,834 ) (234,433 ) Forfeited (13,928 ) (127,183 ) (141,111 ) Unvested restricted stock awards at March 31, 2017 4,935 293,508 298,443 The following table provides a summary of the activity related to unvested restricted stock awards during the three months ended March 31, 2017 that were granted to QHC employees subsequent to the Spin-off: QHC Awards Granted Subsequent to Spin-off Weighted- Average Grant Date Shares Fair Value Unvested restricted stock awards at December 31, 2016 1,081,005 $ 12.77 Granted 880,000 8.54 Vested — — Forfeited (17,667 ) 12.77 Unvested restricted stock awards at March 31, 2017 1,943,338 $ 10.85 Following the Spin-off, the Company began recording stock-based compensation expense related to the vesting of QHC restricted stock awards issued to QHC employees on the Spin-off date, CHS restricted stock awards held by QHC employees on the Spin-off date, and restricted stock awards granted by QHC on May 3, 2016. Stock-based compensation expense is recorded in salaries and benefits for periods following the Spin-off. Prior to the Spin-off, an estimated portion of CHS’ stock-based compensation expense was allocated to QHC through the monthly corporate management fee from CHS, which was recorded in other operating expenses in the consolidated and combined statements of income, and therefore is not included in stock-based compensation expense in the table below. The estimated costs allocated to QHC from CHS were $1.7 million for the three months ended March 31, 2016. The Company accounts for stock-based compensation in accordance with Accounting Standards Codification Topic 718, “Compensation — The following table provides a summary of stock-based compensation expense (in thousands): Three Months Ended March 31, 2017 2016 Stock-based compensation resulting from the Spin-off $ 916 $ — Stock-based compensation related to grants following the Spin-off 1,881 — Total stock-based compensation expense $ 2,797 $ — As of March 31, 2017, the Company had unrecognized stock-based compensation expense related to the outstanding unvested QHC and CHS restricted stock awards held by QHC employees as of the Spin-off date and the QHC restricted stock awards granted subsequent to the Spin-off of $1.7 million and $14.4 million, respectively.

Employee Benefit Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Employee Benefit Plans	NOTE 15 – EMPLOYEE BENEFIT PLANS Following the Spin-off, the Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and deferred compensation plans, of which certain of the Company’s subsidiaries are the plan sponsors. The rights and obligations of these plans were transferred from CHS in connection with the Spin-off, pursuant to the Separation and Distribution Agreement. Defined Contribution Plans The Quorum Health Retirement Savings Plan (the “RSP”) is a defined contribution plan established on January 1, 2016 by CHS in anticipation of the Spin-off. Prior to the Spin-off, the cumulative liability for these benefit costs was recorded in Due to Parent, net. The assets and liabilities under this plan were transferred to QHC in connection with the Spin-off. The RSP covers the majority of the employees at the Company’s subsidiaries. The Company has other minor defined contribution plans at certain of its hospitals that cover employees under the terms of these individual plans. Total expense to the Company under all defined contribution plans was $2.9 million and $3.3 million for the three months ended March 31, 2017 and 2016, respectively. The benefit costs associated with the RSP are recorded as salaries and benefits expense in the consolidated and combined statements of income. Deferred Compensation Plans Certain QHC employees participated in CHS’ unfunded deferred compensation plans that allowed participants to defer receipt of a portion of their compensation. The election period for those employees continued under the CHS plan through December 31, 2016. In January, 2017, the assets and liabilities attributable to QHC employees of $22.9 million and $23.9 million, respectively, were transferred to a new plan established by QHC, as described below. On August 18, 2016, the Compensation Committee of the Board adopted the Executive Nonqualified Excess Plan Adoption Agreement (the “Adoption Agreement”) and the Executive Nonqualified Excess Plan Document (the “Plan Document”), that together, the Adoption Agreement names as the QHCCS, LLC Nonqualified Deferred Compensation Plan (the “NQDCP”). The NQDCP is an unfunded, nonqualified deferred compensation plan that provides deferred compensation benefits for a select group of management, highly compensated employees and independent contractors of the Company’s wholly-owned subsidiary, QHCCS, LLC, a Delaware limited liability company (“QHCCS”), including the Company’s named executive officers. The NQDCP permits participants to defer a portion of their annual base salary, service bonus and performance-based compensation, as well as up to 100% of their incentive compensation in any calendar year. In addition to participant deferrals, QHCCS and/or its affiliates may make discretionary credits to participants’ accounts for any year. As of March 31, 2017, the assets and liabilities under this plan were $22.5 million and $23.6 million, respectively, and are included in other long-term assets and other long-term liabilities in the consolidated and combined balance sheet. Supplemental Executive Retirement Plan On April 1, 2016, the Board adopted the Quorum Health Corporation Supplemental Executive Retirement Plan (the “Original SERP Plan”). Pursuant to the EMA between the Company and CHS, the Company assumed all liabilities for all obligations under the Original SERP Plan for the benefits of QHC employees, as defined in the Employee Matters Agreement, except that no additional benefits were to accrue under the Original SERP Plan following the Spin-off. The accrued benefit liability for the Original SERP Plan that was transferred to the Company in connection with the Spin-off was $6.0 million and is included in other long-term liabilities in the consolidated and combined balance sheet. There were no assets transferred to the Company related to the Original SERP Plan in connection with the Spin-off. On May 24, 2016, the Board, upon recommendation of the Compensation Committee, approved the Company’s Amended and Restated Supplemental Executive Retirement Plan (the “Amended and Restated SERP”), in order to accrue additional benefits with respect to QHC Employees who otherwise qualify as “Participants” under the Amended and Restated SERP. The Amended and Restated SERP is a noncontributory non-qualified deferred compensation plan under Section 409A of the Internal Revenue Code. The benefit costs under both SERP plans were $0.5 million for the three months ended March 31, 2017, and are included in salaries and benefits in the consolidated and combined statements of income. The current and long-term portions of the benefit liability for the Amended and Restated SERP were $2.3 million and $7.6 million, respectively as of March 31, 2017. As of December 31, 2016, the current and long-term portions of the benefit liability were $2.3 million and $7.1 million, respectively. The current portion is included in accrued salaries and benefits and the long-term portion is included in other long-term liabilities in the consolidated and combined balance sheet. Director’s Fees Deferral Plan On September 16, 2016, the Board adopted the Quorum Health Corporation Director’s Fees Deferral Plan (the “Director’s Plan”). Pursuant to the Director’s Plan, members of the Board may elect to defer and accumulate fees, including retainer fees and fees for attendance at Board meetings and Board committees. A director may elect that all or any specified portion of the director’s fees to be earned during a calendar year be credited to a director’s cash account and/or a director’s stock unit account maintained on the individual director’s behalf in lieu of payment. Payment of amounts credited to a director’s cash account and stock unit account will be made upon a payment commencement event, as defined in the Director’s Plan, in accordance with the payment method elected by the individual director, either in lump sum or in a number of annual installments, not to exceed 15 installments. The Director’s Plan extends to directors of the Board not employed by the Company or any of its subsidiaries. Pursuant to the Director’s Plan, the Company registered and made available for issuance under the Director’s Plan a maximum of 150,000 shares of QHC common stock. Defined Benefit Pension Plan QHC provides benefits to employees at one of its hospitals through a defined benefit plan (the “Pension Plan”). The Pension Plan provides benefits to covered individuals satisfying certain age and service requirements. Employer contributions to the Pension Plan are in accordance with the minimum funding requirements of ERISA. Benefit costs related to the Pension Plan was $0.1 million and less than $0.1 million for the three months ended March 31, 2017 and 2016, respectively. The Company recognizes

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 16 – RELATED PARTY TRANSACTIONS CHS was a related party to QHC prior to the Spin-off. The significant transactions and balances with CHS prior to the Spin-off and the agreements between QHC and CHS as of and subsequent to the Spin-off are described below. Carve-Out from Parent Prior to the Spin-off, QHC did not operate as a separate company and stand-alone financial statements were not prepared. Historically, QHC was managed and operated in the normal course of business with all other hospitals and affiliates of CHS. Accordingly, for the purposes of the carve-out financial statements related to the Spin-off, a combined opening balance sheet for the QHC hospitals and QHR was established. The combined opening balance sheet included the assets and liabilities of QHC hospitals and QHR, as reported by CHS, and a net liability to CHS, referred to as Due to Parent, net for the net investment held by CHS related to its contribution of these net assets. The operating results of the QHC hospitals and QHR prior to the Spin-off were derived from the CHS operating results for these entities. In addition, certain corporate overhead costs were allocated to QHC from CHS during the carve-out period for the purpose of estimating QHC’s share of these expenses. Allocated Costs from CHS during the Carve-Out Period CHS allocated costs to QHC during the carve-out period for a portion of its corporate overhead costs and any other costs related to QHC hospitals and QHR that were paid by CHS or covered by an agreement, policy or contract owned by CHS. The following table provides a summary of allocated costs to QHC from CHS (in thousands): Three Months Ended March 31, 2016 Insurance costs $ 33,760 Management fees from Parent 8,826 All other allocated costs 19,715 Total related party operating costs and expenses $ 62,301 The allocation of insurance costs from CHS primarily included costs for self-insurance estimates and third-party policies related to employee health, professional and general liability and workers’ compensation coverage. Insurance costs were primarily allocated to QHC based on claims history of the QHC hospitals, as determined on an individual hospital level. Corporate management fees were allocated to QHC for certain corporate functions of CHS, including services such as, among others, executive and divisional management, treasury, accounting, risk management, legal, procurement, human resources, information technology support and other administrative support services. These corporate overhead costs were allocated to QHC using a ratio based on the number of licensed beds at each QHC hospital in proportion to CHS’ total licensed beds. This methodology is comparable to how CHS allocates corporate overhead costs to all of its hospitals through a management fee charge that eliminates in consolidation. All other allocated costs included any other costs allocated to QHC hospitals or QHR and that were not part of management fees. These costs were allocated to QHC using ratios based on revenues, expenses or licensed beds. If possible, allocations were made on a specific identification basis. Following the Spin-off, the Company began performing corporate functions using internal resources or purchased services, certain of which are required to be provided by CHS pursuant to the transition services agreements and other ancillary agreements. See the section “Agreements with CHS Related to the Spin-off” below. Due to Parent, Net Prior to the Spin-off, Due to Parent, net in the consolidated and combined balance sheets represented the Company’s cumulative liability to CHS for the net assets of QHC hospitals and QHR, as well as an allocation of costs for corporate functions. See Note 1 — — During the carve-out period, QHC was charged interest on a monthly basis by CHS on the amount of Due to Parent, net outstanding at the end of each month. Interest rates were variable and ranged from 4% to 7% during the carve-out period. Interest expense was recorded as an increase in the Due to Parent, net liability and was deemed settled each month. For the three months ended March 31, 2016, interest expense related to Due to Parent, net was $26.9 million. Agreements with CHS Related to the Spin-off In connection with the Spin-off and as of April 29, 2016, the Company entered into certain agreements with CHS that allocated between the Company and CHS the various assets, employees, liabilities and obligations (including investments, property, employee benefits and tax-related assets and liabilities) that were previously part of CHS. In addition, these agreements govern certain relationships between, and activities of, the Company and CHS for a definitive period of time after the Spin-off, as specified by each individual agreement. The agreements were as follows: • Separation and Distribution Agreement. • Tax Matters Agreement • Employee Matters Agreement. In addition to the agreements referenced above, the Company entered into certain transition services agreements and other ancillary agreements with CHS defining agreed upon services to be provided by CHS to certain or all QHC hospitals, as determined by each agreement, commencing on the Spin-off date. The agreements generally have terms of five years. A summary of the major provisions of the transition services agreements follows: • Shared Services Centers Transition Services Agreement. • Computer and Data Processing Transition Services Agreement. • Receivables Collection Agreement (“PASI”). • Billing and Collection Agreement (“PPSI”). • Employee Service Center Agreement. • Eligibility Screening Services Agreement. The total expenses recorded by the Company under transition services agreements with CHS following the Spin-off combined with the allocations from CHS for these same services prior to the Spin-off were $16.3 million for both the three months ended March 31, 2017 and 2016. The Company is disputing certain charges under the transition services agreements with CHS.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 17 - COMMITMENTS AND CONTINGENCIES Legal Matters The Company is a party to various legal, regulatory and governmental proceedings incidental to its business. Based on current knowledge, management does not believe that loss contingencies arising from pending legal, regulatory and governmental proceedings, including the matters described herein, will have a material adverse effect on the operating results, financial position or liquidity of the Company. However, in light of the inherent uncertainties involved in these matters, some of which are beyond the Company’s control, and the very large or indeterminate damages sought in some of these matters, an adverse outcome in one or more of these matters could occur. In connection with the Spin-off, CHS agreed to indemnify QHC for certain liabilities relating to outcomes or events occurring prior to the closing of the Spin-off, including (i) certain claims and proceedings known to be outstanding on or prior to the closing date of the Spin-off and (ii) certain claims, proceedings and investigations by governmental authorities or private plaintiffs related to activities occurring at or related to the Company’s healthcare facilities prior to the closing date of the Spin-off, but only to the extent, in the case of clause (ii), that such claims are covered by insurance policies maintained by CHS, including professional and general liability and workers’ compensation liability. In this regard, CHS will continue to be responsible for certain Health Management Associates, Inc. legal matters covered by its contingent value rights agreement that relate to the portion of CHS’ business now held by QHC. Notwithstanding the foregoing, CHS is not indemnifying QHC in respect of any claims or proceedings arising out of, or related to, the business operations of QHR at any time or its compliance with the Corporate Integrity Agreement (“CIA”) . Subsequent to the Spin-off, the OIG entered into an “Assumption of CIA Liability Letter” with the Company reiterating the applicability of the CIA to certain of the Company’s hospitals, although the OIG declined to enter into a separate agreement with the Company. With respect to all legal, regulatory and governmental proceedings, the Company considers the likelihood of a negative outcome. If the Company determines the likelihood of a negative outcome with respect to any such matter is probable and the amount of the loss can be reasonably estimated, the Company records an accrual for the estimated loss for the expected outcome of the matter. If the likelihood of a negative outcome with respect to material matters is reasonably possible and the Company is able to determine an estimate of the possible loss or a range of loss, whether in excess of a related accrued liability or where there is no accrued liability, the Company discloses the estimate of the possible loss or range of loss. However, the Company is unable to estimate a possible loss or range of loss in some instances based on the significant uncertainties involved in, or the preliminary nature of, certain legal, regulatory and governmental matters. Government Investigations For the legal matters below, the Company cannot at this time assess what the outcome may be and is further unable to determine any estimate of loss or range of loss. The matters below are at a preliminary stage. Because of this and other factors, there are not sufficient facts available to make these assessments. • Tooele, Utah – Physician Compensation • Blue Island, Illinois – Patient Status Commercial Litigation and Other Lawsuits • Zwick Partners LP and Aparna Rao, Individually and On Behalf of All Others Similarly Situated v. Quorum Health Corporation, Community Health Systems, Inc., Wayne T. Smith, W. Larry Cash, Thomas D. Miller and Michael J. Culotta • Quorum Health Resources, LLC v. Hancock Medical Center. The matter relates to an arbitration claim and counterclaim for breach of contract and negligence arising out of a Management Services Agreement between QHR and the hospital. Arbitration in this case began on April 11, 2016 and concluded on April 22, 2016. On July 28, 2016, the arbitrator returned an Interim Award of $9.4 million in favor of Hancock Medical Center on various claims at issue in the arbitration. Both parties filed a motion for reconsideration of the Interim Award. On January 15, 2017, the arbitrator returned a final award of $12.6 million. The award is subject to a self-insured retention and excess insurance arrangements limiting the Company’s liability to $5.0 million. At December 31, 2016, the Company had a liability of $12.6 million and an insurance receivable of $8.9 million related to this matter. The award was paid in full on February 15, 2017 for $3.8 million. • United Tort Claimants v. Quorum Health Resources, LLC (U.S. Bankruptcy Court for the District of New Mexico); Douthitt-Dugger, et al. v. Quorum Health Resources, LLC (Bernalillo County, New Mexico District Court). Plaintiffs in these cases underwent surgical procedures at Gerald Champion Regional Medical Center in New Mexico that they contend were experimental and performed by an unqualified doctor. Their lawsuits, originally filed on June 11, 2010, against the doctors, QHR and the hospital are pending in state court and in federal bankruptcy court in New Mexico. Subject to an adverse result in the insurance coverage litigation referenced below, in 2012, QHR resolved plaintiffs’ claims for QHR’s liability exceeding insurance limits, and for liability not covered by insurance, for $5.1 million. Litigation of plaintiffs’ claims against QHR has continued, and the trial of the claims of most of the plaintiffs is proceeding in phases in a bankruptcy court bench trial. During the liability phase, on December 23, 2016, the federal bankruptcy court in New Mexico ruled that QHR was 16.5% at fault for plaintiffs’ injuries. The final phase, to determine plaintiffs’ damages and QHR offsets, is likely to be tried later in 2017. The New Mexico state court has set March 8, 2018 as the trial date for plaintiffs’ claims against QHR. QHR is vigorously defending the actions. QHR’s insurer Lexington Insurance Company is providing a defense in these cases, subject to a reservation of rights. Lexington has sued QHR in Williamson County, Tennessee seeking a declaration that plaintiffs’ claims and the cost of defending QHR are not covered by Lexington. ( Lexington Insurance Company v. Quorum Health Resources, LLC, et al. (Williamson County, Tennessee Chancery Court)) No trial date has been set for Lexington’s claim against QHR to nullify insurance coverage, which QHR also is vigorously defending. Insurance Reserves As part of the business of owning and operating hospitals, the Company is subject to potential professional and general liability and workers’ compensation liability claims or other legal actions alleging liability on its part. The Company is also subject to similar liabilities related to its QHR business. Prior to the Spin-off, CHS provided professional and general liability insurance and workers’ compensation liability insurance to QHC and indemnified QHC from losses under these insurance arrangements related to its hospital operations business. The liabilities for claims related to QHC’s hospital operations business were determined based on an actuarial study of QHC’s operations and historical claims experience at its hospitals. Corresponding receivables from CHS were established to reflect the indemnification by CHS for each of these liabilities for claims that related to events and circumstances that occurred prior to the Spin-off date. After the Spin-off, QHC entered into its own professional and general liability insurance and workers’ compensation liability insurance arrangements to mitigate the risk for claims exceeding its self-insured retention levels. The Company maintains a self-insured retention level for professional and general liability claims of $5 million per claim and maintains a $0.5 million per claim, high deductible program for workers’ compensation. Due to the differing nature of its business, the Company maintains separate insurance arrangements related to its subsidiary, QHR. The self-insured retention level for QHR is $6 million for professional and general liability insurance. The following tables provide a summary of the Company’s insurance reserves related to professional and general liability claims and workers’ compensation liability claims, distinguished between those indemnified by CHS and those related to the Company’s self-insurance risks (in thousands): March 31, 2017 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 25,570 $ 56,515 $ 25,570 $ 56,515 All other self-insurance reserves — — 799 19,547 Total insurance reserves for professional and general liability 25,570 56,515 26,369 76,062 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 4,486 17,979 4,486 17,979 All other self-insurance reserves — — 2,072 1,883 Total insurance reserves for workers' compensation liability 4,486 17,979 6,558 19,862 Total self-insurance reserves $ 30,056 $ 74,494 $ 32,927 $ 95,924 December 31, 2016 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 17,580 $ 59,652 $ 17,580 $ 59,652 All other self-insurance reserves — — 230 14,542 Total insurance reserves for professional and general liability 17,580 59,652 17,810 74,194 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 4,863 15,958 4,863 15,958 All other self-insurance reserves — — 1,736 1,458 Total insurance reserves for workers' compensation liability 4,863 15,958 6,599 17,416 Total self-insurance reserves $ 22,443 $ 75,610 $ 24,409 $ 91,610 The receivables from CHS are included in other current assets and other long-term assets on the consolidated and combined balance sheets. The liabilities for the current portion of professional and general liability claims are included in other current liabilities, while the current portion of workers’ compensation claims are recorded in accrued salaries and benefits. The long-term portions of both claims liabilities are recorded in other long-term liabilities. Physician Recruiting Commitments As part of its physician recruitment strategy, the Company provides income guarantee agreements to certain physicians who agree to relocate to its communities and commit to remain in practice there. Under such agreements, the Company is required to make payments to a physician in excess of the amount earned in his or her practice, up to the amount of the income guarantee. The income guarantee period over which the Company agrees to subsidize a physician’s income is typically one year and the commitment period over which the physician agrees to practice in the designated community is typically three years. Under the terms of the agreements, such payments are recoverable by the Company from physicians who do not fulfill their commitment periods. The Company’s recorded liabilities related to these income guarantee agreements were $1.3 million and $1.6 million at March 31, 2017 and December 31, 2016, respectively, which are included in other current liabilities on the consolidated and combined balance sheets. At March 31, 2017, the maximum potential amount of future payments under these guarantees in excess of the liabilities recorded was $1.9 million. Construction and Capital Commitments The Company is building a new patient tower and expanding surgical capacity at McKenzie – Willamette Medical Center, its hospital in Springfield, Oregon. During the three months ended March 31, 2017 and March 31, 2016, the Company incurred costs of $11.7 million and $6.9 million, respectively, related to this project. As of March 31, 2017, the Company has incurred a total of $60.6 million of costs for this project. The total estimated cost of this project, including equipment costs, is estimated to be approximately $105.0 million. The project is expected to be completed in early 2018.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2017
Subsequent Events [Abstract]
Subsequent Events	NOTE 18 - SUBSEQUENT EVENTS On April 6, 2017, the Company used the proceeds from the sale of Cherokee to pay down $4.3 million of additional principal on the Term Loan Facility. On April 11, 2017, the Company executed an agreement with its lenders pursuant to its Senior Credit Facility to amend the calculation of the Secured Net Leverage Ratio beginning January 1, 2017 to December 31, 2018, among other provisions. See Note 7 — Long-term Debt for additional information on the Company’s Senior Credit Facility and the terms of the CS Amendment. On April 17, 2017, the Company launched an offer to exchange the 11.625% Senior Notes due 2023 in the aggregate principal amount of $400 million, which are not registered under the Securities Act of 1933, as amended, for a like principal amount of 11.625% Senior Notes due 2023, which have been registered under the Act. The Exchange Offer expires on May 17, 2017, unless extended by the Company. The Exchange Notes are substantially identical to the Initial Notes, except that the Exchange Notes will be registered under the Securities Act and will not be subject to the transfer restrictions and certain registration rights agreement provisions applicable to the Initial Notes. On May 12, 2017, the Company announced that it has a definitive agreement to sell 45-bed McKenzie Regional Hospital, located in McKenzie, TN, and 45-bed Henderson County Community Hospital, located in Lexington, TN. The definitive agreement covers both hospitals and their affiliated outpatient facilities. The Company currently anticipates completing the sale of these hospitals in the third quarter of 2017.

Guarantor and Non-Guarantor Sup

Guarantor and Non-Guarantor Supplemental Information	3 Months Ended
	Mar. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Guarantor and Non-Guarantor Supplemental Information	NOTE 19 - GUARANTOR AND NON-GUARANTOR SUPPLEMENTAL INFORMATION The Senior Notes are senior unsecured obligations of the Company guaranteed on a senior basis by certain of its existing and subsequently acquired or organized 100% owned domestic subsidiaries (the “Guarantors”). The Senior Notes are fully and unconditionally guaranteed on a joint and several basis, with exceptions considered customary for such guarantees, limited to the release of the guarantee when a subsidiary guarantor’s capital stock is sold, or when a sale of all of the subsidiary guarantor’s assets used in operations occurs. These condensed consolidating and combining financial statements have been prepared and presented in accordance with SEC Regulation S-X Rule 3-10 “Financial Statements of Guarantors and Issuers of Guaranteed Securities Registered or Being Registered.” The accounting policies used in the preparation of this financial information are consistent with the accompanying condensed consolidated and combined financial statements of the Company, except as follows: • Intercompany receivables and payables are presented gross in the supplemental condensed consolidating and combining balance sheets. • Due to Parent and Due from Parent are presented gross in the supplemental condensed consolidating and combining balance sheets. • Investments in consolidated subsidiaries, as well as guarantor subsidiaries’ investments in non-guarantor subsidiaries, are presented under the equity method of accounting with the related investments presented within the line items net investment in subsidiaries and other long-term liabilities in the supplemental condensed consolidating and combining balance sheets. • Income tax expense is allocated from the parent issuer to the income producing operations (other guarantors and non-guarantors) through stockholders’ equity. As this approach represents an allocation, the income tax expense allocation is considered non-cash for statement of cash flow purposes. Following the Spin-off, the Company’s intercompany activity consists primarily of daily cash transfers, the allocation of certain expenses and expenditures paid by the parent issuer on behalf of its subsidiaries, and the push down of investment in its subsidiaries. The parent issuer’s investment in its subsidiaries reflects the activity of the period beginning April 29, 2016 through March 31, 2017. Likewise, the parent issuer’s equity in earnings of unconsolidated affiliates represents the Company’s earnings for the same post-spin period. Prior to the Spin-off, the Company’s intercompany activity consisted primarily of cash transfers and the allocation of certain expenses among the various subsidiaries, as well as the pushdown of the Guarantors’ investment in the subsidiary non-guarantors. Due to and due from Parent activity consist of the allocation of certain expenses and expenditures paid by CHS on behalf of QHC entities. The Company’s subsidiaries generally do not purchase services from one another; thus, the intercompany and due to and due from parent activity do not represent revenue generating transactions. Intercompany transactions eliminate in consolidation. Condensed Consolidating and Combining Statement of Income (Loss) Three Months Ended March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 449,000 $ 138,945 $ — $ 587,945 Provision for bad debts — 49,559 10,746 — 60,305 Net operating revenues — 399,441 128,199 — 527,640 Operating costs and expenses: Salaries and benefits — 181,022 83,580 — 264,602 Supplies — 45,873 17,949 — 63,822 Other operating expenses — 129,310 34,114 — 163,424 Depreciation and amortization — 18,528 3,592 — 22,120 Rent — 7,098 5,004 — 12,102 Electronic health records incentives earned — (1,457 ) (995 ) — (2,452 ) Legal, professional and settlement costs — 535 — — 535 Impairment of long-lived assets and goodwill — 3,300 — — 3,300 Loss (gain) on sale of hospitals, net — — (870 ) — (870 ) Transaction costs related to the Spin-off — 23 8 — 31 Total operating costs and expenses — 384,232 142,382 — 526,614 Income (loss) from operations — 15,209 (14,183 ) — 1,026 Interest expense, net 28,584 (1,056 ) 2 — 27,530 Equity in earnings of affiliates (1,747 ) 2,578 — (831 ) — Income (loss) before income taxes (26,837 ) 13,687 (14,185 ) 831 (26,504 ) Provision for (benefit from) income taxes 724 362 (385 ) — 701 Net income (loss) (27,561 ) 13,325 (13,800 ) 831 (27,205 ) Less: Net income (loss) attributable to noncontrolling interests — — 356 — 356 Net income (loss) attributable to Quorum Health Corporation $ (27,561 ) $ 13,325 $ (14,156 ) $ 831 $ (27,561 ) Condensed Consolidating and Combining Statement of Income (Loss) Three Months Ended March 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 459,747 $ 154,737 $ — $ 614,484 Provision for bad debts — 48,355 16,578 — 64,933 Net operating revenues — 411,392 138,159 — 549,551 Operating costs and expenses: Salaries and benefits — 172,202 84,660 — 256,862 Supplies — 44,781 18,880 — 63,661 Other operating expenses — 131,459 33,004 — 164,463 Depreciation and amortization — 25,490 5,667 — 31,157 Rent — 7,021 5,528 — 12,549 Electronic health records incentives earned — (3,999 ) (209 ) — (4,208 ) Legal, professional and settlement costs — 241 — — 241 Transaction costs related to the Spin-off — 2,798 937 — 3,735 Total operating costs and expenses — 379,993 148,467 — 528,460 Income (loss) from operations — 31,399 (10,308 ) — 21,091 Interest expense, net — 25,540 1,912 — 27,452 Income (loss) before income taxes — 5,859 (12,220 ) — (6,361 ) Provision for (benefit from) income taxes — 1,542 (3,216 ) — (1,674 ) Net income (loss) — 4,317 (9,004 ) — (4,687 ) Less: Net income (loss) attributable to noncontrolling interests — — 315 — 315 Net income (loss) attributable to Quorum Health Corporation $ — $ 4,317 $ (9,319 ) $ — $ (5,002 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net income (loss) $ (27,561 ) $ 13,325 $ (13,800 ) $ 831 $ (27,205 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 122 122 — (122 ) 122 Comprehensive income (loss) (27,439 ) 13,447 (13,800 ) 709 (27,083 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 356 — 356 Comprehensive income (loss) attributable to Quorum Health Corporation $ (27,439 ) $ 13,447 $ (14,156 ) $ 709 $ (27,439 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net income (loss) $ — $ 4,317 $ (9,004 ) $ — $ (4,687 ) Amortization and recognition of unrecognized pension cost components, net of income taxes — — — — — Comprehensive income (loss) — 4,317 (9,004 ) — (4,687 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 315 — 315 Comprehensive income (loss) attributable to Quorum Health Corporation $ — $ 4,317 $ (9,319 ) $ — $ (5,002 ) Condensed Consolidating and Combining Balance Sheet March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 77,938 $ 11,399 $ 205 $ — $ 89,542 Patient accounts receivable, net of allowance for doubtful accounts — 307,656 88,374 — 396,030 Inventories — 43,610 9,758 — 53,368 Prepaid expenses — 18,033 4,562 — 22,595 Due from third-party payors — 98,789 7,591 — 106,380 Current assets of hospitals held for sale — 5,810 3,257 — 9,067 Other current assets — 41,860 20,669 — 62,529 Total current assets 77,938 527,157 134,416 — 739,511 Intercompany receivable 3 204,933 111,078 (316,014 ) — Property and equipment, net — 604,882 115,482 — 720,364 Goodwill — 248,733 159,847 — 408,580 Intangible assets, net — 67,003 9,526 — 76,529 Long-term assets of hospitals held for sale — 17,083 9,690 — 26,773 Other long-term assets — 87,551 22,402 — 109,953 Net investment in subsidiaries 1,489,043 — — (1,489,043 ) — Total assets $ 1,566,984 $ 1,757,342 $ 562,441 $ (1,805,057 ) $ 2,081,710 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,411 $ 253 $ — $ 1,664 Accounts payable 205 154,156 20,519 — 174,880 Accrued liabilities: Accrued salaries and benefits — 68,333 29,797 — 98,130 Accrued interest 31,206 — — — 31,206 Due to third-party payors — 42,155 1,568 — 43,723 Current liabilities of hospitals held for sale — 1,420 931 — 2,351 Other current liabilities 268 39,125 10,139 — 49,532 Total current liabilities 31,679 306,600 63,207 — 401,486 Long-term debt 1,293,038 24,579 368 — 1,317,985 Intercompany payable 34,687 155,949 125,378 (316,014 ) — Deferred income tax liabilities, net 32,075 — — — 32,075 Other long-term liabilities — 173,817 24,282 (61,183 ) 136,916 Total liabilities 1,391,479 660,945 213,235 (377,197 ) 1,888,462 Redeemable noncontrolling interests — — 6,279 — 6,279 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 539,727 1,319,960 428,054 (1,748,014 ) 539,727 Accumulated other comprehensive income (loss) (2,638 ) (2,638 ) — 2,638 (2,638 ) Accumulated deficit (361,587 ) (220,925 ) (96,591 ) 317,516 (361,587 ) Total Quorum Health Corporation stockholders' equity 175,505 1,096,397 331,463 (1,427,860 ) 175,505 Nonredeemable noncontrolling interests — — 11,464 — 11,464 Total equity 175,505 1,096,397 342,927 (1,427,860 ) 186,969 Total liabilities and equity $ 1,566,984 $ 1,757,342 $ 562,441 $ (1,805,057 ) $ 2,081,710 Condensed Consolidating and Combining Balance Sheet December 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 21,609 $ 3,498 $ 348 $ — $ 25,455 Patient accounts receivable, net of allowance for doubtful accounts — 277,155 103,530 — 380,685 Inventories — 46,318 11,806 — 58,124 Prepaid expenses — 17,874 5,154 — 23,028 Due from third-party payors — 109,793 6,442 — 116,235 Current assets of hospitals held for sale — 1,502 — — 1,502 Other current assets — 41,673 16,269 — 57,942 Total current assets 21,609 497,813 143,549 — 662,971 Intercompany receivable 3 126,035 84,827 (210,865 ) — Property and equipment, net — 624,457 109,443 — 733,900 Goodwill — 252,433 164,400 — 416,833 Intangible assets, net — 73,404 11,578 — 84,982 Long-term assets of hospitals held for sale — 6,851 — — 6,851 Other long-term assets — 72,967 15,866 — 88,833 Net investment in subsidiaries 1,485,213 — — (1,485,213 ) — Total assets $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ 3,819 $ 1,560 $ 304 $ — $ 5,683 Accounts payable 158 147,521 22,005 — 169,684 Accrued liabilities: Accrued salaries and benefits — 69,896 28,907 — 98,803 Accrued interest 19,915 — — — 19,915 Due to third-party payors — 40,595 1,942 — 42,537 Current liabilities of hospitals held for sale — 492 — — 492 Other current liabilities — 46,002 7,266 — 53,268 Total current liabilities 23,892 306,066 60,424 - 390,382 Long-term debt 1,215,836 24,899 407 - 1,241,142 Intercompany payable 34,495 86,084 90,286 (210,865 ) — Deferred income tax liabilities, net 31,474 — — — 31,474 Other long-term liabilities — 144,950 22,651 (58,605 ) 108,996 Total liabilities 1,305,697 561,999 173,768 (269,470 ) 1,771,994 Redeemable noncontrolling interests — — 6,807 — 6,807 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 537,911 1,333,347 412,705 (1,746,052 ) 537,911 Accumulated other comprehensive income (loss) (2,760 ) (2,760 ) - 2,760 (2,760 ) Accumulated deficit (334,026 ) (238,626 ) (78,058 ) 316,684 (334,026 ) Total Quorum Health Corporation stockholders' equity 201,128 1,091,961 334,647 (1,426,608 ) 201,128 Nonredeemable noncontrolling interests — — 14,441 — 14,441 Total equity 201,128 1,091,961 349,088 (1,426,608 ) 215,569 Total liabilities and equity $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370 Condensed Consolidating and Combining Statement of Cash Flows Three Months Ended March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (15,121 ) $ 36,105 $ (2,458 ) $ — $ 18,526 Cash flows from investing activities: Capital expenditures for property and equipment — (9,537 ) (13,680 ) — (23,217 ) Capital expenditures for software — (1,269 ) (237 ) — (1,506 ) Proceeds from the sale of hospitals — — 4,282 — 4,282 Changes in intercompany balances with affiliates, net — (15,901 ) — 15,901 — Net cash provided by (used in) investing activities — (26,707 ) (9,635 ) 15,901 (20,441 ) Cash flows from financing activities: Borrowings (repayments) of revolving credit facilities, net 78,000 — — — 78,000 Repayments of long-term debt (6,550 ) (469 ) (90 ) — (7,109 ) Payments of debt issuance costs (47 ) — — — (47 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,028 ) — — (1,028 ) Cash distributions to noncontrolling investors — — (3,814 ) — (3,814 ) Changes in intercompany balances with affiliates, net 47 — 15,854 (15,901 ) — Net cash provided by (used in) financing activities 71,450 (1,497 ) 11,950 (15,901 ) 66,002 Net change in cash and cash equivalents 56,329 7,901 (143 ) — 64,087 Cash and cash equivalents at beginning of period 21,609 3,498 348 — 25,455 Cash and cash equivalents at end of period $ 77,938 $ 11,399 $ 205 $ — $ 89,542 Condensed Consolidating and Combining Statement of Cash Flows Three Months Ended March 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ — $ 44,593 $ (20,196 ) $ — $ 24,397 Cash flows from investing activities: Capital expenditures for property and equipment — (11,393 ) (1,447 ) — (12,840 ) Capital expenditures for software — (1,849 ) (677 ) — (2,526 ) Proceeds from asset sales — — 858 — 858 Other investing activities — (52 ) 104 — 52 Net cash provided by (used in) investing activities — (13,294 ) (1,162 ) — (14,456 ) Cash flows from financing activities: Borrowings of long-term debt — 20 — — 20 Repayments of long-term debt — (937 ) (152 ) — (1,089 ) Increase (decrease) in Due to Parent, net — (30,361 ) 23,875 — (6,486 ) Cash distributions to noncontrolling investors — — (2,484 ) — (2,484 ) Purchases of shares from noncontrolling investors — — (12 ) — (12 ) Net cash provided by (used in) financing activities — (31,278 ) 21,227 — (10,051 ) Net change in cash and cash equivalents — 21 (131 ) — (110 ) Cash and cash equivalents at beginning of period — 524 582 — 1,106 Cash and cash equivalents at end of period $ — $ 545 $ 451 $ — $ 996

Basis of Presentation and Sig27

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation (Policies)	Basis of Presentation The condensed consolidated and combined financial statements and accompanying notes of the Company presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP” or “GAAP”). In the opinion of the Company’s management, the condensed consolidated and combined financial information presented herein includes all adjustments necessary to present fairly the results of operations, financial position and cash flows of the Company for the interim periods presented. Results of operations for interim periods should not be considered indicative of the results of operations expected for the full year ending December 31, 2017. Certain information and disclosures have been condensed or omitted as presented herein and as permitted by the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim period presentation. The Company’s management believes the financial statements and disclosures presented herein are adequate in order to make the information presented not misleading. The condensed consolidated and combined financial statements should be read in conjunction with the consolidated and combined financial statements and accompanying notes thereto for the year ended December 31, 2016, contained in the Company’s Annual Report on Form 10-K filed with the SEC on April 12, 2017 (the “2016 Form 10-K”). Prior to its separation from CHS on April 29, 2016, QHC did not operate as a separate company and stand-alone financial statements were not historically prepared; however, QHC was comprised of certain stand-alone legal entities for which discrete financial information was available under CHS’ ownership. The accompanying condensed consolidated and combined financial statements include amounts and disclosures for QHC that have been derived from the consolidated financial statements and accounting records of CHS for the periods prior to the Spin-off in combination with the amounts and disclosures related to the stand-alone financial statements and accounting records of QHC after the Spin-off. The accompanying condensed consolidated and combined financial statements may not necessarily be indicative of the results of operations, financial position and cash flows of QHC in the future or those that would have occurred had the Company operated on a stand-alone basis during the entirety of the periods presented herein. See Note 16 — Related Party Transactions for additional information on the carve-out of financial information from CHS. The Company’s financial statements have been prepared under the assumption that it will continue as a going concern. The Company has limited stand-alone operating history and has experienced net losses in each of the quarters subsequent to the Spin-off from CHS. On December 31, 2016, the Company adopted Financial Accounting Standards Board’s (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, Presentation of Financial Statements — Going Concern, which requires management to evaluate if there are conditions or events that raise substantial doubt about an entity’s ability to continue as a going concern. As a result of adopting ASU No. 2014-15, management was required to evaluate the Company’s ability to comply with the Secured Net Leverage Ratio under its Senior Credit Facility for one year following the issuance of the financial statements for the three month period ended March 31, 2017. Although the Company was in compliance with its financial covenants as of March 31, 2017, the new standard requires management to base its evaluation about the ability to continue to comply with those covenants on results and events considered “probable” of occurring considering historical results, implemented plans, and executed agreements as of the date the financial statements are issued. In light of (i) the Company’s historical net operating results; (ii) delays in the approval by Centers for Medicare and Medicaid Services (“CMS”) of the California Hospital Quality Assurance Fee program for the 2017 to 2019 program period, which impacts the Company due to the inability to recognize any earned revenues until CMS approval of the program has been issued; and (iii) the amount of net operating losses from hospitals the Company intends to divest, management amended certain provisions of its Senior Credit Facility. On April 11, 2017, the Company executed an agreement with its Senior Credit Facility lenders to amend certain provisions of its Senior Credit Facility (the “CS Amendment”) to, among other things, raise the maximum Secured Net Leverage Ratio (as defined in the credit agreement (the “CS Agreement”), among the Company, the lenders party thereto and Credit Suisse AG, Cayman Islands Branch, as administrative agent and collateral agent) to 4.75x from 4.25x for the period July 1, 2017 to December 31, 2018 (which was previously 4.25x for the period July 1, 2017 to June 30, 2018), at which point it drops to 4.00x for the remainder of the agreement. The CS Amendment also provides for additional Consolidated EBITDA add backs under the covenant calculation for certain items. For additional information related to the CS Amendment, see Note 7 — Long-term Debt. Management has concluded that the CS Amendment alleviates any substantial doubt about its ability to continue as a going concern for the one year period following the issuance of its financial statements for the three month period ended March 31, 2017. The Company is actively engaged in initiatives to divest underperforming hospitals and outpatient facilities, for which proceeds will be used to pay down the Company’s term loan under its credit facility. For all defined terms related to the Company’s Senior Credit Facility, see Note 7 – Long-term Debt.
Principles of Consolidation and Combination (Policies)	Principles of Consolidation and Combination The consolidated and combined financial statements include the accounts of the Company and its subsidiaries in which it holds either a direct or indirect ownership of a majority voting interest. Investments in less-than-wholly-owned consolidated subsidiaries of QHC are presented separately in the equity component of the consolidated and combined balance sheets to distinguish between the interests of QHC and the interests of the noncontrolling investors. Revenues and expenses from these subsidiaries are included in the respective individual line items of the Company’s consolidated and combined statements of income, and net income is presented both in total and separately to distinguish the amounts attributable to the Company and the amounts attributable to the interests of the noncontrolling investors. Noncontrolling interests that are redeemable, or may become redeemable at a fixed or determinable price at the option of the holder or upon the occurrence of an event outside of the control of the Company, are presented in mezzanine equity in the consolidated and combined balance sheets. Intercompany transactions and accounts of the Company are eliminated in consolidation. Additionally, all significant transactions with CHS that occurred prior to the Spin-off were included in the consolidated and combined balance sheets within Due to Parent, net. This liability to CHS was settled in the Spin-off.
Reclassifications (Policies)	Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. In the third quarter of 2016, the Company reclassified and separately presented certain items in its consolidated and combined statements of cash flows. Specifically, changes in self-insurance reserves related to employee health, professional and general liability and workers’ compensation liability were reclassified to changes in reserves for self-insurance claims, net of payments, and changes in reserves for legal, professional and settlement costs were reclassified to changes in reserves for legal, professional and settlement costs, net of payments. The Company believes the current presentation more accurately distinguishes the changes in these liabilities from changes in operating assets and liabilities considered to be part of its normal business operations. Both items are included in cash flows from operating activities. Beginning in the second quarter of 2016, the Company began classifying equity in earnings of unconsolidated subsidiaries as other operating expenses in the consolidated and combined statements of income. Previously, these amounts were classified as non-operating income. These amounts are immaterial to the Company. This change in classification has no effect on the Company’s net income or cash flows included in previously issued consolidated and combined financial statements.
Use of Estimates (Policies)	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated and combined financial statements and accompanying notes. Actual results could differ from those estimates under different assumptions or conditions.
Revenue Recognition (Policies)	Revenue Recognition The Company recognizes revenues from patient services at its hospitals and affiliated facilities in the period services are performed and reports these revenues at the net realizable amount expected to be collected from patients and third-party payors. Billings and collections are outsourced to CHS under the transition services agreements that were entered into in connection with the Spin-off. See Note 16 — The amounts that are collected for patient services are generally less than established billing rates, or standard billing charges, due to contractual agreements with third-party payors, governmental programs that require reduced billing rates, discounts offered as incentives for payment, and a portion related to bad debts. The Company recognizes revenues related to its QHR business when management advisory and consulting services are provided and reports these revenues at the net realizable amount expected to be collected from the non-affiliated hospital clients. Payor Sources The primary sources of payment for patient healthcare services are third-party payors, including federal and state agencies administering the Medicare and Medicaid programs, other governmental agencies, managed care health plans, commercial insurance companies, workers’ compensation carriers and employers. Self-pay revenues are the portion of patient service revenues derived from patients who do not have health insurance coverage and the patient responsibility portion of services that are not covered by health insurance plans. Non-patient revenues primarily include revenues from QHR’s hospital management advisory and consulting services business, rental income and hospital cafeteria sales. Beginning in the second quarter of 2016, the Company began classifying its revenues related to Medicare Advantage Plans as Medicare revenues. As a result, the Company retroactively reclassified $41.7 million for the three months ended March 31, 2016 from managed care and commercial revenues to Medicare revenues. Revenues from Medicare Advantage Plans that are included in Medicare revenues in the table above were $48.3 million and $41.7 million for the three months ended March 31, 2017 and 2016, respectively. Contractual Allowances and Discounts The net realizable amount of patient service revenues due from third-party payors is subject to complexities and interpretations of payor-specific contractual agreements and governmental regulations that are frequently changing. The Medicare and Medicaid programs, which represent a large portion of the Company’s operating revenues, are highly complex programs to administer and are subject to interpretation of federal and state-specific reimbursement rates, new legislation and final cost report settlements. Contractual allowances, or differences in standard billing rates and the payments derived from contractual terms with governmental and non-governmental third–party payors, are recorded based on management’s best estimates in the period in which services are performed and a payment methodology is established with the patient. Recorded estimates for past contractual allowances are subject to change, in large part, due to ongoing contract negotiations and regulation changes, which are typical in the U.S. healthcare industry. Revisions to estimates are recorded as contractual allowance adjustments in the periods in which they become known and may be subject to further revisions. Self-pay and other payor discounts are incentives offered to uninsured or underinsured payors to reduce their costs of healthcare services with the purpose of maximizing the Company’s collection efforts. Third-Party Program Reimbursements Cost report settlements under reimbursement programs with Medicare, Medicaid and other managed care plans are estimated and recorded in the period the related services are performed and are adjusted in future periods, as needed, until the final cost report settlements are determined. Currently, several states utilize supplemental payment programs, including disproportionate share programs, for the purpose of providing reimbursement to providers to offset a portion of the cost of providing care to Medicaid and indigent patients. These programs are designed with input from CMS and are funded with a combination of federal and state resources, including, in certain instances, taxes, fees or other program expenses (collectively, “provider taxes”) levied on the providers. Similar programs are also currently being considered by other states. These amounts are included in due from and due to third-party payors in the consolidated and combined balance sheets. After a state supplemental payment program is approved and fully authorized by the appropriate state legislative or governmental agency, the Company recognizes revenue and related expenses based on the terms of the program in the period in which amounts are estimable and revenue collection is reasonably assured. The revenues earned by the Company under these programs are included in net operating revenues and the expenses associated with these programs are included in other operating expenses in the consolidated and combined statements of income. The California Department of Health Care Services implemented the California Hospital Quality Assurance Fee (“HQAF”) program, imposing a fee on certain general and acute care California hospitals. Revenues generated from these fees provide funding for the non-federal supplemental payments to California hospitals that serve California’s Medi-Cal and uninsured patients. Under the most recent phase of the program, covering the period January 2014 through December 2016, the Company recognized $11.0 million of Medicaid revenues and $2.7 million of provider taxes for the three months ended March 31, 2016 with no corresponding amounts for the three months ended March 31, 2017. The current program expired on December 31, 2016 and CMS has not approved a new program. Consistent with the first four phases of the HQAF program, the Company is not recognizing revenues under the pending program in 2017 or thereafter until CMS completes the approval process. Charity Care In the ordinary course of business, the Company provides services to patients who are financially unable to pay for hospital care. The related charges for those patients who are financially unable to pay that otherwise do not qualify for reimbursement from a governmental program are classified as charity care. The Company determines amounts that qualify for charity care primarily based on the patient’s household income relative to the poverty level guidelines established by the federal government. The Company’s policy is to not pursue collections for such amounts; therefore, the related charges are recorded in operating revenues at the standard billing rates and fully offset in contractual allowances. The gross amounts of charity care revenues were $12.5 million and $7.8 million for the three months ended March 31, 2017 and 2016, respectively.
Accounts Receivable and Allowance for Doubtful Accounts (Policies)	Accounts Receivable and Allowance for Doubtful Accounts Substantially all of the Company’s receivables are related to providing healthcare services to patients at its hospitals and affiliated outpatient facilities. Accounts receivable are reduced by an allowance for amounts that could become uncollectible in the future. The Company estimates the allowance for doubtful accounts by reserving a percentage of all self-pay accounts receivable without regard to aging category. The allowance percentage is based on a model that considers the historical write-off activity and is adjusted for expected recoveries and any anticipated changes in trends. The Company’s ability to estimate the allowance for doubtful accounts is not significantly impacted by the aging of accounts receivable, as management believes that substantially all of the risk exists at the point in time such accounts are identified as self-pay. For insured receivables, which are the non-self-pay receivables, the Company estimates the allowance for doubtful accounts based on a model that considers the uncontractualized portion of all accounts aging over 365 days from the date of patient discharge, reduced by an estimate for recoveries. Collections are impacted by the economic ability of patients to pay, the effectiveness of CHS’ billing and collection efforts, including their current policies on collections, and the ability of the Company to further attempt collection efforts. Billings and collections are outsourced to CHS under the transition services agreements that were established with the Spin-off. See Note 16 — Related Party Transactions for additional information on these agreements. Significant changes in payor mix, centralized business office operations, including the CHS shared service centers’ efforts in collecting the Company’s accounts receivable, economic conditions or trends in federal and state governmental healthcare coverage, among others, could affect the Company’s estimates of accounts receivable collectability. The Company also continually reviews its overall allowance adequacy by monitoring historical cash collections as a percentage of trailing net operating revenues after the provision for bad debts, as well as by analyzing current period net operating revenues and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables, and the impact of recent acquisitions and dispositions.
Concentration of Credit Risk (Policies)	Concentration of Credit Risk The Company grants unsecured credit to its patients, most of whom reside in the service area of the Company’s hospitals and affiliated facilities and are insured under third-party payor agreements. Because of the economic diversity of the Company’s markets and non-governmental third-party payors, Medicare represents a significant concentration of credit risk from payors. Accounts receivable, net of contractual allowances, from Medicare were $72.8 million and $72.6 million, or 9.7% and 9.8% of total patient accounts receivable, net as of March 31, 2017 and December 31, 2016, respectively. Additionally, due to fiscal problems in the state of Illinois, the Company believes Illinois Medicaid represents a concentration of credit risk. The Company’s accounts receivable, net of contractual allowances, from Illinois Medicaid were $38.5 million and $34.8 million, or 5.1% and 4.7% of total patient accounts receivable, net as of March 31, 2017 and December 31, 2016, respectively. The Company’s revenues are particularly sensitive to regulatory and economic changes in certain states where the Company generates significant revenues. Accordingly, any changes in the current demographic, economic, competitive or regulatory conditions in certain states in which revenues are significant could have an adverse effect on the Company’s results of operations, financial condition or cash flows. Changes to Medicaid and other government-managed payor programs in these states, including reductions in reimbursement rates or delays in reimbursement payments under state supplemental payment or other programs, could also have a similar adverse effect.
Other Operating Expenses (Policies)	Other Operating Expenses Following the Spin-off, the Company began recording costs associated with the transition services agreements and other ancillary agreements with CHS in accordance with the terms of these agreements. These costs, which primarily include the costs of providing information technology, patient billing and collections and payroll services, are included in “Transition services agreements and allocations from Parent” in the table above. Amounts allocated to the Company by CHS for periods prior to the Spin-off are also included in “Transition services agreements and allocations from Parent” in the table above. Prior to the Spin-off, QHC recorded a monthly corporate management fee from CHS that represented a portion of CHS’ corporate office costs, and this fee was included in other operating expenses. Following the Spin-off, the costs for corporate office functions are primarily included in salaries and benefits expenses in the consolidated and combined statements of income. See Note 16 —
General and Administrative Costs (Policies)	General and Administrative Costs Substantially all of the Company’s operating costs and expenses are “cost of revenues” items. Operating expenses that could be classified as general and administrative by the Company are costs related to corporate office functions, including, but not limited to tax, treasury, audit, risk management, legal, investor relations and human resources. These costs are primarily salaries and benefits expenses associated with these corporate office functions. General and administrative costs of the Company were $15.7 million and $12.0 million during the three months ended March 31, 2017 and 2016, respectively. Prior to the Spin-off, the majority of these costs were allocations from CHS. See Note 16 —
Electronic Health Records Incentives Earned (Policies)	Electronic Health Records Incentives Earned Pursuant to the Health Information Technology for Economic and Clinical Health Act (“HITECH”), the Company is eligible to receive incentive payments under the Medicare and Medicaid programs for its eligible hospitals and physician clinics that demonstrate meaningful use of certified Electronic Health Records (“EHR”) technology. Each of the Company’s eligible hospitals and physician clinics has completed the initial adoption phase of EHR implementation and is currently in the process of implementing the remaining two phases. EHR incentive payments are subject to audit and potential recoupment if it is determined that the applicable meaningful use standards were not met. EHR incentive payments are also subject to retrospective adjustment because the cost report data upon which the incentive payments are based are further subject to audit. The Company utilizes a gain contingency model to recognize EHR incentive payments. When the recognition criteria have been fully met, the Company recognizes the income from EHR incentives payments as a part of operating costs and expenses in the consolidated and combined statements of income. Medicaid EHR incentive payments are calculated based on prior period Medicare cost report information available at the time when eligible hospitals demonstrate meaningful use of certified EHR technology. Medicare EHR incentive payments are calculated when eligible hospitals demonstrate meaningful use of certified EHR technology and the information for the applicable full Medicare cost report year used to determine the final incentive payment is available. In some instances, the Company may receive estimated Medicare EHR incentive payments prior to when the Medicare cost report information used to determine the final incentive payment is available. In these instances, recognition of the income from EHR incentive payments is deferred until all recognition criteria are met. The Company recognizes r eceivables for EHR incentive payments that have been earned, but are uncollected at period end, as other current assets in the consolidated and combined balance sheets. The receivables are adjusted for any known audit or retrospective adjustments related to prior periods. Deferred revenue from EHR incentive payments is recorded in other current liabilities in the consolidated and combined balance sheets. The Company incurs both capital expenditures and operating expenses in connection with the implementation of EHR technology initiatives. The amounts and timing of these expenditures does not directly correlate with the timing of the Company’s receipt or recognition of EHR incentive payments as earned. As the Company completes its full implementation of certified EHR technology in accordance with all three phases of the program, its EHR incentive payments will decline and ultimately end.
Legal, Professional and Settlement Costs (Policies)	Legal, Professional and Settlement Costs Legal, professional and settlement costs in the consolidated and combined statements of income primarily includes legal costs and related settlements, if any, related to regulatory claims, government investigations into reimbursement payments and claims associated with QHR’s hospital management contracts. Professional costs include legal costs for investigations, data gathering and analysis associated with investigation projects approved by the Company’s Board of Directors (the “Board”).
Loss (Gain) on Sale of Hospitals, Net (Policies)	Loss (Gain) on Sale of Hospitals, Net Loss (gain) on sale of hospitals, net is the loss (gain) related to the Company’s divestiture of hospitals and their related ancillary facilities. It is calculated as the difference between the cash received from the sale and the carrying value of the associated net assets at the date of sale, less certain incremental direct selling costs.
Transaction Costs Related to the Spin-off (Policies)	Transaction Costs Related to the Spin-off Transaction costs related to the Spin-off consists of QHC’s portion of the costs to effect the Spin-off and the costs associated with forming a new company. These costs include audit, management advisory and consulting costs, investment advisory costs, legal expenses and other miscellaneous costs.
Income Taxes (Policies)	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company assesses the likelihood that deferred tax assets will be recovered from future taxable income. To the extent the Company believes that recovery is not likely, a valuation allowance is established. To the extent the Company establishes a valuation allowance or increases this allowance, the related expense is included in the provision for income taxes in the consolidated and combined statements of income. The Company classifies interest and penalties, if any, related to its tax positions as a component of income tax expense. See Note 11 —
Cash and Cash Equivalents (Policies)	Cash and Cash Equivalents Cash includes cash on hand and cash with banks. Cash equivalents are short-term, highly liquid investments with a maturity of three months or less from the date acquired that are subject to an insignificant risk of change in value.
Inventories (Policies)	Inventories Inventories, primarily consisting of medical supplies and drugs, are stated at the lower of cost or market on a first-in, first-out basis.
Property and Equipment (Policies)	Property and Equipment Purchases of property and equipment are recorded at cost. Property and equipment acquired in a business combination are recorded at estimated fair value. Routine maintenance and repairs are expensed as incurred. Expenditures that increase capacities or extend useful lives are capitalized. The Company capitalizes interest related to financing of major capital additions with the respective asset. Depreciation is recognized using the straight-line method over the estimated useful life of an asset. The Company depreciates land improvements over 3 to 20 years, buildings and improvements over 5 to 40 years, and equipment and fixtures over 3 to 18 years. The Company also leases certain facilities and equipment under capital lease obligations. These assets are amortized on a straight-line basis over the lesser of the lease term or the remaining useful life of the asset. Property and equipment assets that are held for sale are not depreciated.
Goodwill (Policies)	Goodwill The Company’s hospital operations and QHR’s hospital management advisory and consulting services operations meet the criteria to be classified as reporting units for goodwill. Goodwill was initially determined for QHC’s hospital operations reporting unit based on a relative fair value approach as of September 30, 2013 (CHS’ goodwill impairment testing date). Additional goodwill was allocated on a similar basis for four hospitals acquired by CHS in 2014 and included in the group of hospitals spun-off to QHC. For the QHR reporting unit, goodwill was allocated based on the amount recorded by CHS at the time of its acquisition in 2007. All subsequent goodwill generated from hospital, physician practice or other ancillary business acquisitions was recorded at fair value at the time of acquisition.
Intangible Assets (Policies)	Intangible Assets The Company’s intangible assets primarily consist of purchase and development costs of software for internal use and contract-based intangible assets, including physician guarantee contracts, medical licenses, hospital management contracts, non-compete agreements and certificates of need. There are no expected residual values related to the Company’s intangible assets. Capitalized software costs are generally amortized over three years, except for software costs for significant system conversions, which are amortized over 8 to 10 years. Capitalized software costs that are in the development stage are not amortized until the related projects are complete. Assets for physician guarantee contracts, hospital management contracts, non-compete agreements and certificates of need are amortized over the life of the individual contracts. Intangible assets held for sale are not amortized. The Company may, in the future, elect to incur costs to renew or extend the useful lives of certain of its intangible assets. Costs incurred to extend the useful life of capitalized software would be recognized as an intangible asset and amortized over the anticipated extension period. Costs incurred to renew certain contract-based intangibles, such as hospital management contracts and certificates of need, would be recognized as intangible assets and amortized over the respective renewed contract periods. The Company does not expect to extend or renew any of its physician guarantee contracts or non-compete agreements.
Impairment of Long-Lived Assets and Goodwill (Policies)	Impairment of Long-Lived Assets and Goodwill Whenever an event occurs or changes in circumstances indicate that the carrying values of certain long-lived assets may be impaired, the Company projects the undiscounted cash flows expected to be generated by these assets. If the projections indicate that the carrying values are not expected to be recovered, such amounts are reduced to their estimated fair value based on a quoted market price, if available, or an estimated fair value based on valuation techniques available in the circumstances. Goodwill arising from business combinations is not amortized. Goodwill is evaluated for impairment at the same time every year and when an event occurs or circumstances change that, more likely than not, reduce the fair value of the reporting unit below its carrying value. There is a two-step method for determining goodwill impairment. Step one is to compare the fair value of the reporting unit with the unit’s carrying amount, including goodwill. If this test indicates the fair value is less than the carrying value, then step two is required to compare the implied fair value of the reporting unit’s goodwill with the carrying value of the reporting unit’s goodwill. The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year. The fair value of the related reporting units is estimated using both a discounted cash flow model as well as a multiple model based on earnings before interest, taxes, depreciation and amortization. The cash flow forecasts are adjusted by an appropriate discount rate based on the Company’s best estimate of a market participant’s weighted-average cost of capital. Both models are based on the Company’s best estimate of future revenues and operating costs and are reconciled to the Company’s consolidated market capitalization, with consideration of the amount a potential acquirer would be required to pay, in the form of a control premium, in order to gain sufficient ownership to set policies, direct operations and control management decisions of the Company. See Note 3 —
Professional and General Liability and Workers’ Compensation Liability Insurance Reserves (Policies)	Professional and General Liability and Workers’ Compensation Liability Insurance Reserves As part of the business of owning and operating hospitals, the Company is subject to legal actions alleging liability on its part. To mitigate a portion of this risk, the Company maintains insurance exceeding a self-insured retention level for these types of claims. The Company’s self-insurance reserves reflect the current estimate of all outstanding losses, including incurred but not reported losses, based on actuarial calculations as of period end. The loss estimates included in the actuarial calculations may change in the future based on updated facts and circumstances. The Company’s insurance expense includes the actuarially determined estimate of losses for the current year, including claims incurred but not reported, the change in the estimate of losses for prior years based upon actual claims development experience as compared to prior actuarial projections, the insurance premiums for losses in excess of the Company’s self-insured retention levels, the administrative costs of the insurance programs, and interest expense related to the discounted portion of the liability. The Company’s reserves for workers’ compensation and professional and general liability claims are based on semi-annual actuarial calculations, which are discounted to present value and consider historical claims data, demographic factors, severity factors and other actuarial assumptions. The reserves for self-insured claims are discounted based on the Company’s risk-free interest rate that corresponds to the period when the self-insured claims are incurred and projected to be paid. See Note 17 — Self-Insured Employee Health Benefits The Company is self-insured for substantially all of the medical benefits of its employees. The Company maintains a liability for its current estimate of incurred but not reported employee health claims based on historical claims data provided by third-party administrators. The undiscounted reserve for self-insured employee health benefits was $8.8 million and $11.0 million as of March 31, 2017 and December 31, 2016, respectively and is included in accrued salaries and benefits in the consolidated and combined balance sheets. Expense each period is based on the actual claims received during the period plus any adjustment to the liability. Prior to the Spin-off, QHC was allocated employee health expense as part of the monthly corporate overhead charges from CHS. The allocation was determined based on claims made by QHC employees during the period plus an estimate for the change in liability related to QHC employee health claims incurred but not reported. The liability was included in Due to Parent, net in the consolidated and combined balance sheets, as the related employee health insurance policy was owned by CHS. Employee health expense is included in salaries and benefits expenses in the consolidated and combined statements of income for all periods. See Note 16 —
Noncontrolling Interests and Redeemable Noncontrolling Interests (Policies)	Noncontrolling Interests and Redeemable Noncontrolling Interests The Company’s consolidated and combined financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls. Certain of the Company’s consolidated subsidiaries have noncontrolling physician ownership interests with redemption features that require the Company to deliver cash upon the occurrence of certain events outside its control, such as the retirement, death, or disability of a physician-owner. The carrying amount of redeemable noncontrolling interests is recorded in the consolidated and combined balance sheets at the greater of: (1) the initial carrying amount, increased or decreased for the noncontrolling interests’ share of cumulative net income (loss), net of cumulative amounts distributed, if any, or (2) the redemption value.
Assets and Liabilities of Hospitals Held for Sale (Policies)	Assets and Liabilities of Hospitals Held for Sale The Company reports separately from other assets on the consolidated and combined balance sheet those assets that meet the criteria for classification as held for sale. Generally, assets that meet the criteria include those for which the carrying amount will be settled principally through a sale transaction rather than through continuing use. The asset must be available for immediate sale in its present condition, subject to usual or customary terms, and the sale must be probable to occur in the next 12 months. Similarly, the liabilities of a disposal group are classified as held for sale upon meeting these criteria. Immediately following classification as held for sale, the Company remeasures these assets and liabilities and adjusts the value to the lesser of the carrying amount or fair value less costs to sell. The assets and liabilities classified as held for sale are no longer depreciated or amortized into expense. The carrying value of assets classified as held for sale are reported net of impairment charges in the consolidated and combined balance sheets as of March 31, 2017 and December 31, 2016.
Stock-Based Compensation (Policies)	Stock-Based Compensation In connection with the Spin-off, the Company issued QHC restricted stock awards to all CHS restricted stock award holders as of the Record Date. Each holder of CHS restricted stock awards received one QHC restricted stock award for every four CHS restricted stock awards held. In addition, QHC employees that held CHS restricted stock awards were allowed to continue to hold the CHS awards under the same terms and conditions that existed prior to the Spin-off, excluding certain shares granted on March 1, 2016 that were canceled in connection with the Spin-off. The unrecognized compensation expense related to the vesting of the CHS restricted stock awards held by QHC employees was transferred to QHC with the Spin-off. As a result, the Company is responsible for recording stock-based compensation expense attributable to the unvested portion of CHS restricted stock awards held by QHC employees and the unvested portion of all QHC restricted stock awards held by its employees, consisting of both QHC awards issued on the Record Date and additional awards granted under the Quorum Health Corporation 2016 Stock Award Plan (the “2016 Stock Award Plan”) following the Spin-off. See Note 14 —
Benefit Plans (Policies)	Benefit Plans Following the Spin-off, the Company maintains various benefit plans, including defined contribution plans, a defined benefit plan and deferred compensation plans, for which certain of the Company’s subsidiaries are the plan sponsors. In connection with the Spin-off, the rights and obligations of these plans were transferred from CHS to the Company, pursuant to the Separation and Distribution Agreement. Prior to the Spin-off, QHC was allocated a portion of CHS’ benefit costs under its defined contribution plans. The allocation was based on specific identification for plans associated exclusively with QHC hospitals and on QHC’s proportional share of employees covered under all other applicable plans. The expense was recorded as salaries and benefits in the consolidated and combined statements of income, and the cumulative liability for these benefit costs, which was transferred to the Company in the Spin-off, was recorded in Due to Parent, net in the consolidated and combined balance sheets. QHC recognizes the unfunded liability of its defined benefit plan in other long-term liabilities in the consolidated and combined balance sheets. Unrecognized gains (losses) and prior service credits (costs) are recorded as changes in other comprehensive income (loss). The measurement date of the plan’s assets and liabilities coincides with the Company’s year end. The Company’s pension benefit obligation is measured using actuarial calculations that incorporate discount rates, rate of compensation increases and expected long-term returns on plan assets. The calculations additionally consider expectations related to the retirement age and mortality of plan participants. The Company records pension benefit costs related to all of its plans as salaries and benefits expenses in the consolidated and combined statements of income.
Segment Reporting (Policies)	Segment Reporting The principal business of the Company is to provide healthcare services at its hospitals and affiliated facilities. The Company’s only other line of business is the hospital management advisory and consulting services it provides through QHR. The Company has determined that its hospital operations business meets the criteria for separate segment reporting. The financial information for QHR’s business does not meet the quantitative thresholds for separate segment reporting, and therefore has been combined with the Company’s corporate functions into the all other reportable segment. See Note 13 —
New Accounting Pronouncements (Policies)	New Accounting Pronouncements In January 2017, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2017-04, Intangibles — In August 2016, the FASB issued ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which clarifies the classification of certain cash receipts and cash payments in the statement of cash flows. ASU No. 2016-15 is effective retrospectively for fiscal years beginning after December 15, 2017, including interim periods within those years. Early adoption is permitted. The Company is currently evaluating the impact this new guidance may have on its consolidated cash flows. In March 2016, the FASB issued ASU No. 2016-09, Compensation — Stock Compensation, In February 2016, the FASB issued ASU No. 2016-02, Leases, which amends the accounting for leases, requiring lessees to recognize most leases on their balance sheet with a right-of-use asset and a lease liability. Leases will be classified as either finance or operating leases, which will impact the expense recognition of such leases over the lease term. The ASU also modifies the lease classification criteria for lessors and eliminates some of the real estate leasing guidance previously applied for certain leasing transactions. This ASU is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. The Company expects to adopt this ASU on January 1, 2019. The Company utilizes a number of leases to support its operations. As such, the adoption of this ASU is expected to have a significant impact on the Company’s consolidated and combined financial position. The Company is currently evaluating the quantitative and qualitative impact the adoption of this ASU will have on its operations, policies and procedures. The Company is additionally evaluating any modifications to its leasing strategy in response to the requirements of this standard. In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, which outlines a single comprehensive model for recognizing revenue and supersedes most existing revenue recognition guidance, including guidance specific to the healthcare industry. This ASU provides companies the option of applying a full or modified retrospective approach upon adoption. This ASU is effective for fiscal years beginning after December 15, 2017, with early adoption permitted for annual periods beginning after December 15, 2016. The Company expects to adopt this ASU on January 1, 2018 and is currently evaluating its plan for adoption and the impact on its revenue recognition policies, procedures and internal control framework, and the resulting impact on its consolidated and combined results of operations, financial position and cash flows. The Company has established an implementation group for this ASU with an implementation plan to transition to the new standard and determine its impact during 2017. A significant element of executing this plan is the process of reviewing sources of revenue and evaluating the patient account population to determine the appropriate distribution of patient accounts into portfolios with similar collection experience that, when evaluated for collectability, will result in a materially consistent revenue amount for such portfolios as if each patient account was evaluated on a contract-by-contract basis. The Company expects this process will be completed later in 2017. The Company is also in the process of assessing the impact of the new standard on various reimbursement programs that represent variable consideration, including settlements with third party payors, disproportionate share payments, supplemental state Medicaid programs, bundled payment of care programs and other reimbursement programs in which the Company’s hospitals participate. Due to the many different forms of calculation and reimbursement that these programs take that vary from state to state, the application of the new accounting standard could have an impact on the revenue recognized for variable consideration. Moreover, industry guidance is continuing to develop around this issue, and any conclusions in the final industry guidance that is inconsistent with the Company’s application could result in changes to the Company’s expectations regarding the impact that this new accounting standard could have on the Company’s financial statements. Additionally, the adoption of the new accounting standard will impact the presentation on the Company’s statement of operations for a significant component of its provision for bad debts. After adoption of the new standard, the majority of what is currently classified as the provision for bad debts will be reflected as an implicit price concession as defined in the standard and therefore an adjustment to net patient revenue. The Company will continue to evaluate certain changes in collectability on its self-pay patient accounts receivable resulting from certain credit and collection issues not assessed at the date of service, including bankruptcy, and recognize such amounts in the provision for bad debts included in operating expenses on the statement of operations. The Company is in the process of evaluating the various approaches upon adoption and will finalize its selection in the second quarter of 2017. The Company cannot reasonably estimate at this time the quantitative impact that the adoption of this accounting standard will have on the financial statements of the Company.

Description of the Business a28

Description of the Business and Spin-Off (Tables)	3 Months Ended
	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Summary of Transactions to Effect the Spin-Off	The following table provides a summary of the major transactions to effect the Spin-off of QHC as a newly formed, independent company (dollars in thousands): Additional Long-Term Due to Common Stock Paid-in Parent's Debt Parent, Net Shares Amount Capital Equity Balance at April 29, 2016 (prior to the Spin-off) $ 24,179 $ 1,813,836 — $ — $ — $ 3,137 Borrowings of long-term debt, net of debt issuance discounts 1,255,464 — — — — — Payments of debt issuance costs (29,146 ) — — — — — Cash proceeds paid to Parent — (1,217,336 ) — — — — Transfer of liabilities from Parent — (22,292 ) — — — — Net deferred income tax liability resulting from the Spin-off — (46,783 ) — — — — Non-cash capital contribution from Parent — (527,425 ) — — 530,562 (3,137 ) Distribution of common stock — — 27,719,645 3 (3 ) — Distribution of restricted stock awards — — 692,409 — — — Balance at April 29, 2016 (after the Spin-off) $ 1,250,497 $ — 28,412,054 $ 3 $ 530,559 $ —
Summary of Liabilities Transferred from Parent	The following table provides a summary of the liabilities transferred to QHC from CHS in connection with the Spin-off (in thousands): April 29, Accounts payable $ 13,607 Benefit plan liabilities 5,964 Other liabilities 2,721 Total liabilities transferred from Parent $ 22,292

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Summary of Components of Net Operating Revenues Before Provision for Bad Debts	The following table provides a summary of the components of net operating revenues, before the provision for bad debts (in thousands): Three Months Ended March 31, 2017 2016 Operating revenues $ 3,068,323 $ 3,080,653 Less: Contractual allowances (2,371,292 ) (2,361,035 ) Less: Discounts (109,086 ) (105,134 ) Total net operating revenues, before the provision for bad debts $ 587,945 $ 614,484
Summary of Net Operating Revenues, Before the Provision for Bad Debts, by Payor Source	The following table provides a summary of net operating revenues, before the provision for bad debts, by payor source (dollars in thousands): Three Months Ended March 31, 2017 2016 $ Amount % of Total $ Amount % of Total Medicare $ 175,293 29.8 % $ 175,534 28.6 % Medicaid 96,669 16.4 % 103,068 16.8 % Managed care and commercial plans 231,557 39.4 % 244,284 39.8 % Self-pay 59,080 10.0 % 64,754 10.5 % Non-patient 25,346 4.4 % 26,844 4.3 % Total net operating revenues, before the provision for bad debts $ 587,945 100.0 % $ 614,484 100.0 %
Summary of Components of Amounts Due from and Due to Third-Party Payors	The following table provides a summary of the components of amounts due from and due to third-party payors (in thousands): March 31, December 31, 2017 2016 Amounts due from third-party payors: Previous program reimbursements and final cost report settlements $ 23,573 $ 23,876 State supplemental payment programs 82,807 92,359 Total amounts due from third-party payors $ 106,380 $ 116,235 Amounts due to third-party payors: Previous program reimbursements and final cost report settlements $ 34,675 $ 33,366 State supplemental payment programs 9,048 9,171 Total amounts due to third-party payors $ 43,723 $ 42,537
Summary of Portion of Medicaid Reimbursements Attributable to State Supplemental Payment Programs	The following table provides a summary of the portion of Medicaid reimbursements attributable to state supplemental payment programs (in thousands): Three Months Ended March 31, 2017 2016 Medicaid revenues $ 45,297 $ 52,215 Provider taxes and other expenses 16,893 19,426 Reimbursements attributable to state supplemental payment programs, net of expenses $ 28,404 $ 32,789
Summary of Components of Accounts Receivable Before Contractual Allowances Discounts and Allowance for Doubtful Accounts	The following table provides a summary of the components of accounts receivable before contractual allowances, discounts and allowance for doubtful accounts (dollars in thousands): March 31, 2017 December 31, 2016 $ Amount % of Total $ Amount % of Total Third-parties $ 2,050,321 75.8 % $ 1,930,103 74.6 % Self-pay 654,955 24.2 % 656,373 25.4 % Total patient accounts receivable, gross $ 2,705,276 100.0 % $ 2,586,476 100.0 %
Summary of Changes in Allowance for Doubtful Accounts	The following table provides a summary of the changes in the allowance for doubtful accounts (in thousands): Three Months Ended March 31, 2017 Balance at beginning of period $ 360,796 Provision for bad debts 60,305 Amounts written off, net of recoveries (63,904 ) Balance at end of period $ 357,197
Summary of States in Which Company Generates More Than 5% of its Total Revenues	The following table provides a summary of the states in which the Company generates more than 5% of total net patient revenues, before the provision for bad debts, as determined in each period (dollars in thousands): Number of Three Months Ended March 31, Hospitals at 2017 2016 March 31, 2017 $ Amount % of Total $ Amount % of Total Illinois 9 $ 203,372 36.1 % $ 201,851 34.3 % Oregon 1 52,996 9.4 % 52,848 9.0 % Georgia 3 45,876 8.2 % 54,254 9.2 % California 2 38,957 6.9 % 51,045 8.7 % Kentucky 3 30,984 5.5 % 30,892 5.3 % Alabama 2 28,629 5.1 % 27,312 4.6 %
Summary of Major Components of Other Operating Expenses	The following table provides a summary of the major components of other operating expenses (in thousands): Three Months Ended March 31, 2017 2016 Purchased services $ 45,596 $ 44,438 Taxes and insurance 34,243 35,306 Medical specialist fees 28,463 24,350 Transition services agreements and allocations from Parent 16,282 16,257 Repairs and maintenance 11,443 11,236 Utilities 6,665 7,155 Management fees from Parent — 8,826 Other miscellaneous operating expenses 20,732 16,895 Total other operating expenses $ 163,424 $ 164,463
Summary of Activity Related to Electronic Health Records Incentives	The following table provides a summary of activity related to EHR incentives (in thousands): Three Months Ended March 31, 2017 2016 Electronic health records incentives receivable at beginning of period $ 4,189 $ 11,227 Electronic health records incentives earned 2,452 4,208 Cash incentive payments received (842 ) (7,625 ) Adjustments to receivable based on final cost report settlement or audit (221 ) (1,925 ) Electronic health records incentives receivable at end of period $ 5,578 $ 5,885 Deferred revenue related to electronic health records incentives at beginning of period $ — $ — Cash received and deferred during period — (4,693 ) Recognition of deferred incentives as earned — — Deferred revenue related to electronic health records incentives at end of period $ — $ (4,693 ) Total electronic health records incentives earned during period $ 2,452 $ 4,208 Total cash incentive payments received during period 842 12,318

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2017
Property Plant And Equipment [Abstract]
Summary of Components of Property and Equipment	The following table provides a summary of the components of property and equipment (in thousands): March 31, December 31, 2017 2016 Property and equipment, at cost: Land and improvements $ 80,846 $ 84,474 Building and improvements 756,040 782,892 Equipment and fixtures 532,830 592,463 Construction in progress 65,556 60,146 Total property and equipment, at cost 1,435,272 1,519,975 Less: Accumulated depreciation and amortization (714,908 ) (786,075 ) Total property and equipment, net $ 720,364 $ 733,900

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Changes in Goodwill	The following table provides a summary of changes in goodwill (in thousands): Three Months Ended March 31, 2017 Balance at beginning of period $ 416,833 Reclassification to held-for-sale (6,885 ) Impairment (1,368 ) Balance at end of period $ 408,580
Summary of Intangible Assets	The following table provides a summary of intangible assets (in thousands): March 31, December 31, 2017 2016 Finite-lived intangible assets: Capitalized software costs: Cost $ 164,006 $ 180,855 Accumulated amortization (107,611 ) (118,391 ) Capitalized software costs, net 56,395 62,464 Physician guarantee contracts: Cost 8,148 11,355 Accumulated amortization (4,409 ) (6,329 ) Physician guarantee contracts, net 3,739 5,026 Other finite-lived intangible assets: Cost 43,883 44,342 Accumulated amortization (33,169 ) (33,059 ) Other finite-lived intangible assets, net 10,714 11,283 Total finite-lived intangible assets Cost 216,037 236,552 Accumulated amortization (145,189 ) (157,779 ) Total finite-lived intangible assets, net $ 70,848 $ 78,773 Indefinite-lived intangible assets: Tradenames $ 4,000 $ 4,000 Medical licenses and other indefinite-lived intangible assets 1,681 2,209 Total indefinite-lived intangible assets $ 5,681 $ 6,209 Total intangible assets: Cost $ 221,718 $ 242,761 Accumulated amortization (145,189 ) (157,779 ) Total intangible assets, net $ 76,529 $ 84,982
Summary of the Components of Amortization Expense	The following table provides a summary of the components of amortization expense (in thousands): Three Months Ended March 31, 2017 2016 Amortization of finite-lived intangible assets: Capitalized software costs $ 4,744 $ 6,595 Physician guarantee contracts 557 711 Other finite-lived intangible assets 569 757 Total amortization expense related to finite-lived intangible assets 5,870 8,063 Amortization of leasehold improvements and property and equipment assets held under capital lease obligations 456 683 Total amortization expense $ 6,326 $ 8,746

Long-Term Debt (Tables)

Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Summary of Components of Long-Term Debt	The following table provides a summary of the components of long-term debt (in thousands): March 31, December 31, 2017 2016 Senior Credit Facility: Revolving Credit Facility, maturing 2021 $ 39,000 $ — Term Loan Facility, maturing 2022 861,869 868,419 ABL Credit Facility, maturing 2021 39,000 — Senior Notes, maturing 2023 400,000 400,000 Unamortized debt issuance costs and discounts (46,831 ) (48,764 ) Capital lease obligations 25,224 25,588 Other debt 1,387 1,582 Total debt 1,319,649 1,246,825 Less: Current maturities of long-term debt (1,664 ) (5,683 ) Total long-term debt $ 1,317,985 $ 1,241,142
Summary of Maximum Secured Net Leverage Ratio Permitted Under Credit Facility	After giving effect to the CS Amendment, the maximum Secured Net Leverage Ratio permitted under the CS Agreement, as determined based on 12 month trailing Consolidated EBITDA and as defined in the CS Agreement, follows: Maximum Secured Net Period Leverage Ratio Period from January 1, 2017 to June 30, 2017 4.50 to 1.00 Period from July 1, 2017 to December 31, 2018 4.75 to 1.00 Period from January 1, 2019 and thereafter 4.00 to 1.00
Summary of Redemption Dates and Prices of Senior Notes	The following table provides a summary of the redemption dates and prices related to the Senior Notes: Redemption Period Prices Period from April 15, 2019 to April 14, 2020 108.719 % Period from April 15, 2020 to April 14, 2021 105.813 % Period from April 15, 2021 to April 14, 2022 102.906 % Period from April 15, 2022 to April 14, 2023 100.000 %
Summary of Unamortized Debt Issuance Costs and Discounts	The following table provides a summary of unamortized debt issuance costs and discounts (in thousands): March 31, December 31, 2017 2016 Debt issuance costs $ 29,193 $ 29,146 Debt discounts 24,536 24,536 Total debt issuance costs and discounts 53,729 53,682 Less: Amortization of debt issuance costs and discounts (6,898 ) (4,918 ) Total unamortized debt issuance costs and discounts $ 46,831 $ 48,764
Summary of Debt Maturities for Next Five Years and Thereafter	The following table provides a summary of debt maturities for the next five years and thereafter (in thousands): March 31, 2017 Remainder of 2017 $ 1,312 2018 7,786 2019 10,144 2020 10,245 2021 10,356 Thereafter 1,326,637 Total debt, excluding unamortized debt issuance costs and discounts $ 1,366,480
Summary of Components of Interest Expense, Net	The following table provides a summary of the components of interest expense, net (in thousands): Three Months Ended March 31, 2017 2016 Senior Credit Facility: Revolving Credit Facility $ 139 $ — Term Loan Facility 14,641 — ABL Credit Facility 256 — Senior Notes 11,626 — Amortization of debt issuance costs and discounts 1,980 — All other interest expense (income), net (1,112 ) 569 Total interest expense, net from long-term debt 27,530 569 Due to Parent, net — 26,883 Total interest expense, net $ 27,530 $ 27,452

Other Long-Term Liabilities (Ta

Other Long-Term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2017
Other Liabilities Disclosure [Abstract]
Summary of Components of Other Long-Term Liabilities	The following table provides a summary of the components of other long-term liabilities (in thousands): March 31, December 31, 2017 2016 Professional and general liability insurance reserves $ 76,062 $ 74,194 Workers' compensation liability insurance reserves 19,862 17,416 Benefit plan liabilities 34,737 10,722 Deferred rent 3,586 4,001 Other miscellaneous long-term liabilities 2,669 2,663 Total other long-term liabilities $ 136,916 $ 108,996

Fair Value of Financial Instr34

Fair Value of Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt	The following table provides a summary of the carrying amounts and estimated fair values of the Company’s long-term debt (in thousands): March 31, 2017 December 31, 2016 Carrying Estimated Carrying Estimated Amount Fair Value Amount Fair Value Revolving Credit Facility $ 39,000 $ 39,000 $ — $ — Term Loan Facility 861,869 843,554 868,419 849,427 ABL Credit Facility 39,000 39,000 — — Senior Notes 400,000 349,456 400,000 334,720 Other debt 26,611 26,611 27,170 27,170 Total debt, excluding unamortized debt issuance costs and discounts $ 1,366,480 $ 1,297,621 $ 1,295,589 $ 1,211,317

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Summary of Computation of Basic and Diluted Earnings (Loss) Per Share	The following table provides a summary of the computation of basic and diluted earnings (loss) per share (in thousands, except earnings per share and shares): Three Months Ended March 31, 2017 2016 Numerator: Net income (loss) $ (27,205 ) $ (4,687 ) Less: Net income (loss) attributable to noncontrolling interests 356 315 Net income (loss) attributable to Quorum Health Corporation $ (27,561 ) $ (5,002 ) Denominator: Weighted-average shares outstanding - basic and diluted 27,800,597 28,412,054 Basic and diluted earnings (loss) per share attributable to Quorum Health Corporation stockholders $ (0.99 ) $ (0.18 )

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Summary of Financial Information Related to Segments	The following tables provide a summary of financial information related to the Company’s segments (in thousands): Three Months Ended March 31, 2017 2016 Net operating revenues: Hospital operations $ 506,418 $ 527,424 All other 21,222 22,127 Total net operating revenues $ 527,640 $ 549,551 Adjusted EBITDA: Hospital operations $ 37,466 $ 52,171 All other (11,324 ) 4,053 Total Adjusted EBITDA $ 26,142 $ 56,224 March 31, December 31, 2017 2016 Assets: Hospital operations $ 1,812,402 $ 1,802,121 All other 269,308 192,249 Total assets $ 2,081,710 $ 1,994,370
Summary of Reconciliation of Adjusted EBITDA to Net Income (Loss)	The following table provides a reconciliation of Adjusted EBITDA to net income (loss), its most directly comparable U.S. GAAP financial measure (in thousands): Three Months Ended March 31, 2017 2016 Adjusted EBITDA $ 26,142 $ 56,224 Interest expense, net (27,530 ) (27,452 ) Provision for (benefit from) income taxes (701 ) 1,674 Depreciation and amortization (22,120 ) (31,157 ) Legal, professional and settlement costs (535 ) (241 ) Impairment of long-lived assets and goodwill (3,300 ) — Gain (loss) on sale of hospitals, net 870 — Transaction costs related to the Spin-off (31 ) (3,735 ) Net income (loss) $ (27,205 ) $ (4,687 )

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2017
Summary of Stock-Based Compensation Expense	The following table provides a summary of stock-based compensation expense (in thousands): Three Months Ended March 31, 2017 2016 Stock-based compensation resulting from the Spin-off $ 916 $ — Stock-based compensation related to grants following the Spin-off 1,881 — Total stock-based compensation expense $ 2,797 $ —
QHC Awards Distributed in Spin-off [Member]
Summary of Activity Related to Unvested Restricted Stock Awards	The following table provides a summary of the activity related to unvested QHC restricted stock awards held by QHC and CHS employees during the three months ended March 31, 2017 that were distributed in the Spin-off (in shares): QHC Awards Distributed in Spin-off QHC Employees CHS Employees Total Unvested restricted stock awards at December 31, 2016 52,462 621,525 673,987 Vested (33,599 ) (200,834 ) (234,433 ) Forfeited (13,928 ) (127,183 ) (141,111 ) Unvested restricted stock awards at March 31, 2017 4,935 293,508 298,443
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Summary of Activity Related to Unvested Restricted Stock Awards	The following table provides a summary of the activity related to unvested restricted stock awards during the three months ended March 31, 2017 that were granted to QHC employees subsequent to the Spin-off: QHC Awards Granted Subsequent to Spin-off Weighted- Average Grant Date Shares Fair Value Unvested restricted stock awards at December 31, 2016 1,081,005 $ 12.77 Granted 880,000 8.54 Vested — — Forfeited (17,667 ) 12.77 Unvested restricted stock awards at March 31, 2017 1,943,338 $ 10.85

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2017
Related Party Transactions [Abstract]
Summary of Allocated Costs from Parent	The following table provides a summary of allocated costs to QHC from CHS (in thousands): Three Months Ended March 31, 2016 Insurance costs $ 33,760 Management fees from Parent 8,826 All other allocated costs 19,715 Total related party operating costs and expenses $ 62,301

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Summary of Insurance Reserves Related to Professional and General Liability Claims and Workers' Compensation Claims	The following tables provide a summary of the Company’s insurance reserves related to professional and general liability claims and workers’ compensation liability claims, distinguished between those indemnified by CHS and those related to the Company’s self-insurance risks (in thousands): March 31, 2017 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 25,570 $ 56,515 $ 25,570 $ 56,515 All other self-insurance reserves — — 799 19,547 Total insurance reserves for professional and general liability 25,570 56,515 26,369 76,062 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 4,486 17,979 4,486 17,979 All other self-insurance reserves — — 2,072 1,883 Total insurance reserves for workers' compensation liability 4,486 17,979 6,558 19,862 Total self-insurance reserves $ 30,056 $ 74,494 $ 32,927 $ 95,924 December 31, 2016 Current Long-Term Current Long-Term Receivable Receivable Liability Liability Professional and general liability: Insurance reserves indemnified by CHS, Inc. $ 17,580 $ 59,652 $ 17,580 $ 59,652 All other self-insurance reserves — — 230 14,542 Total insurance reserves for professional and general liability 17,580 59,652 17,810 74,194 Workers' compensation liability: Insurance reserves indemnified by CHS, Inc. 4,863 15,958 4,863 15,958 All other self-insurance reserves — — 1,736 1,458 Total insurance reserves for workers' compensation liability 4,863 15,958 6,599 17,416 Total self-insurance reserves $ 22,443 $ 75,610 $ 24,409 $ 91,610

Guarantor and Non-Guarantor S40

Guarantor and Non-Guarantor Supplemental Information (Tables)	3 Months Ended
	Mar. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Schedule of Condensed Consolidating and Combining Statement of Income (Loss)	Condensed Consolidating and Combining Statement of Income (Loss) Three Months Ended March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 449,000 $ 138,945 $ — $ 587,945 Provision for bad debts — 49,559 10,746 — 60,305 Net operating revenues — 399,441 128,199 — 527,640 Operating costs and expenses: Salaries and benefits — 181,022 83,580 — 264,602 Supplies — 45,873 17,949 — 63,822 Other operating expenses — 129,310 34,114 — 163,424 Depreciation and amortization — 18,528 3,592 — 22,120 Rent — 7,098 5,004 — 12,102 Electronic health records incentives earned — (1,457 ) (995 ) — (2,452 ) Legal, professional and settlement costs — 535 — — 535 Impairment of long-lived assets and goodwill — 3,300 — — 3,300 Loss (gain) on sale of hospitals, net — — (870 ) — (870 ) Transaction costs related to the Spin-off — 23 8 — 31 Total operating costs and expenses — 384,232 142,382 — 526,614 Income (loss) from operations — 15,209 (14,183 ) — 1,026 Interest expense, net 28,584 (1,056 ) 2 — 27,530 Equity in earnings of affiliates (1,747 ) 2,578 — (831 ) — Income (loss) before income taxes (26,837 ) 13,687 (14,185 ) 831 (26,504 ) Provision for (benefit from) income taxes 724 362 (385 ) — 701 Net income (loss) (27,561 ) 13,325 (13,800 ) 831 (27,205 ) Less: Net income (loss) attributable to noncontrolling interests — — 356 — 356 Net income (loss) attributable to Quorum Health Corporation $ (27,561 ) $ 13,325 $ (14,156 ) $ 831 $ (27,561 ) Condensed Consolidating and Combining Statement of Income (Loss) Three Months Ended March 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Operating revenues, net of contractual allowances and discounts $ — $ 459,747 $ 154,737 $ — $ 614,484 Provision for bad debts — 48,355 16,578 — 64,933 Net operating revenues — 411,392 138,159 — 549,551 Operating costs and expenses: Salaries and benefits — 172,202 84,660 — 256,862 Supplies — 44,781 18,880 — 63,661 Other operating expenses — 131,459 33,004 — 164,463 Depreciation and amortization — 25,490 5,667 — 31,157 Rent — 7,021 5,528 — 12,549 Electronic health records incentives earned — (3,999 ) (209 ) — (4,208 ) Legal, professional and settlement costs — 241 — — 241 Transaction costs related to the Spin-off — 2,798 937 — 3,735 Total operating costs and expenses — 379,993 148,467 — 528,460 Income (loss) from operations — 31,399 (10,308 ) — 21,091 Interest expense, net — 25,540 1,912 — 27,452 Income (loss) before income taxes — 5,859 (12,220 ) — (6,361 ) Provision for (benefit from) income taxes — 1,542 (3,216 ) — (1,674 ) Net income (loss) — 4,317 (9,004 ) — (4,687 ) Less: Net income (loss) attributable to noncontrolling interests — — 315 — 315 Net income (loss) attributable to Quorum Health Corporation $ — $ 4,317 $ (9,319 ) $ — $ (5,002 )
Schedule of Condensed Consolidating and Combining Statement of Comprehensive Income (Loss)	Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net income (loss) $ (27,561 ) $ 13,325 $ (13,800 ) $ 831 $ (27,205 ) Amortization and recognition of unrecognized pension cost components, net of income taxes 122 122 — (122 ) 122 Comprehensive income (loss) (27,439 ) 13,447 (13,800 ) 709 (27,083 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 356 — 356 Comprehensive income (loss) attributable to Quorum Health Corporation $ (27,439 ) $ 13,447 $ (14,156 ) $ 709 $ (27,439 ) Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) Three Months Ended March 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net income (loss) $ — $ 4,317 $ (9,004 ) $ — $ (4,687 ) Amortization and recognition of unrecognized pension cost components, net of income taxes — — — — — Comprehensive income (loss) — 4,317 (9,004 ) — (4,687 ) Less: Comprehensive income (loss) attributable to noncontrolling interests — — 315 — 315 Comprehensive income (loss) attributable to Quorum Health Corporation $ — $ 4,317 $ (9,319 ) $ — $ (5,002 )
Schedule of Condensed Consolidating and Combining Balance Sheet	Condensed Consolidating and Combining Balance Sheet March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 77,938 $ 11,399 $ 205 $ — $ 89,542 Patient accounts receivable, net of allowance for doubtful accounts — 307,656 88,374 — 396,030 Inventories — 43,610 9,758 — 53,368 Prepaid expenses — 18,033 4,562 — 22,595 Due from third-party payors — 98,789 7,591 — 106,380 Current assets of hospitals held for sale — 5,810 3,257 — 9,067 Other current assets — 41,860 20,669 — 62,529 Total current assets 77,938 527,157 134,416 — 739,511 Intercompany receivable 3 204,933 111,078 (316,014 ) — Property and equipment, net — 604,882 115,482 — 720,364 Goodwill — 248,733 159,847 — 408,580 Intangible assets, net — 67,003 9,526 — 76,529 Long-term assets of hospitals held for sale — 17,083 9,690 — 26,773 Other long-term assets — 87,551 22,402 — 109,953 Net investment in subsidiaries 1,489,043 — — (1,489,043 ) — Total assets $ 1,566,984 $ 1,757,342 $ 562,441 $ (1,805,057 ) $ 2,081,710 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ — $ 1,411 $ 253 $ — $ 1,664 Accounts payable 205 154,156 20,519 — 174,880 Accrued liabilities: Accrued salaries and benefits — 68,333 29,797 — 98,130 Accrued interest 31,206 — — — 31,206 Due to third-party payors — 42,155 1,568 — 43,723 Current liabilities of hospitals held for sale — 1,420 931 — 2,351 Other current liabilities 268 39,125 10,139 — 49,532 Total current liabilities 31,679 306,600 63,207 — 401,486 Long-term debt 1,293,038 24,579 368 — 1,317,985 Intercompany payable 34,687 155,949 125,378 (316,014 ) — Deferred income tax liabilities, net 32,075 — — — 32,075 Other long-term liabilities — 173,817 24,282 (61,183 ) 136,916 Total liabilities 1,391,479 660,945 213,235 (377,197 ) 1,888,462 Redeemable noncontrolling interests — — 6,279 — 6,279 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 539,727 1,319,960 428,054 (1,748,014 ) 539,727 Accumulated other comprehensive income (loss) (2,638 ) (2,638 ) — 2,638 (2,638 ) Accumulated deficit (361,587 ) (220,925 ) (96,591 ) 317,516 (361,587 ) Total Quorum Health Corporation stockholders' equity 175,505 1,096,397 331,463 (1,427,860 ) 175,505 Nonredeemable noncontrolling interests — — 11,464 — 11,464 Total equity 175,505 1,096,397 342,927 (1,427,860 ) 186,969 Total liabilities and equity $ 1,566,984 $ 1,757,342 $ 562,441 $ (1,805,057 ) $ 2,081,710 Condensed Consolidating and Combining Balance Sheet December 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated ASSETS Current assets: Cash and cash equivalents $ 21,609 $ 3,498 $ 348 $ — $ 25,455 Patient accounts receivable, net of allowance for doubtful accounts — 277,155 103,530 — 380,685 Inventories — 46,318 11,806 — 58,124 Prepaid expenses — 17,874 5,154 — 23,028 Due from third-party payors — 109,793 6,442 — 116,235 Current assets of hospitals held for sale — 1,502 — — 1,502 Other current assets — 41,673 16,269 — 57,942 Total current assets 21,609 497,813 143,549 — 662,971 Intercompany receivable 3 126,035 84,827 (210,865 ) — Property and equipment, net — 624,457 109,443 — 733,900 Goodwill — 252,433 164,400 — 416,833 Intangible assets, net — 73,404 11,578 — 84,982 Long-term assets of hospitals held for sale — 6,851 — — 6,851 Other long-term assets — 72,967 15,866 — 88,833 Net investment in subsidiaries 1,485,213 — — (1,485,213 ) — Total assets $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370 LIABILITIES AND EQUITY Current liabilities: Current maturities of long-term debt $ 3,819 $ 1,560 $ 304 $ — $ 5,683 Accounts payable 158 147,521 22,005 — 169,684 Accrued liabilities: Accrued salaries and benefits — 69,896 28,907 — 98,803 Accrued interest 19,915 — — — 19,915 Due to third-party payors — 40,595 1,942 — 42,537 Current liabilities of hospitals held for sale — 492 — — 492 Other current liabilities — 46,002 7,266 — 53,268 Total current liabilities 23,892 306,066 60,424 - 390,382 Long-term debt 1,215,836 24,899 407 - 1,241,142 Intercompany payable 34,495 86,084 90,286 (210,865 ) — Deferred income tax liabilities, net 31,474 — — — 31,474 Other long-term liabilities — 144,950 22,651 (58,605 ) 108,996 Total liabilities 1,305,697 561,999 173,768 (269,470 ) 1,771,994 Redeemable noncontrolling interests — — 6,807 — 6,807 Equity: Quorum Health Corporation stockholders' equity: Preferred stock — — — — — Common stock 3 — — — 3 Additional paid-in capital 537,911 1,333,347 412,705 (1,746,052 ) 537,911 Accumulated other comprehensive income (loss) (2,760 ) (2,760 ) - 2,760 (2,760 ) Accumulated deficit (334,026 ) (238,626 ) (78,058 ) 316,684 (334,026 ) Total Quorum Health Corporation stockholders' equity 201,128 1,091,961 334,647 (1,426,608 ) 201,128 Nonredeemable noncontrolling interests — — 14,441 — 14,441 Total equity 201,128 1,091,961 349,088 (1,426,608 ) 215,569 Total liabilities and equity $ 1,506,825 $ 1,653,960 $ 529,663 $ (1,696,078 ) $ 1,994,370
Schedule of Condensed Consolidating and Combining Statement of Cash Flows	Condensed Consolidating and Combining Statement of Cash Flows Three Months Ended March 31, 2017 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ (15,121 ) $ 36,105 $ (2,458 ) $ — $ 18,526 Cash flows from investing activities: Capital expenditures for property and equipment — (9,537 ) (13,680 ) — (23,217 ) Capital expenditures for software — (1,269 ) (237 ) — (1,506 ) Proceeds from the sale of hospitals — — 4,282 — 4,282 Changes in intercompany balances with affiliates, net — (15,901 ) — 15,901 — Net cash provided by (used in) investing activities — (26,707 ) (9,635 ) 15,901 (20,441 ) Cash flows from financing activities: Borrowings (repayments) of revolving credit facilities, net 78,000 — — — 78,000 Repayments of long-term debt (6,550 ) (469 ) (90 ) — (7,109 ) Payments of debt issuance costs (47 ) — — — (47 ) Cancellation of restricted stock awards for payroll tax withholdings on vested shares — (1,028 ) — — (1,028 ) Cash distributions to noncontrolling investors — — (3,814 ) — (3,814 ) Changes in intercompany balances with affiliates, net 47 — 15,854 (15,901 ) — Net cash provided by (used in) financing activities 71,450 (1,497 ) 11,950 (15,901 ) 66,002 Net change in cash and cash equivalents 56,329 7,901 (143 ) — 64,087 Cash and cash equivalents at beginning of period 21,609 3,498 348 — 25,455 Cash and cash equivalents at end of period $ 77,938 $ 11,399 $ 205 $ — $ 89,542 Condensed Consolidating and Combining Statement of Cash Flows Three Months Ended March 31, 2016 (In Thousands) Parent Other Non- Issuer Guarantors Guarantors Eliminations Consolidated Net cash provided by (used in) operating activities $ — $ 44,593 $ (20,196 ) $ — $ 24,397 Cash flows from investing activities: Capital expenditures for property and equipment — (11,393 ) (1,447 ) — (12,840 ) Capital expenditures for software — (1,849 ) (677 ) — (2,526 ) Proceeds from asset sales — — 858 — 858 Other investing activities — (52 ) 104 — 52 Net cash provided by (used in) investing activities — (13,294 ) (1,162 ) — (14,456 ) Cash flows from financing activities: Borrowings of long-term debt — 20 — — 20 Repayments of long-term debt — (937 ) (152 ) — (1,089 ) Increase (decrease) in Due to Parent, net — (30,361 ) 23,875 — (6,486 ) Cash distributions to noncontrolling investors — — (2,484 ) — (2,484 ) Purchases of shares from noncontrolling investors — — (12 ) — (12 ) Net cash provided by (used in) financing activities — (31,278 ) 21,227 — (10,051 ) Net change in cash and cash equivalents — 21 (131 ) — (110 ) Cash and cash equivalents at beginning of period — 524 582 — 1,106 Cash and cash equivalents at end of period $ — $ 545 $ 451 $ — $ 996

Description of the Business a41

Description of the Business and Spin-Off (Narrative) (Details)	Apr. 29, 2016USD ($)Hospital$ / sharesshares	Apr. 22, 2016USD ($)	Mar. 31, 2017USD ($)Hospitalbedstate$ / shares	Dec. 31, 2016USD ($)$ / shares
Description Of Business And Spin Off [Line Items]
Number of hospitals owned or leased | Hospital			35
Number of licensed beds | bed			3,399
Number of States in which Entity Operates | state			16
Common stock, par value | $ / shares			$ 0.0001	$ 0.0001
Cash proceeds paid to Parent	$ 1,217,336,000
Debt Instrument, Unamortized Discount			$ 24,536,000	$ 24,536,000
Contributed capital, in excess of par value of common stock			539,727,000	$ 537,911,000
Senior Notes, maturing 2023 [Member]
Description Of Business And Spin Off [Line Items]
Debt Instrument, Face Amount		$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt Instrument, Unamortized Discount		$ 6,900,000
Debt instrument issue discount percentage		1.734%
ABL Credit Facility, maturing 2021 [Member]
Description Of Business And Spin Off [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	125,000,000		$ 86,000,000
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Description Of Business And Spin Off [Line Items]
Debt Instrument, Face Amount	880,000,000
Debt Instrument, Unamortized Discount	$ 17,600,000
Term Facility Issued Percentage on Par Value	98.00%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Description Of Business And Spin Off [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000,000
Spin-off from CHS [Member]
Description Of Business And Spin Off [Line Items]
Number of hospitals owned or leased | Hospital	38
Percentage ownership of number of stock shares held by the parent	100.00%
Common stock, par value | $ / shares	$ 0.0001
Record date for stockholders of the parent to be eligible to receive share distribution in spin-off	Apr. 22, 2016
Number of shares distributed to each stockholder in spin-off | shares	1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares	4
Contributed capital, in excess of par value of common stock	$ 530,600,000
Cash contribution from parent	13,500,000
Cash contribution from parent for initial working capital	20,000,000
Differences in estimated and actual financing transaction fees for the Spin-off	$ 6,500,000
Sales Revenue, Segment [Member] | Segment Concentration Risk [Member] | Hospital Operations Reporting Unit [Member]
Description Of Business And Spin Off [Line Items]
Concentration risk, percentage			95.00%

Description of the Business a42

Description of the Business and Spin-Off - Summary of Transactions to Effect the Spin-Off (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Mar. 31, 2017	Mar. 31, 2016
Description Of Business And Spin Off [Line Items]
Long-Term Debt, balance at April 29, 2016 (prior to the spin-off)	$ 24,179	$ 1,241,142
Borrowings of long-term debt, net of debt issuance discounts	1,255,464
Payments of debt issuance costs	(29,146)	(47)	$ 0
Long-Term Debt, balance at April 29, 2016 (after the spin-off)	1,250,497	1,317,985
Due to Parent, Net, balance at April 29, 2016 (prior to the spin-off)	1,813,836
Cash proceeds paid to Parent	(1,217,336)
Transfer of liabilities from Parent	(22,292)
Net deferred income tax liability resulting from the Spin-off	(46,783)
Non-cash capital contribution from Parent	(527,425)
Due to Parent, Net, balance at April 29, 2016 (after the spin-off)	$ 0
Stockholders' equity, beginning balance		$ 215,569	15,943
Stockholders' equity, beginning balance, shares		29,482,050
Stockholders' equity, ending balance		$ 186,969	14,211
Stockholders' equity, ending balance, shares	28,412,054	30,203,170
Common Stock [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	$ 0	$ 3
Stockholders' equity, beginning balance, shares	0	29,482,050
Distribution of common stock	$ 3
Distribution of common stock, shares	27,719,645
Distribution of restricted stock awards	$ 0
Distribution of restricted stock awards, shares	692,409
Stockholders' equity, ending balance	$ 3	$ 3
Stockholders' equity, ending balance, shares	28,412,054	30,203,170
Additional Paid-In Capital [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	$ 0	$ 537,911
Non-cash capital contribution from Parent	530,562
Distribution of common stock	(3)
Stockholders' equity, ending balance	530,559	$ 539,727
Parent [Member]
Description Of Business And Spin Off [Line Items]
Stockholders' equity, beginning balance	3,137		3,184
Non-cash capital contribution from Parent	(3,137)
Stockholders' equity, ending balance	$ 0		$ 3,137

Description of the Business a43

Description of the Business and Spin-Off - Summary of Liabilities Transferred from Parent (Details) - Spin-off from CHS [Member] $ in Thousands	Apr. 29, 2016USD ($)
Description Of Business And Spin Off [Line Items]
Total liabilities transferred from Parent	$ 22,292
Accounts Payable [Member]
Description Of Business And Spin Off [Line Items]
Total liabilities transferred from Parent	13,607
Benefit Plan Liabilities [Member]
Description Of Business And Spin Off [Line Items]
Total liabilities transferred from Parent	5,964
Other Liabilities [Member]
Description Of Business And Spin Off [Line Items]
Total liabilities transferred from Parent	$ 2,721

Basis of Presentation and Sig44

Basis of Presentation and Significant Accounting Policies (Narrative) (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2017USD ($)Hospital	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2014Hospital	Apr. 29, 2016shares
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts	$ 587,945,000	$ 614,484,000
Reclassification from managed care and commercial revenues to Medicare revenues		41,700,000
Increase (decrease) in net operating revenues during period for contractual allowance adjustments related to final cost report settlements on previous program reimbursements	(1,400,000)	(1,800,000)
Operating revenues	3,068,323,000	3,080,653,000
Provider taxes and other expenses	526,614,000	528,460,000
Accounts receivable, net of contractual allowances	396,030,000		$ 380,685,000
General and administrative costs	15,700,000	12,000,000
Acquired finite-lived intangible asset, residual value	$ 0
New date of annual goodwill impairment test	The Company performs its annual testing of impairment for goodwill in the fourth quarter of each year.
Noncontrolling interests and redeemable noncontrolling interests	The Company’s consolidated and combined financial statements include all assets, liabilities, revenues and expenses of less than 100% owned entities that it controls.
Maximum period during which assets held for sale sold	12 months
Spin-off from CHS [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of shares distributed to each stockholder in spin-off | shares					1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares					4
Restricted Stock [Member] | Spin-off from CHS [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of shares distributed to each stockholder in spin-off | shares					1
Number of shares held by each stockholder of the parent used to determine share distribution in spin-off | shares					4
Accrued Salaries and Benefits [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Undiscounted reserve for self-insured employee health benefits	$ 8,800,000		$ 11,000,000
Capitalized Internal Use Software, Except Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	3 years
Community Health Systems, Inc [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of Hospitals | Hospital				4
Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of Hospitals | Hospital	9
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage	100.00%		100.00%
Sales Revenue, Net [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage	5.00%		5.00%
Medicare Revenues [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts	$ 48,300,000	41,700,000
California Hospital Quality Assurance Fee [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues	0	11,000,000
Provider taxes and other expenses	0	2,700,000
Charity Care [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues	12,500,000	7,800,000
Medicare [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts	175,293,000	175,534,000
Accounts receivable, net of contractual allowances	$ 72,800,000		$ 72,600,000
Medicare [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage	9.70%		9.80%
Medicaid [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Operating revenues, net of contractual allowances and discounts	$ 96,669,000	$ 103,068,000
Medicaid [Member] | Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Accounts receivable, net of contractual allowances	$ 38,500,000		$ 34,800,000
Medicaid [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member] | Illinois [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Concentration risk, percentage	5.10%		4.70%
Maximum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	10 years
Maximum [Member] | Land Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset	20 years
Maximum [Member] | Buildings and Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset	40 years
Maximum [Member] | Equipment and Fixtures [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset	18 years
Minimum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Number of days from date of discharge in which company establishes doubtful accounts reserve on non-self pay payor receivables	365 days
Minimum [Member] | Capitalized Internal Use Software, Significant System Conversions [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Finite-lived intangible assets, useful life	8 years
Minimum [Member] | Land Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset	3 years
Minimum [Member] | Buildings and Improvements [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset	5 years
Minimum [Member] | Equipment and Fixtures [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Estimated useful life of asset	3 years
Senior Credit Facility [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Secured net leverage ratio	383.00%		393.00%
Senior Credit Facility [Member] | Period from July 1, 2017 to December 31, 2018 [Member] | Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Secured net leverage ratio	475.00%
Senior Credit Facility [Member] | Period from July 1, 2017 to June 30, 2018 [Member] | Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Secured net leverage ratio	425.00%
Senior Credit Facility [Member] | Period from January 1, 2019 and thereafter [Member] | Maximum [Member]
Basis Of Presentation And Significant Accounting Policies [Line Items]
Secured net leverage ratio	400.00%

Basis of Presentation and Sig45

Basis of Presentation and Significant Accounting Policies (Summary of Components of Net Operating Revenues Before Provision for Bad Debts) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Health Care Organizations [Abstract]
Operating revenues	$ 3,068,323	$ 3,080,653
Less: Contractual allowances	(2,371,292)	(2,361,035)
Less: Discounts	(109,086)	(105,134)
Total net operating revenues, before the provision for bad debts	$ 587,945	$ 614,484

Basis of Presentation and Sig46

Basis of Presentation and Significant Accounting Policies (Summary of Net Operating Revenues, Before the Provision for Bad Debts, by Payor Source) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 587,945	$ 614,484
Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	100.00%	100.00%
Medicare [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 175,293	$ 175,534
Medicare [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	29.80%	28.60%
Medicaid [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 96,669	$ 103,068
Medicaid [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	16.40%	16.80%
Managed Care and Commercial Plans [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 231,557	$ 244,284
Managed Care and Commercial Plans [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	39.40%	39.80%
Self-Pay [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 59,080	$ 64,754
Self-Pay [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	10.00%	10.50%
Non-Patient [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Total net operating revenues, before the provision for bad debts	$ 25,346	$ 26,844
Non-Patient [Member] | Sales Revenue, Net [Member] | Payor Concentration Risk [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Concentration risk, percentage	4.40%	4.30%

Basis of Presentation and Sig47

Basis of Presentation and Significant Accounting Policies (Summary of Components of Amounts Due from and Due to Third-Party Payors) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	$ 106,380	$ 116,235
Due to third-party payors	43,723	42,537
Previous Program Reimbursements and Final Cost Report Settlements [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	23,573	23,876
Due to third-party payors	34,675	33,366
State Supplemental Payment Programs [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Due from third-party payors	82,807	92,359
Due to third-party payors	$ 9,048	$ 9,171

Basis of Presentation and Sig48

Basis of Presentation and Significant Accounting Policies (Summary of Portion of Medicaid Reimbursements Attributable to State Supplemental Payment Programs) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Medicaid revenues	$ 3,068,323	$ 3,080,653
Provider taxes and other expenses	526,614	528,460
State Supplemental Payment Programs [Member]
Health Care Organization Receivable And Revenue Disclosures [Line Items]
Medicaid revenues	45,297	52,215
Provider taxes and other expenses	16,893	19,426
Reimbursements attributable to state supplemental payment programs, net of expenses	$ 28,404	$ 32,789

Basis of Presentation and Sig49

Basis of Presentation and Significant Accounting Policies (Summary of Components of Accounts Receivable Before Contractual Allowances Discounts and Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Accounts Notes And Loans Receivable [Line Items]
Total patient accounts receivable gross, Amount	$ 2,705,276	$ 2,586,476
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Accounts Notes And Loans Receivable [Line Items]
Concentration risk, percentage	100.00%	100.00%
Third-Parties [Member]
Accounts Notes And Loans Receivable [Line Items]
Total patient accounts receivable gross, Amount	$ 2,050,321	$ 1,930,103
Third-Parties [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Accounts Notes And Loans Receivable [Line Items]
Concentration risk, percentage	75.80%	74.60%
Self-Pay [Member]
Accounts Notes And Loans Receivable [Line Items]
Total patient accounts receivable gross, Amount	$ 654,955	$ 656,373
Self-Pay [Member] | Accounts Receivable [Member] | Credit Concentration Risk [Member]
Accounts Notes And Loans Receivable [Line Items]
Concentration risk, percentage	24.20%	25.40%

Basis of Presentation and Sig50

Basis of Presentation and Significant Accounting Policies (Summary of Changes in Allowance for Doubtful Accounts) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Accounting Policies [Abstract]
Balance at beginning of period	$ 360,796
Provision for bad debts	60,305
Amounts written off, net of recoveries	(63,904)
Balance at end of period	$ 357,197

Basis of Presentation and Sig51

Basis of Presentation and Significant Accounting Policies (Summary of States in Which Company Generates More Than 5% of its Total Revenues) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)Hospital	Mar. 31, 2016USD ($)
Concentration Risk [Line Items]
Total net operating revenues before the provision for bad debts, Amount	$ 527,640	$ 549,551
Illinois [Member]
Concentration Risk [Line Items]
Number of Hospitals | Hospital	9
Total net operating revenues before the provision for bad debts, Amount	$ 203,372	$ 201,851
Illinois [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	36.10%	34.30%
Oregon [Member]
Concentration Risk [Line Items]
Number of Hospitals | Hospital	1
Total net operating revenues before the provision for bad debts, Amount	$ 52,996	$ 52,848
Oregon [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	9.40%	9.00%
Georgia [Member]
Concentration Risk [Line Items]
Number of Hospitals | Hospital	3
Total net operating revenues before the provision for bad debts, Amount	$ 45,876	$ 54,254
Georgia [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	8.20%	9.20%
California [Member]
Concentration Risk [Line Items]
Number of Hospitals | Hospital	2
Total net operating revenues before the provision for bad debts, Amount	$ 38,957	$ 51,045
California [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	6.90%	8.70%
Kentucky [Member]
Concentration Risk [Line Items]
Number of Hospitals | Hospital	3
Total net operating revenues before the provision for bad debts, Amount	$ 30,984	$ 30,892
Kentucky [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	5.50%	5.30%
Alabama [Member]
Concentration Risk [Line Items]
Number of Hospitals | Hospital	2
Total net operating revenues before the provision for bad debts, Amount	$ 28,629	$ 27,312
Alabama [Member] | Sales Revenue, Net [Member] | Geographic Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	5.10%	4.60%

Basis of Presentation and Sig52

Basis of Presentation and Significant Accounting Policies (Summary of Major Components of Other Operating Expenses) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Other Operating Expenses [Line Items]
Taxes and insurance	$ 34,243	$ 35,306
Transition services agreements and allocations from Parent	16,282	16,257
Repairs and maintenance	11,443	11,236
Utilities	6,665	7,155
Other miscellaneous operating expenses	20,732	16,895
Total other operating expenses	163,424	164,463
Purchased Services [Member]
Other Operating Expenses [Line Items]
Professional fees	45,596	44,438
Medical Specialist Fees [Member]
Other Operating Expenses [Line Items]
Professional fees	$ 28,463	24,350
Community Health Systems, Inc [Member] | Management Fees From Parent [Member]
Other Operating Expenses [Line Items]
Other operating expenses		$ 8,826

Basis of Presentation and Sig53

Basis of Presentation and Significant Accounting Policies (Summary of Activity Related to Electronic Health Records Incentives) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Electronic Health Records Incentives Earned [Abstract]
Electronic health records incentives receivable at beginning of period	$ 4,189	$ 11,227
Electronic health records incentives earned	2,452	4,208
Cash incentive payments received	(842)	(7,625)
Adjustments to receivable based on final cost report settlement or audit	(221)	(1,925)
Electronic health records incentives receivable at end of period	5,578	5,885
Deferred revenue related to electronic health records incentives at beginning of period	0	0
Cash received and deferred during period	0	(4,693)
Recognition of deferred incentives as earned	0	0
Deferred revenue related to electronic health records incentives at end of period	0	(4,693)
Total electronic health records incentives earned during period	2,452	4,208
Total cash incentive payments received during period	$ 842	$ 12,318

Impairment of Long-Lived Asse54

Impairment of Long-Lived Assets and Goodwill (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016	Jun. 30, 2016	Mar. 31, 2016
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill	$ 3,300			$ 0
Impairment of long-lived assets			$ 45,400
Goodwill impairment charge	1,368
Hospital Operations Reporting Unit [Member]
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets		$ 82,700
Goodwill impairment charge		2,700	200,000
Goodwill impaired adjustment to initial estimate amount		80,000
Additional recorded impairment of long-lived assets		$ 38,800
Hospitals Held for Sale [Member]
Impaired Long Lived Assets And Goodwill [Line Items]
Impairment of long-lived assets and goodwill	3,300
Impairment of long-lived assets	1,100
Impairment of capitalized software costs	800
Goodwill impairment charge	$ 1,368		$ 5,000

Divestitures (Narrative) (Detai

Divestitures (Narrative) (Details) $ in Thousands	Mar. 30, 2017bed	Dec. 31, 2016USD ($)bed	Dec. 01, 2016USD ($)bed	Mar. 31, 2017USD ($)bed	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Proceeds from sale of hospitals				$ 4,282	$ 0
Impairment of long-lived assets				3,300	0
Gain (loss) on sale of business				$ 870	0
Augusta, Georgia [Member] | Definitive Agreement to Trinity Hospital [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Number of beds in hospital being sold | bed	231
Centre, Alabama [Member] | Cherokee Medical Center [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal date				Mar. 31, 2017
Number of beds in hospital sold | bed				60
Proceeds from sale of hospitals				$ 4,282
Pre-tax gain (loss) from disposal of discontinued operation				(900)	(1,700)
Gain (loss) on sale of business				$ 800
Centre, Alabama [Member] | Cherokee Medical Center [Member] | Property, Equipment and Capitalized Software [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Impairment of long-lived assets						$ 3,900	$ 2,000
Winder, Georgia | Barrow Regional Medical Center [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal date				Dec. 31, 2016
Number of beds in hospital sold | bed		56
Proceeds from sale of hospitals		$ 6,600
Pre-tax gain (loss) from disposal of discontinued operation				$ 600	(2,900)
Gain (loss) on sale of business						(1,200)
Winder, Georgia | Barrow Regional Medical Center [Member] | Property, Equipment and Capitalized Software [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Impairment of long-lived assets						4,000
Hamlet, North Carolina [Member] | Sandhills Regional Medical Center [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Disposal date				Dec. 1, 2016
Number of beds in hospital sold | bed			64
Proceeds from sale of hospitals			$ 7,200
Pre-tax gain (loss) from disposal of discontinued operation				$ (600)	$ (600)
Gain (loss) on sale of business						(1,000)
Hamlet, North Carolina [Member] | Sandhills Regional Medical Center [Member] | Property, Equipment and Capitalized Software [Member]
Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]
Impairment of long-lived assets						$ 4,800

Property and Equipment (Summary

Property and Equipment (Summary of Components of Property and Equipment) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 1,435,272	$ 1,519,975
Less: Accumulated depreciation and amortization	(714,908)	(786,075)
Total property and equipment, net	720,364	733,900
Land and Improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	80,846	84,474
Building and improvements [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	756,040	782,892
Equipment and Fixtures [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	532,830	592,463
Construction in progress [Member]
Property Plant And Equipment [Line Items]
Total property and equipment, at cost	$ 65,556	$ 60,146

Property and Equipment (Narrati

Property and Equipment (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Property Plant And Equipment [Abstract]
Depreciation expense	$ 15.8	$ 22.4
Assets held under capital lease obligations, at cost	29.1		$ 30.2
Assets held under capital lease obligations, net of accumulated amortization	26.9		27.5
Purchases of property and equipment accrued in accounts payable	$ 6.9		$ 15.7

Goodwill and Intangible Asset58

Goodwill and Intangible Assets (Summary of Changes in Goodwill) (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill, beginning balance	$ 416,833
Reclassification to held-for-sale	(6,885)
Impairment	(1,368)
Goodwill, ending balance	$ 408,580

Goodwill and Intangible Asset59

Goodwill and Intangible Assets (Goodwill Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Goodwill [Line Items]
Goodwill	$ 408,580	$ 416,833
Hospital Operations Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	375,300	383,500
Hospital Management Advisory and Consulting Services Reporting Unit [Member]
Goodwill [Line Items]
Goodwill	$ 33,300	$ 33,300

Goodwill and Intangible Asset60

Goodwill and Intangible Assets (Summary of Intangible Assets ) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	$ 216,037	$ 236,552
Accumulated amortization	(145,189)	(157,779)
Total finite-lived intangible assets, net	70,848	78,773
Total indefinite-lived intangible assets	5,681	6,209
Total intangible assets, gross	221,718	242,761
Total intangible assets, net	76,529	84,982
Trade Names [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	4,000	4,000
Medical Licenses and Other Indefinite-Lived Intangible Assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Total indefinite-lived intangible assets	1,681	2,209
Capitalized Software Costs [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	164,006	180,855
Accumulated amortization	(107,611)	(118,391)
Total finite-lived intangible assets, net	56,395	62,464
Physician Income Guarantee Contracts [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	8,148	11,355
Accumulated amortization	(4,409)	(6,329)
Total finite-lived intangible assets, net	3,739	5,026
Other Finite-Lived Intangible Assets [Member]
Finite-Lived and Indefinite-Lived Intangible Assets [Line Items]
Cost	43,883	44,342
Accumulated amortization	(33,169)	(33,059)
Total finite-lived intangible assets, net	$ 10,714	$ 11,283

Goodwill and Intangible Asset61

Goodwill and Intangible Assets (Intangible Assets Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 216,037	$ 236,552
Capitalized Software Costs in Development Stage [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross	$ 3,200

Goodwill and Intangible Asset62

Goodwill and Intangible Assets (Summary of the Components of Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 5,870	$ 8,063
Amortization of leasehold improvements and property and equipment assets held under capital lease obligations	456	683
Total amortization expense	6,326	8,746
Capitalized Software Costs [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	4,744	6,595
Physician Income Guarantee Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	557	711
Other Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Total amortization expense related to finite-lived intangible assets	$ 569	$ 757

Goodwill and Intangible Asset63

Goodwill and Intangible Assets (Amortization Expense Narrative) (Details)	3 Months Ended
	Mar. 31, 2017
Intangible Assets Except Software Costs and Physician Income Guarantee Contracts [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, weighted-average useful life	5 years 3 months 18 days

Long-Term Debt (Summary of Comp

Long-Term Debt (Summary of Components of Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	$ 1,366,480	$ 1,295,589
Unamortized debt issuance costs and discounts	(46,831)	(48,764)
Capital lease obligations	25,224	25,588
Other debt	1,387	1,582
Total debt	1,319,649	1,246,825
Less: Current maturities of long-term debt	(1,664)	(5,683)
Long-term debt	1,317,985	1,241,142	$ 1,250,497	$ 24,179
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	400,000	400,000
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	39,000	0
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	39,000	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Total debt, excluding debt issuance costs and discounts	$ 861,869	$ 868,419

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details)	Apr. 29, 2016Agreement
Debt Disclosure [Abstract]
Number of credit agreement	2

Long-Term Debt (Senior Credit F

Long-Term Debt (Senior Credit Facility Narrative) (Details) - USD ($)	Apr. 29, 2016	Mar. 31, 2017	Jan. 01, 2018	Dec. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount		$ 24,536,000			$ 24,536,000
Senior Credit Facility [Member]
Debt Instrument [Line Items]
Secured net leverage ratio		383.00%			393.00%
Line of credit, additional borrowing capacity		$ 152,600,000
Secured net leverage ratio to exercise incremental term loan commitments description		Through December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments, as defined in the CS Agreement, only if the Secured Net Leverage Ratio, adjusted for the requested Incremental Term Loan borrowing, is below 3.35 to 1.00. After December 31, 2018, the Company may request to exercise Incremental Term Loan Commitments for the greater of $100 million or an amount which would produce a Secured Net Leverage Ratio of 3.35 to 1.00.
Leverage ratio to incur permitted additional debt description		Through December 31, 2018, the Company is allowed to incur Permitted Additional Debt, as defined in the CS Agreement, only if the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 4.50 to 1.00. After December 31, 2018, the Company may incur Permitted Additional Debt so long as the Total Leverage Ratio, adjusted for the Permitted Additional Debt, is below 5.50 to 1.00.
Letters of credit outstanding		$ 6,500,000
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 880,000,000
Debt Instrument, Unamortized Discount	$ 17,600,000
Term Facility Issued Percentage on Par Value	98.00%
Debt Instrument, Maturity Date		Apr. 29, 2022
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		7.69%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	5.75%
Derivative, Floor Interest Rate	1.00%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Agreement [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	4.75%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Effective Percentage		8.73%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		6.75%
Derivative, Floor Interest Rate		1.00%
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member] | CS Amendment [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		5.75%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 100,000,000
Debt Instrument, Maturity Date		Apr. 29, 2021
Line of credit, outstanding balance		$ 39,000,000
Line of credit, borrowing capacity		$ 42,000,000
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | CS Amendment [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		2.75%
Derivative, Floor Interest Rate		0.00%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | CS Amendment [Member] | Alternate Base Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate		1.75%
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member] | Scenario Forecast [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity			$ 75,000,000	$ 87,500,000

Long-Term Debt (Maximum Secured

Long-Term Debt (Maximum Secured Net Leverage Ratio Permitted) (Details) - Senior Credit Facility [Member]	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Secured net leverage ratio	383.00%	393.00%
Period from January 1, 2017 to June 30, 2017 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	450.00%
Period from July 1, 2017 to December 31, 2018 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	475.00%
Period from January 1, 2019 and thereafter [Member] | Maximum [Member]
Debt Instrument [Line Items]
Secured net leverage ratio	400.00%

Long-Term Debt (ABL Credit Faci

Long-Term Debt (ABL Credit Facility Narrative) (Details) - ABL Credit Facility, maturing 2021 [Member] - USD ($)	Apr. 29, 2016	Mar. 31, 2017
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 125,000,000	$ 86,000,000
Line of credit, outstanding balance		39,000,000
Line of Credit Facility, Maturity Date	Apr. 29, 2021
Covenant Trigger Event, minimum required excess availability amount		$ 12,500,000
Covenant Trigger Event, minimum required excess availability as percentage of aggregate commitments		10.00%
Minimum Consolidated Fixed Charge Ratio required to be maintained if covenant trigger event occurs		110.00%
Cash Dominion Trigger Event, minimum required excess availability as percentage of aggregate commitments		12.50%
Cash Dominion Trigger Event, minimum required excess availability amount		$ 15,000,000
London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Derivative, Floor Interest Rate	0.00%
London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
London Interbank Offered Rate (LIBOR) [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Base Rate [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.75%
Base Rate [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.25%

Long-Term Debt (Senior Notes Na

Long-Term Debt (Senior Notes Narrative) (Details) - USD ($)	Apr. 17, 2017	Apr. 22, 2016	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount			$ 24,536,000	$ 24,536,000
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount		$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt Instrument, Unamortized Discount		$ 6,900,000
Debt instrument issue discount percentage		1.734%
Debt Instrument, Maturity Date		Apr. 15, 2023
Debt Instrument, Payment Terms			Payable semi-annually in arrears on April 15 and October 15 of each year, beginning on October 15, 2016.
Debt Instrument, Frequency of Periodic Payment			semi-annually
Debt Instrument, Date of First Required Payment		Oct. 15, 2016
Debt Instrument, Interest Rate, Effective Percentage			12.469%
Debt Instrument, Redemption Price Percentage		100.00%
Senior Notes, maturing 2023 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price Percentage		35.00%
Senior Notes, maturing 2023 [Member] | Subsequent Events [Member]
Debt Instrument [Line Items]
Senior Notes, exchange offer expiration date	May 17, 2017
Senior Notes, maturing 2023 [Member] | Initial Notes [Member] | Subsequent Events [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 400,000,000
Debt Instrument, Interest Rate, Stated Percentage	11.625%
Debt instrument due date	2,023
Senior Notes, maturing 2023 [Member] | Exchange Notes [Member] | Subsequent Events [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	11.625%
Debt instrument due date	2,023

Long-Term Debt (Summary of Rede

Long-Term Debt (Summary of Redemption Dates and Prices of Senior Notes) (Details) - Senior Notes, maturing 2023 [Member]	Apr. 22, 2016	Mar. 31, 2017
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage	100.00%
Period from April 15, 2019 to April 14, 2020 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		108.719%
Period from April 15, 2020 to April 14, 2021 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		105.813%
Period from April 15, 2021 to April 14, 2022 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		102.906%
Period from April 15, 2022 to April 14, 2023 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Price Percentage		100.00%

Long-Term Debt (Summary of Re71

Long-Term Debt (Summary of Redemption Dates and Prices of Senior Notes) (Parenthetical) (Details) - Senior Notes, maturing 2023 [Member]	3 Months Ended
	Mar. 31, 2017
Period from April 15, 2019 to April 14, 2020 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2019
Debt Instrument, Redemption Period, End Date	Apr. 14, 2020
Period from April 15, 2020 to April 14, 2021 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2020
Debt Instrument, Redemption Period, End Date	Apr. 14, 2021
Period from April 15, 2021 to April 14, 2022 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2021
Debt Instrument, Redemption Period, End Date	Apr. 14, 2022
Period from April 15, 2022 to April 14, 2023 [Member]
Debt Instrument Redemption [Line Items]
Debt Instrument, Redemption Period, Start Date	Apr. 15, 2022
Debt Instrument, Redemption Period, End Date	Apr. 14, 2023

Long-Term Debt (Summary of Unam

Long-Term Debt (Summary of Unamortized Debt Issuance Costs and Discounts) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Debt issuance costs	$ 29,193	$ 29,146
Debt discounts	24,536	24,536
Total debt issuance costs and discounts	53,729	53,682
Less: Amortization of debt issuance costs and discounts	(6,898)	(4,918)
Total unamortized debt issuance costs and discounts	$ 46,831	$ 48,764

Long-Term Debt (Capital Lease O

Long-Term Debt (Capital Lease Obligations and Other Debt Narrative) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Instrument [Line Items]
Capital lease obligations	$ 25,224	$ 25,588
New Corporate Office [Member] | Brentwood, Tennessee [Member]
Debt Instrument [Line Items]
Capital lease obligations	$ 18,500

Long-Term Debt (Summary of Debt

Long-Term Debt (Summary of Debt Maturities for Next Five Years and Thereafter) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Remainder of 2017	$ 1,312
2,018	7,786
2,019	10,144
2,020	10,245
2,021	10,356
Thereafter	1,326,637
Total debt, excluding unamortized debt issuance costs and discounts	$ 1,366,480	$ 1,295,589

Long-Term Debt (Summary of Co75

Long-Term Debt (Summary of Components of Interest Expense, Net) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Amortization of debt issuance costs and discounts	$ 1,980	$ 0
All other interest expense (income), net	(1,112)	569
Total interest expense, net	27,530	27,452
Due to Parent, net	0	26,883
Senior Notes, maturing 2023 [Member]
Debt Instrument [Line Items]
Interest expense	11,626	0
ABL Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Interest expense	256	0
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Debt Instrument [Line Items]
Interest expense	139	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Debt Instrument [Line Items]
Interest expense	14,641	0
Interest Expense Portion From Long Term Debt [Member]
Debt Instrument [Line Items]
Total interest expense, net	$ 27,530	$ 569

Other Long-Term Liabilities (Su

Other Long-Term Liabilities (Summary of Components of Other Long-Term Liabilities) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Other Liabilities Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term liability	$ 76,062	$ 74,194
Insurance reserve for workers' compensation liability, long-term liability	19,862	17,416
Benefit plan liabilities	34,737	10,722
Deferred rent	3,586	4,001
Other miscellaneous long-term liabilities	2,669	2,663
Total other long-term liabilities	136,916	108,996
Professional and General Liability Insurance [Member]
Other Liabilities Noncurrent [Line Items]
Insurance reserves for professional and general liability, long-term liability	$ 76,062	$ 74,194

Fair Value of Financial Instr77

Fair Value of Financial Instruments (Summary of Carrying Amounts and Estimated Fair Values of Long-Term Debt) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	$ 1,366,480	$ 1,295,589
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	1,297,621	1,211,317
ABL Credit Facility, maturing 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	39,000	0
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	39,000	0
Senior Notes, maturing 2023 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	400,000	400,000
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	349,456	334,720
Other debt [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	26,611	27,170
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	26,611	27,170
Senior Credit Facility [Member] | Revolving Credit Facility, maturing 2021 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	39,000	0
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	39,000	0
Senior Credit Facility [Member] | Term Loan Facility, maturing 2022 [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Total debt, excluding unamortized debt issuance costs and discounts, Carrying Amount	861,869	868,419
Total debt, excluding unamortized debt issuance costs and discounts, Estimated Fair Value	$ 843,554	$ 849,427

Equity (Narrative) (Details)

Equity (Narrative) (Details) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares	Apr. 29, 2016USD ($)vote / shares$ / sharesshares
Class Of Stock [Line Items]
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, par value | $ / shares	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	30,203,170	29,482,050
Common stock, shares outstanding	30,203,170	29,482,050	28,412,054
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001
Contributed capital, in excess of par value of common stock | $	$ 539,727	$ 537,911
Spin-off from CHS [Member]
Class Of Stock [Line Items]
Preferred stock, shares authorized			100,000,000
Preferred stock, par value | $ / shares			$ 0.0001
Common stock, shares authorized			300,000,000
Common stock, shares issued			28,412,054
Common stock, par value | $ / shares			$ 0.0001
Common stock voting description	Holders of the Company’s common stock are entitled to one vote for each share held of record on all matters for which stockholders may vote. Holders of the Company’s common stock will not have cumulative voting rights in the election of directors.
Number of vote | vote / shares			1
Contributed capital, in excess of par value of common stock | $			$ 530,600

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Effective Income Tax Rate, Continuing Operations	(2.60%)	26.30%
Deferred income tax liabilities, net	$ 32,075,000		$ 31,474,000
Increase (decrease) in deferred income taxes	600,000
Unrecognized tax benefit	$ 0	$ 0

Earnings Per Share (Summary of

Earnings Per Share (Summary of Computation of Basic and Diluted Earnings (Loss) Per Share) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net income (loss)	$ (27,205)	$ (4,687)
Less: Net income (loss) attributable to noncontrolling interests	356	315
Net income (loss) attributable to Quorum Health Corporation	$ (27,561)	$ (5,002)
Denominator:
Weighted-average shares outstanding - basic and diluted	27,800,597	28,412,054
Basic and diluted earnings (loss) per share attributable to Quorum Health Corporation stockholders	$ (0.99)	$ (0.18)

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	Apr. 27, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016	Apr. 29, 2016
Earnings Per Share [Abstract]
Common stock, shares outstanding		30,203,170		29,482,050	28,412,054
Dilutive Shares	0	0	0

Segments (Narrative) (Details)

Segments (Narrative) (Details)	3 Months Ended
	Mar. 31, 2017segment
Segment Reporting [Abstract]
Number of operating segments	2

Segments (Summary of Financial

Segments (Summary of Financial Information Related to the Company`s Segments) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Segment Reporting Information [Line Items]
Total net operating revenues	$ 527,640	$ 549,551
Total adjusted EBITDA	26,142	56,224
Total assets	2,081,710		$ 1,994,370
Hospital Operations Reporting Unit [Member]
Segment Reporting Information [Line Items]
Total net operating revenues	506,418	527,424
Total adjusted EBITDA	37,466	52,171
Total assets	1,812,402		1,802,121
All Other Operations [Member]
Segment Reporting Information [Line Items]
Total net operating revenues	21,222	22,127
Total adjusted EBITDA	(11,324)	$ 4,053
Total assets	$ 269,308		$ 192,249

Segments (Summary of Reconcilia

Segments (Summary of Reconciliation of Adjusted EBITDA to Net Income (Loss)) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting [Abstract]
Total adjusted EBITDA	$ 26,142	$ 56,224
Interest expense, net	(27,530)	(27,452)
Provision for (benefit from) income taxes	(701)	1,674
Depreciation and amortization	(22,120)	(31,157)
Legal, professional and settlement costs	(535)	(241)
Impairment of long-lived assets and goodwill	(3,300)	0
Gain (loss) on sale of hospitals, net	870	0
Transaction costs related to the Spin-off	(31)	(3,735)
Net income (loss)	$ (27,205)	$ (4,687)

Stock-Based Compensation (Narra

Stock-Based Compensation (Narrative) (Details) $ in Thousands	Feb. 22, 2017shares	May 03, 2016Directorshares	Apr. 29, 2016shares	Mar. 31, 2017USD ($)shares	Mar. 31, 2016USD ($)
Community Health Systems, Inc [Member] | Corporate Allocations [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation expense included in corporate management fee | $					$ 62,301
Community Health Systems, Inc [Member] | Corporate Allocations [Member] | Share-based Compensation Expense Included in Corporate Management Fee [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Share based compensation expense included in corporate management fee | $					$ 1,700
Spin-off from CHS [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of cancelled shares in connection with the Spin-off			66.67%
QHC and CHS Restricted Stock Awards Held By QHC Employees as of Spin-off Date [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock-based compensation expense | $				$ 1,700
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted				880,000
Unrecognized stock-based compensation expense | $				$ 14,400
2016 Stock Award Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock that may be issued under stock award plan			4,700,000
2016 Stock Award Plan [Member] | Restricted Stock [Member] | Performance-Based Vesting [Member] | Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	230,000	460,000
Share-based compensation, vesting period	3 years	3 years
2016 Stock Award Plan [Member] | Restricted Stock [Member] | Time-Based Vesting [Member] | Executive Officers [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	230,000
Share-based compensation, vesting period	3 years
2016 Stock Award Plan [Member] | Restricted Stock [Member] | Time-Based Vesting [Member] | Certain Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted	420,000	551,005
Share-based compensation, vesting period	3 years	3 years
2016 Stock Award Plan [Member] | Restricted Stock [Member] | Time-Based Vesting [Member] | Non-Employee Director, Individual [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted		10,000
Share-based compensation, vesting description				The restrictions on the time-vested restricted stock awards will lapse on the first anniversary of the grant date.
Number of directors | Director		7
2016 Stock Award Plan [Member] | Restricted Stock, Recoupment Awards [Member] | Time-Based Vesting [Member] | Certain Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Restricted stock units, shares granted		106,005
Share-based compensation, vesting description				Restrictions on the recoupment awards lapse in equal installments on the second and third anniversaries of the grant date.

Stock-Based Compensation (Summa

Stock-Based Compensation (Summary of Activity Related to Unvested Restricted Stock Awards) (Details)	3 Months Ended
	Mar. 31, 2017$ / sharesshares
QHC Awards Distributed in Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	673,987
Vested, Shares	(234,433)
Forfeited, Shares	(141,111)
Unvested restricted stock awards at end of period, Shares	298,443
QHC Awards Distributed in Spin-off [Member] | QHC Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	52,462
Vested, Shares	(33,599)
Forfeited, Shares	(13,928)
Unvested restricted stock awards at end of period, Shares	4,935
QHC Awards Distributed in Spin-off [Member] | CHS Employees [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	621,525
Vested, Shares	(200,834)
Forfeited, Shares	(127,183)
Unvested restricted stock awards at end of period, Shares	293,508
QHC Restricted Stock Awards Granted Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested restricted stock awards at beginning of period, Shares	1,081,005
Granted, Shares	880,000
Vested, Shares	0
Forfeited, Shares	(17,667)
Unvested restricted stock awards at end of period, Shares	1,943,338
Unvested restricted stock awards at beginning of period, Weighted Average Grant Date Fair Value | $ / shares	$ 12.77
Granted, Weighted Average Grant Date Fair Value | $ / shares	8.54
Vested, Weighted Average Grant Date Fair Value | $ / shares	0
Forfeited, Weighted Average Grant Date Fair Value | $ / shares	12.77
Unvested restricted stock awards at end of period, Weighted Average Grant Date Fair Value | $ / shares	$ 10.85

Stock-Based Compensation (Sum87

Stock-Based Compensation (Summary of Stock-Based Compensation Expense) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,797	$ 0
Resulting from Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	916	0
Related to Grants Following Spin-off [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,881	$ 0

Employee Benefit Plans (Narrati

Employee Benefit Plans (Narrative) (Details)	Sep. 16, 2016Installmentshares	Aug. 18, 2016	Apr. 01, 2016USD ($)	Jan. 31, 2017USD ($)	Mar. 31, 2017USD ($)Hospital	Mar. 31, 2016USD ($)	Dec. 31, 2016USD ($)
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, total expense					$ 2,900,000	$ 3,300,000
Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan net periodic benefit cost					$ 100,000
Number of Hospitals | Hospital					1
Accrued benefit liability					$ 1,200,000		$ 1,100,000
Original SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, assets transferred			$ 0
Amended and Restated SERP Plan [Member] | Salaries and Benefits [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan net periodic benefit cost					500,000
Maximum [Member] | Pension Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan net periodic benefit cost						$ 100,000
Maximum [Member] | Director's Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Number of annual installments | Installment	15
Common stock shares available for issue | shares	150,000
Other long-term liabilities [Member] | Original SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability			$ 6,000,000
Other long-term liabilities [Member] | Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability					7,600,000		7,100,000
Accrued Salaries and Benefits [Member] | Amended and Restated SERP Plan [Member]
Defined Benefit Plan Disclosure [Line Items]
Current portion of benefit liability					2,300,000		$ 2,300,000
CHS Unfunded Deferred Compensation Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan, assets transferred				$ 22,900,000
Defined benefit plan, liabilities transferred				$ 23,900,000
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Percentage of incentive compensation participants are permitted to defer		100.00%
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Other long-term liabilities [Member]
Defined Benefit Plan Disclosure [Line Items]
Accrued benefit liability					23,600,000
QHCCS, LLC Nonqualified Deferred Compensation Plan [Member] | Other long-term Assets [Member]
Defined Benefit Plan Disclosure [Line Items]
Long-term portion of benefit Asset					$ 22,500,000

Related Party Transactions (Sum

Related Party Transactions (Summary of Allocated Costs from Parent) (Details) - Community Health Systems, Inc [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)
Management Fees From Parent [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	$ 8,826
Corporate Allocations [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	62,301
Corporate Allocations [Member] | Insurance Costs [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	33,760
Corporate Allocations [Member] | Management Fees From Parent [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	8,826
Corporate Allocations [Member] | All Other Allocated Costs [Member]
Related Party Transaction [Line Items]
Related party operating costs and expenses	$ 19,715

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Related Party Transaction [Line Items]
Interest Expense, Related Party	$ 0	$ 26,883
Community Health Systems, Inc [Member]
Related Party Transaction [Line Items]
Interest Expense, Related Party		26,900
Community Health Systems, Inc [Member] | Transition Services Agreements
Related Party Transaction [Line Items]
Terms of transitional service agreements	5 years
Community Health Systems, Inc [Member] | Transition Services Agreements and Allocation from Parent Prior to Spin-Off [Member]
Related Party Transaction [Line Items]
Total expenses incurred and allocation from parent	$ 16,300	$ 16,300
Community Health Systems, Inc [Member] | Minimum [Member]
Related Party Transaction [Line Items]
Related party transaction, rate	4.00%
Community Health Systems, Inc [Member] | Maximum [Member]
Related Party Transaction [Line Items]
Related party transaction, rate	7.00%

Commitments and Contingencies91

Commitments and Contingencies (Narrative) (Details) - USD ($)	Feb. 15, 2017	Jan. 15, 2017	Dec. 23, 2016	Jul. 28, 2016	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Other Commitments [Line Items]
Property and equipment, at cost					$ 1,435,272,000		$ 1,519,975,000
McKenzie – Willamette Medical Center Project [Member] | Asset Under Construction [Member] | Construction and Capital Commitments [Member]
Other Commitments [Line Items]
Construction costs incurred during the period					11,700,000	$ 6,900,000
Property and equipment, at cost					$ 60,600,000
Expected project to be completed period					early 2,018
Physician Recruiting Commitments, Income Guarantee [Member]
Other Commitments [Line Items]
Maximum potential amount of future payments in excess of liabilities recorded					$ 1,900,000
Guarantee period					1 year
Commitment periods over which physician agrees to practice in designated community					3 years
Liabilities related to income guarantee agreements					$ 1,300,000		$ 1,600,000
Professional and General Liability Insurance [Member]
Other Commitments [Line Items]
Self-insured retention level					5,000,000
Worker's Compensation Liability [Member]
Other Commitments [Line Items]
Self-insured retention level					500,000
Quorum Health Resources [Member] | Professional and General Liability Insurance [Member]
Other Commitments [Line Items]
Self-insured retention level					6,000,000
Quorum Health Resources [Member] | Hancock Medical Center [Member]
Other Commitments [Line Items]
Litigation award payable		$ 12,600,000		$ 9,400,000
Liability related to litigation				12,600,000
Insurance receivable to litigation				$ 8,900,000
Estimated liability of company		$ 5,000,000
Payments for legal settlements	$ 3,800,000
Quorum Health Resources [Member] | United Tort Claimants and Douthitt-Dugger, et al. [Member]
Other Commitments [Line Items]
Plaintiffs' claims liability not covered by insurance					$ 5,100,000
Percentage of fault of company for plaintiffs' injuries			16.50%
Lawsuit filing date					June 11, 2010

Commitments and Contingencies -

Commitments and Contingencies - (Summary of Insurance Reserves Related to Professional and General Liability Claims and Workers Compensation Claims) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	$ 25,570	$ 17,580
Insurance reserve for workers' compensation liability, current receivable	4,486	4,863
Total self-insurance reserves, current receivable	30,056	22,443
Insurance reserves for professional and general liability, long-term receivable	56,515	59,652
Insurance reserve for workers' compensation liability, long-term receivable	17,979	15,958
Total self-insurance reserves, long-term receivable	74,494	75,610
Insurance reserves for professional and general liability, current liability	26,369	17,810
Insurance reserve for workers' compensation liability, current liability	6,558	6,599
Total self-insurance reserves, current liability	32,927	24,409
Insurance reserves for professional and general liability, long-term liability	76,062	74,194
Insurance reserve for workers' compensation liability, long-term liability	19,862	17,416
Total self-insurance reserves, long-term liability	95,924	91,610
Insurance Reserves Indemnified By CHS, Inc. [Member]
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	25,570	17,580
Insurance reserve for workers' compensation liability, current receivable	4,486	4,863
Insurance reserves for professional and general liability, long-term receivable	56,515	59,652
Insurance reserve for workers' compensation liability, long-term receivable	17,979	15,958
Insurance reserves for professional and general liability, current liability	25,570	17,580
Insurance reserve for workers' compensation liability, current liability	4,486	4,863
Insurance reserves for professional and general liability, long-term liability	56,515	59,652
Insurance reserve for workers' compensation liability, long-term liability	17,979	15,958
All Other Self-insurance Reserves [Member]
Loss Contingencies [Line Items]
Insurance reserves for professional and general liability, current receivable	0	0
Insurance reserve for workers' compensation liability, current receivable	0	0
Insurance reserves for professional and general liability, long-term receivable	0	0
Insurance reserve for workers' compensation liability, long-term receivable	0	0
Insurance reserves for professional and general liability, current liability	799	230
Insurance reserve for workers' compensation liability, current liability	2,072	1,736
Insurance reserves for professional and general liability, long-term liability	19,547	14,542
Insurance reserve for workers' compensation liability, long-term liability	$ 1,883	$ 1,458

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details)	May 12, 2017bed	Apr. 17, 2017USD ($)	Apr. 06, 2017USD ($)	Mar. 31, 2017USD ($)	Mar. 31, 2016USD ($)	Apr. 22, 2016USD ($)
Subsequent Event [Line Items]
Pay down of term loan				$ 7,109,000	$ 1,089,000
Senior Notes, maturing 2023 [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage						11.625%
Debt Instrument, Face Amount						$ 400,000,000
Subsequent Events [Member] | Definitive Agreement to Sell Bed in McKenzie Regional Hospital [Member] | Brentwood, Tennessee [Member]
Subsequent Event [Line Items]
Disposal date	May 12, 2017
Number of beds in hospital sold | bed	45
Subsequent Events [Member] | Definitive Agreement to Sell Bed in Henderson County Community Hospital [Member] | Brentwood, Tennessee [Member]
Subsequent Event [Line Items]
Disposal date	May 12, 2017
Number of beds in hospital sold | bed	45
Subsequent Events [Member] | Senior Notes, maturing 2023 [Member]
Subsequent Event [Line Items]
Senior Notes, exchange offer expiration date		May 17, 2017
Subsequent Events [Member] | Senior Notes, maturing 2023 [Member] | Initial Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt instrument due date		2,023
Debt Instrument, Face Amount		$ 400,000,000
Subsequent Events [Member] | Senior Notes, maturing 2023 [Member] | Exchange Notes [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		11.625%
Debt instrument due date		2,023
Cherokee Medical Center [Member] | Subsequent Events [Member] | Term Loan Facility [Member]
Subsequent Event [Line Items]
Pay down of term loan			$ 4,300,000

Guarantor and Non-Guarantor S94

Guarantor and Non-Guarantor Supplemental Information (Narrative) (Details)	3 Months Ended
	Mar. 31, 2017
Condensed Financial Information Of Parent Company Only Disclosure [Abstract]
Percentage of owned domestic subsidiaries which guaranteed senior notes	100.00%

Guarantor and Non-Guarantor S95

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts	$ 587,945	$ 614,484
Provision for bad debts	60,305	64,933
Net operating revenues	527,640	549,551
Operating costs and expenses:
Salaries and benefits	264,602	256,862
Supplies	63,822	63,661
Other operating expenses	163,424	164,463
Depreciation and amortization	22,120	31,157
Rent	12,102	12,549
Electronic health records incentives earned	(2,452)	(4,208)
Legal, professional and settlement costs	535	241
Impairment of long-lived assets and goodwill	3,300	0
Gain (loss) on sale of business	870	0
Transaction costs related to the Spin-off	31	3,735
Total operating costs and expenses	526,614	528,460
Income (loss) from operations	1,026	21,091
Interest expense, net	27,530	27,452
Equity in earnings of affiliates	0
Income (loss) before income taxes	(26,504)	(6,361)
Provision for (benefit from) income taxes	701	(1,674)
Net income (loss)	(27,205)	(4,687)
Less: Net income (loss) attributable to noncontrolling interests	356	315
Net income (loss) attributable to Quorum Health Corporation	(27,561)	(5,002)
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts	0	0
Provision for bad debts	0	0
Net operating revenues	0	0
Operating costs and expenses:
Salaries and benefits	0	0
Supplies	0	0
Other operating expenses	0	0
Depreciation and amortization	0	0
Rent	0	0
Electronic health records incentives earned	0	0
Legal, professional and settlement costs	0	0
Impairment of long-lived assets and goodwill	0
Gain (loss) on sale of business	0
Transaction costs related to the Spin-off	0	0
Total operating costs and expenses	0	0
Income (loss) from operations	0	0
Interest expense, net	28,584	0
Equity in earnings of affiliates	(1,747)
Income (loss) before income taxes	(26,837)	0
Provision for (benefit from) income taxes	724	0
Net income (loss)	(27,561)	0
Less: Net income (loss) attributable to noncontrolling interests	0	0
Net income (loss) attributable to Quorum Health Corporation	(27,561)	0
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts	449,000	459,747
Provision for bad debts	49,559	48,355
Net operating revenues	399,441	411,392
Operating costs and expenses:
Salaries and benefits	181,022	172,202
Supplies	45,873	44,781
Other operating expenses	129,310	131,459
Depreciation and amortization	18,528	25,490
Rent	7,098	7,021
Electronic health records incentives earned	(1,457)	(3,999)
Legal, professional and settlement costs	535	241
Impairment of long-lived assets and goodwill	3,300
Gain (loss) on sale of business	0
Transaction costs related to the Spin-off	23	2,798
Total operating costs and expenses	384,232	379,993
Income (loss) from operations	15,209	31,399
Interest expense, net	(1,056)	25,540
Equity in earnings of affiliates	2,578
Income (loss) before income taxes	13,687	5,859
Provision for (benefit from) income taxes	362	1,542
Net income (loss)	13,325	4,317
Less: Net income (loss) attributable to noncontrolling interests	0	0
Net income (loss) attributable to Quorum Health Corporation	13,325	4,317
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts	138,945	154,737
Provision for bad debts	10,746	16,578
Net operating revenues	128,199	138,159
Operating costs and expenses:
Salaries and benefits	83,580	84,660
Supplies	17,949	18,880
Other operating expenses	34,114	33,004
Depreciation and amortization	3,592	5,667
Rent	5,004	5,528
Electronic health records incentives earned	(995)	(209)
Legal, professional and settlement costs	0	0
Impairment of long-lived assets and goodwill	0
Gain (loss) on sale of business	870
Transaction costs related to the Spin-off	8	937
Total operating costs and expenses	142,382	148,467
Income (loss) from operations	(14,183)	(10,308)
Interest expense, net	2	1,912
Equity in earnings of affiliates	0
Income (loss) before income taxes	(14,185)	(12,220)
Provision for (benefit from) income taxes	(385)	(3,216)
Net income (loss)	(13,800)	(9,004)
Less: Net income (loss) attributable to noncontrolling interests	356	315
Net income (loss) attributable to Quorum Health Corporation	(14,156)	(9,319)
Eliminations [Member]
Condensed Income Statements Captions [Line Items]
Operating revenues, net of contractual allowances and discounts	0	0
Provision for bad debts	0	0
Net operating revenues	0	0
Operating costs and expenses:
Salaries and benefits	0	0
Supplies	0	0
Other operating expenses	0	0
Depreciation and amortization	0	0
Rent	0	0
Electronic health records incentives earned	0	0
Legal, professional and settlement costs	0	0
Impairment of long-lived assets and goodwill	0
Gain (loss) on sale of business	0
Transaction costs related to the Spin-off	0	0
Total operating costs and expenses	0	0
Income (loss) from operations	0	0
Interest expense, net	0	0
Equity in earnings of affiliates	(831)
Income (loss) before income taxes	831	0
Provision for (benefit from) income taxes	0	0
Net income (loss)	831	0
Less: Net income (loss) attributable to noncontrolling interests	0	0
Net income (loss) attributable to Quorum Health Corporation	$ 831	$ 0

Guarantor and Non-Guarantor S96

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	$ (27,205)	$ (4,687)
Amortization and recognition of unrecognized pension cost components, net of income taxes	122	0
Comprehensive income (loss)	(27,083)	(4,687)
Less: Comprehensive income (loss) attributable to noncontrolling interests	356	315
Comprehensive income (loss) attributable to Quorum Health Corporation	(27,439)	(5,002)
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	(27,561)	0
Amortization and recognition of unrecognized pension cost components, net of income taxes	122	0
Comprehensive income (loss)	(27,439)	0
Less: Comprehensive income (loss) attributable to noncontrolling interests	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation	(27,439)	0
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	13,325	4,317
Amortization and recognition of unrecognized pension cost components, net of income taxes	122	0
Comprehensive income (loss)	13,447	4,317
Less: Comprehensive income (loss) attributable to noncontrolling interests	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation	13,447	4,317
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	(13,800)	(9,004)
Amortization and recognition of unrecognized pension cost components, net of income taxes	0	0
Comprehensive income (loss)	(13,800)	(9,004)
Less: Comprehensive income (loss) attributable to noncontrolling interests	356	315
Comprehensive income (loss) attributable to Quorum Health Corporation	(14,156)	(9,319)
Eliminations [Member]
Condensed Statement Of Income Captions [Line Items]
Net income (loss)	831	0
Amortization and recognition of unrecognized pension cost components, net of income taxes	(122)	0
Comprehensive income (loss)	709	0
Less: Comprehensive income (loss) attributable to noncontrolling interests	0	0
Comprehensive income (loss) attributable to Quorum Health Corporation	$ 709	$ 0

Guarantor and Non-Guarantor S97

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Balance Sheet) (Details) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Apr. 29, 2016	Apr. 27, 2016	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 89,542	$ 25,455			$ 996	$ 1,106
Patient accounts receivable, net of allowance for doubtful accounts of $357,197 and $360,796 at March 31, 2017 and December 31, 2016, respectively	396,030	380,685
Inventories	53,368	58,124
Prepaid expenses	22,595	23,028
Due from third-party payors	106,380	116,235
Current assets of hospitals held for sale	9,067	1,502
Other current assets	62,529	57,942
Total current assets	739,511	662,971
Intercompany receivable	0	0
Property and equipment, net	720,364	733,900
Goodwill	408,580	416,833
Intangible assets, net	76,529	84,982
Long-term assets of hospitals held for sale	26,773	6,851
Other long-term assets	109,953	88,833
Net investment in subsidiaries	0	0
Total assets	2,081,710	1,994,370
Current liabilities:
Current maturities of long-term debt	1,664	5,683
Accounts payable	174,880	169,684
Accrued liabilities:
Accrued salaries and benefits	98,130	98,803
Accrued interest	31,206	19,915
Due to third-party payors	43,723	42,537
Current liabilities of hospitals held for sale	2,351	492
Other current liabilities	49,532	53,268
Total current liabilities	401,486	390,382
Long-term debt	1,317,985	1,241,142	$ 1,250,497	$ 24,179
Intercompany payable	0	0
Deferred income tax liabilities, net	32,075	31,474
Other long-term liabilities	136,916	108,996
Total liabilities	1,888,462	1,771,994
Redeemable noncontrolling interests	6,279	6,807			8,335	8,958
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	3	3
Additional paid-in capital	539,727	537,911
Accumulated other comprehensive income (loss)	(2,638)	(2,760)
Accumulated deficit	(361,587)	(334,026)
Total Quorum Health Corporation stockholders' equity	175,505	201,128
Nonredeemable noncontrolling interests	11,464	14,441
Total equity	186,969	215,569			14,211	15,943
Total liabilities and equity	2,081,710	1,994,370
Reportable Legal Entities [Member] | Parent Issuer [Member]
Current assets:
Cash and cash equivalents	77,938	21,609			0	0
Patient accounts receivable, net of allowance for doubtful accounts of $357,197 and $360,796 at March 31, 2017 and December 31, 2016, respectively	0	0
Inventories	0	0
Prepaid expenses	0	0
Due from third-party payors	0	0
Current assets of hospitals held for sale	0	0
Other current assets	0	0
Total current assets	77,938	21,609
Intercompany receivable	3	3
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long-term assets of hospitals held for sale	0	0
Other long-term assets	0	0
Net investment in subsidiaries	1,489,043	1,485,213
Total assets	1,566,984	1,506,825
Current liabilities:
Current maturities of long-term debt	0	3,819
Accounts payable	205	158
Accrued liabilities:
Accrued salaries and benefits	0	0
Accrued interest	31,206	19,915
Due to third-party payors	0	0
Current liabilities of hospitals held for sale	0	0
Other current liabilities	268	0
Total current liabilities	31,679	23,892
Long-term debt	1,293,038	1,215,836
Intercompany payable	34,687	34,495
Deferred income tax liabilities, net	32,075	31,474
Other long-term liabilities	0	0
Total liabilities	1,391,479	1,305,697
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	3	3
Additional paid-in capital	539,727	537,911
Accumulated other comprehensive income (loss)	(2,638)	(2,760)
Accumulated deficit	(361,587)	(334,026)
Total Quorum Health Corporation stockholders' equity	175,505	201,128
Nonredeemable noncontrolling interests	0	0
Total equity	175,505	201,128
Total liabilities and equity	1,566,984	1,506,825
Reportable Legal Entities [Member] | Other Guarantors [Member]
Current assets:
Cash and cash equivalents	11,399	3,498			545	524
Patient accounts receivable, net of allowance for doubtful accounts of $357,197 and $360,796 at March 31, 2017 and December 31, 2016, respectively	307,656	277,155
Inventories	43,610	46,318
Prepaid expenses	18,033	17,874
Due from third-party payors	98,789	109,793
Current assets of hospitals held for sale	5,810	1,502
Other current assets	41,860	41,673
Total current assets	527,157	497,813
Intercompany receivable	204,933	126,035
Property and equipment, net	604,882	624,457
Goodwill	248,733	252,433
Intangible assets, net	67,003	73,404
Long-term assets of hospitals held for sale	17,083	6,851
Other long-term assets	87,551	72,967
Net investment in subsidiaries	0	0
Total assets	1,757,342	1,653,960
Current liabilities:
Current maturities of long-term debt	1,411	1,560
Accounts payable	154,156	147,521
Accrued liabilities:
Accrued salaries and benefits	68,333	69,896
Accrued interest	0	0
Due to third-party payors	42,155	40,595
Current liabilities of hospitals held for sale	1,420	492
Other current liabilities	39,125	46,002
Total current liabilities	306,600	306,066
Long-term debt	24,579	24,899
Intercompany payable	155,949	86,084
Deferred income tax liabilities, net	0	0
Other long-term liabilities	173,817	144,950
Total liabilities	660,945	561,999
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	1,319,960	1,333,347
Accumulated other comprehensive income (loss)	(2,638)	(2,760)
Accumulated deficit	(220,925)	(238,626)
Total Quorum Health Corporation stockholders' equity	1,096,397	1,091,961
Nonredeemable noncontrolling interests	0	0
Total equity	1,096,397	1,091,961
Total liabilities and equity	1,757,342	1,653,960
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Current assets:
Cash and cash equivalents	205	348			451	582
Patient accounts receivable, net of allowance for doubtful accounts of $357,197 and $360,796 at March 31, 2017 and December 31, 2016, respectively	88,374	103,530
Inventories	9,758	11,806
Prepaid expenses	4,562	5,154
Due from third-party payors	7,591	6,442
Current assets of hospitals held for sale	3,257	0
Other current assets	20,669	16,269
Total current assets	134,416	143,549
Intercompany receivable	111,078	84,827
Property and equipment, net	115,482	109,443
Goodwill	159,847	164,400
Intangible assets, net	9,526	11,578
Long-term assets of hospitals held for sale	9,690	0
Other long-term assets	22,402	15,866
Net investment in subsidiaries	0	0
Total assets	562,441	529,663
Current liabilities:
Current maturities of long-term debt	253	304
Accounts payable	20,519	22,005
Accrued liabilities:
Accrued salaries and benefits	29,797	28,907
Accrued interest	0	0
Due to third-party payors	1,568	1,942
Current liabilities of hospitals held for sale	931	0
Other current liabilities	10,139	7,266
Total current liabilities	63,207	60,424
Long-term debt	368	407
Intercompany payable	125,378	90,286
Deferred income tax liabilities, net	0	0
Other long-term liabilities	24,282	22,651
Total liabilities	213,235	173,768
Redeemable noncontrolling interests	6,279	6,807
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	428,054	412,705
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(96,591)	(78,058)
Total Quorum Health Corporation stockholders' equity	331,463	334,647
Nonredeemable noncontrolling interests	11,464	14,441
Total equity	342,927	349,088
Total liabilities and equity	562,441	529,663
Eliminations [Member]
Current assets:
Cash and cash equivalents	0	0			$ 0	$ 0
Patient accounts receivable, net of allowance for doubtful accounts of $357,197 and $360,796 at March 31, 2017 and December 31, 2016, respectively	0	0
Inventories	0	0
Prepaid expenses	0	0
Due from third-party payors	0	0
Current assets of hospitals held for sale	0	0
Other current assets	0	0
Total current assets	0	0
Intercompany receivable	(316,014)	(210,865)
Property and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Long-term assets of hospitals held for sale	0	0
Other long-term assets	0	0
Net investment in subsidiaries	(1,489,043)	(1,485,213)
Total assets	(1,805,057)	(1,696,078)
Current liabilities:
Current maturities of long-term debt	0	0
Accounts payable	0	0
Accrued liabilities:
Accrued salaries and benefits	0	0
Accrued interest	0	0
Due to third-party payors	0	0
Current liabilities of hospitals held for sale	0	0
Other current liabilities	0	0
Total current liabilities	0	0
Long-term debt	0	0
Intercompany payable	(316,014)	(210,865)
Deferred income tax liabilities, net	0	0
Other long-term liabilities	(61,183)	(58,605)
Total liabilities	(377,197)	(269,470)
Redeemable noncontrolling interests	0	0
Quorum Health Corporation stockholders' equity:
Preferred stock	0	0
Common stock	0	0
Additional paid-in capital	(1,748,014)	(1,746,052)
Accumulated other comprehensive income (loss)	2,638	2,760
Accumulated deficit	317,516	316,684
Total Quorum Health Corporation stockholders' equity	(1,427,860)	(1,426,608)
Nonredeemable noncontrolling interests	0	0
Total equity	(1,427,860)	(1,426,608)
Total liabilities and equity	$ (1,805,057)	$ (1,696,078)

Guarantor and Non-Guarantor S98

Guarantor and Non-Guarantor Supplemental Information (Schedule of Condensed Consolidating and Combining Statement of Cash Flows (Details) - USD ($) $ in Thousands	Apr. 29, 2016	Mar. 31, 2017	Mar. 31, 2016
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		$ 18,526	$ 24,397
Cash flows from investing activities:
Capital expenditures for property and equipment		(23,217)	(12,840)
Capital expenditures for software		(1,506)	(2,526)
Proceeds from the sale of hospitals		4,282	0
Proceeds from other asset sales		0	858
Other investing activities		0	52
Changes in intercompany balances with affiliates, net		0
Net cash provided by (used in) investing activities		(20,441)	(14,456)
Cash flows from financing activities:
Borrowings (repayments) of revolving credit facilities, net		78,000	0
Borrowings of long-term debt		0	20
Repayments of long-term debt		(7,109)	(1,089)
Increase (decrease) in Due to Parent, net		0	(6,486)
Payments of debt issuance costs	$ (29,146)	(47)	0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		(1,028)	0
Cash distributions to noncontrolling investors		(3,814)	(2,484)
Purchases of shares from noncontrolling investors		0	(12)
Changes in intercompany balances with affiliates, net		0
Net cash provided by (used in) financing activities		66,002	(10,051)
Net change in cash and cash equivalents		64,087	(110)
Cash and cash equivalents at beginning of period		25,455	1,106
Cash and cash equivalents at end of period		89,542	996
Reportable Legal Entities [Member] | Parent Issuer [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		(15,121)	0
Cash flows from investing activities:
Capital expenditures for property and equipment		0	0
Capital expenditures for software		0	0
Proceeds from the sale of hospitals		0
Proceeds from other asset sales			0
Other investing activities			0
Changes in intercompany balances with affiliates, net		0
Net cash provided by (used in) investing activities		0	0
Cash flows from financing activities:
Borrowings (repayments) of revolving credit facilities, net		78,000
Borrowings of long-term debt			0
Repayments of long-term debt		(6,550)	0
Increase (decrease) in Due to Parent, net			0
Payments of debt issuance costs		(47)
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		0
Cash distributions to noncontrolling investors		0	0
Purchases of shares from noncontrolling investors			0
Changes in intercompany balances with affiliates, net		47
Net cash provided by (used in) financing activities		71,450	0
Net change in cash and cash equivalents		56,329	0
Cash and cash equivalents at beginning of period		21,609	0
Cash and cash equivalents at end of period		77,938	0
Reportable Legal Entities [Member] | Other Guarantors [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		36,105	44,593
Cash flows from investing activities:
Capital expenditures for property and equipment		(9,537)	(11,393)
Capital expenditures for software		(1,269)	(1,849)
Proceeds from the sale of hospitals		0
Proceeds from other asset sales			0
Other investing activities			(52)
Changes in intercompany balances with affiliates, net		(15,901)
Net cash provided by (used in) investing activities		(26,707)	(13,294)
Cash flows from financing activities:
Borrowings (repayments) of revolving credit facilities, net		0
Borrowings of long-term debt			20
Repayments of long-term debt		(469)	(937)
Increase (decrease) in Due to Parent, net			(30,361)
Payments of debt issuance costs		0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		(1,028)
Cash distributions to noncontrolling investors		0	0
Purchases of shares from noncontrolling investors			0
Changes in intercompany balances with affiliates, net		0
Net cash provided by (used in) financing activities		(1,497)	(31,278)
Net change in cash and cash equivalents		7,901	21
Cash and cash equivalents at beginning of period		3,498	524
Cash and cash equivalents at end of period		11,399	545
Reportable Legal Entities [Member] | Non-Guarantors [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		(2,458)	(20,196)
Cash flows from investing activities:
Capital expenditures for property and equipment		(13,680)	(1,447)
Capital expenditures for software		(237)	(677)
Proceeds from the sale of hospitals		4,282
Proceeds from other asset sales			858
Other investing activities			104
Changes in intercompany balances with affiliates, net		0
Net cash provided by (used in) investing activities		(9,635)	(1,162)
Cash flows from financing activities:
Borrowings (repayments) of revolving credit facilities, net		0
Borrowings of long-term debt			0
Repayments of long-term debt		(90)	(152)
Increase (decrease) in Due to Parent, net			23,875
Payments of debt issuance costs		0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		0
Cash distributions to noncontrolling investors		(3,814)	(2,484)
Purchases of shares from noncontrolling investors			(12)
Changes in intercompany balances with affiliates, net		15,854
Net cash provided by (used in) financing activities		11,950	21,227
Net change in cash and cash equivalents		(143)	(131)
Cash and cash equivalents at beginning of period		348	582
Cash and cash equivalents at end of period		205	451
Eliminations [Member]
Condensed Cash Flow Statements Captions [Line Items]
Net cash provided by (used in) operating activities		0	0
Cash flows from investing activities:
Capital expenditures for property and equipment		0	0
Capital expenditures for software		0	0
Proceeds from the sale of hospitals		0
Proceeds from other asset sales			0
Other investing activities			0
Changes in intercompany balances with affiliates, net		15,901
Net cash provided by (used in) investing activities		15,901	0
Cash flows from financing activities:
Borrowings (repayments) of revolving credit facilities, net		0
Borrowings of long-term debt			0
Repayments of long-term debt		0	0
Increase (decrease) in Due to Parent, net			0
Payments of debt issuance costs		0
Cancellation of restricted stock awards for payroll tax withholdings on vested shares		0
Cash distributions to noncontrolling investors		0	0
Purchases of shares from noncontrolling investors			0
Changes in intercompany balances with affiliates, net		(15,901)
Net cash provided by (used in) financing activities		(15,901)	0
Net change in cash and cash equivalents		0	0
Cash and cash equivalents at beginning of period		0	0
Cash and cash equivalents at end of period		$ 0	$ 0